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Abstract 
The material for this thesis is based on the European Sero-Epidemiology Network 2 
(ESEN2), a study funded by the European Commission. As part of the ESEN2 project, 
age-specific population seroprevalence of 8 antigens tested in 22 national laboratories was 
estimated and compared between countries. To achieve harmonised serological results, a 
reference panel was tested by each participant laboratory. Each laboratory's panel results 
were regressed against the reference centre, thus obtaining standardisation equations. 
These equations were used to convert the quantitative measurements of the serosurveys 
into common units that were subsequently classified into negative (susceptible) or positive 
(protected) according to a serological cut-off. 
The aim of this thesis was to further develop and validate the methodology for 
standardising serological outcomes, and to propose alternative methods for achieving 
comparable population seroprevalence. 
As part of this thesis, a statistical algorithm was established to standardise serological 
results. Censored regression methods were considered to account for measurements outside 
the assay detection range. The impact of standardisation on seroprevalence was examined. 
Mixture modelling of the serological results was proposed as an alternative method to 
standardisation for estimating seroprevalence. Although mixture modelling may provide 
better seroprevalence estimates in certain situations, it is heavily dependent on model 
assumptions, mainly of well-separated underlying distributions. 
2 
In terms of seroprevalence estimation using standardisation, the validity of the assay cut-
off point was examined. A method for re-estimating cut-offs was proposed based on 
mixture modelling that improved seroprevalence estimates under certain distributional 
assumptions. 
The impact of variability occurring due to serum testing in batches (plate-to-plate 
variability) on seroprevalence was assessed. The method currently used by the laboratories 
was examined, and a new method was proposed to adjust for this based on mixture models. 
In conclusion, the standardisation method used for the ESEN2 project was validated and 
some improvements were proposed. 
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Chapter 1: An introduction to seroepidemiology 
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1.1 The burden of infections 
Despite predictions of their eradication following the introduction of vaccinations in the 
20th century, communicable diseases continue to cause health, economic, and social 
problems worldwide (Walsh CT & Fischbach MA, 2009). In 2004, infectious and parasitic 
diseases were estimated to be responsible for 13.8 million deaths or 23.4% of the global 
mortality. In particular, six diseases - pneumonia, tuberculosis, diarrhoeal diseases, 
malaria, measles and HIV / AIDS - caused 19% of global mortality (World Health 
Organization, 2008d). 
When comparing infectious disease mortality rates, there are big inequalities by wealth and 
age groups. During 2004, infectious diseases were responsible for 55.9% of total deaths in 
the developing countries of Africa in comparison to 4.9% of total deaths in Europe. 
Infectious diseases were estimated to be the main cause of death for 55.9% of all deaths in 
children under the age of IS, compared to 15.2 % of total deaths for adults of 15 years or 
older (World Health Organization, 2oo8d). Although in 2004 the number of deaths caused 
by communicable diseases remained high, the proportion of deaths caused by infectious 
diseases was lower. In 1993, infectious and parasitic diseases were totalling 16.4 million 
deaths worldwide i.e. 32.2% of the global mortality. 
For most infectious diseases the number of deaths decreased between 1993 and 2004, with 
some exceptions, the most significant being HIV / AIDS (World Health Organization, 
1995). The number of deaths in 1993 and in 2004 for some of the most common infectious 
diseases is given in Table 1.1. Note that 2004 has been used as the reference year 
throughout, because it was then that the latest "The global burden of disease" report was 
published by the World Health Organization (WHO) that year (World Health Organization, 
2oo8d). 
21 
Table 1.1 Global mortality estimates for infectious and parasitic diseases by cause 
through the decade 1993 - 2004 
1993 2004 
Deaths Percentage Deaths Percentage 
Cause (thousands) of all deaths (thousands) of all deaths 
Childhood-cluster diseases 1,678 3.3 847 1.4 
Diphtheria 3.9 0.0 5 0.0 
Measles 1,160 2.3 424 0.7 
Pertussis 360 0.7 254 0.4 
Poliomyelitis 5.5 0.0 0.0 
Tetanus 149 0.3 163 0.3 
Diarrhoeal infections 3,010 5.9 2,163 3.7 
Hepatitis B* 933 1.8 105 0.2 
HIV/AIDS 700 1.4 2,040 3.5 
Lower respiratory infections 4,110 8.1 4,177 7.1 
Malaria 2,000 3.9 889 1.5 
Tuberculosis 2,709 5.3 1,464 2.5 
Total - Infectious and parasitic 
diseases 16,445 32.2 13,778 23.4 
Total- All causes 51,000 100.0 58,772 100.0 
* does not include liver cancer and cirrhosis resulting from chronic hepatitis B infection 
Source: World health Organization (World Health Organization. 2008d;World Health 
Organization, 1995) 
The mortality rates are only part of the infectious disease burden, since hundreds of 
millions of people especially in developing countries are disabled every year. A 
quantitative measurement of the overall disease burden that incorporates morbidity, named 
disability-adjusted life year (DALY), was originally invented and is being used by WHO. 
Measured in DALY s, 6.2% of the total disease and injury burden of the world in 2004 was 
due to lower respiratory infections, 4.8% due to diarrhoeal diseases, 3.8% due to HIV / 
AIDS and 2.2% attributed to each of tuberculosis and malaria diseases. There were also 
large regional differences, with no infectious diseases reported within the five diseases 
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with the highest DALY s for high income countries, whereas four out of five diseases 
(lower respiratory infections, diarrhoeal diseases, HIV / AIDS and malaria) had the highest 
DAL Y s for low income countries (World Health Organization, 2008d). 
1.2 Vaccine-prevention 
Much of the mortality reduction of infectious diseases can be attributed to the success of 
vaccination programmes. An example is the reduction from 1,160,000 to 424,000 deaths 
caused by measles between 1993 and 2004 (Table 1.1). However, although it is estimated 
that immunisation averts 2.5 million deaths every year, a further 2.5 million could also be 
prevented by applying more effective immunisation campaigns (World Health 
Organization, 2008d;World Health Organization, 2009). 
The immunisation strategies can vary depending on the aims of the vaccination 
programme. These can be grouped into the following three categories: 
(i) Control or containment is the reduction of disease incidence, prevalence, morbidity or 
mortality to an acceptable level, so it does not constitute a public health problem. When the 
aim of the vaccination programme is the containment of the disease, selective 
immunisation targeting specific subgroups of the population can be used. Given that such 
subgroups are easily identifiable, this type of immunisation campaign can be of low cost 
(Dowdle WR, 1999). 
(ii) Elimination is when the endemic transmission of the infection is interrupted locally. 
Examples of this are the measles vaccine, where measles elimination has been achieved in 
Western Europe, and the poliomyelitis vaccine, where polio elimination has been achieved 
in the Western hemisphere (Dowdle WR, I 999;Nelson KE & Masters Williams C, 2007). 
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(iii) Eradication means that both the disease and the organism cease to exist in the 
population. In other words, there is no risk of infection or disease in the absence of 
immunisation. The only example of eradication is that of smallpox. A campaign for global 
eradication of the disease that started in 1956, ended in 1977; the last case was reported in 
Somalia. This is considered by many as the biggest public health achievement of the last 
century (Nelson KE & Masters Williams C, 2007). 
If the aim of the vaccination is the elimination or eradication of the disease, a programme 
of mass immunisation targeting early childhood is required to prevent natural infections. 
Such a programme does not need to achieve 100% vaccination coverage to accomplish its 
aim (coverage is defined as a proportion of the population being vaccinated) (Nelson KE & 
Masters Williams C, 2007). If vaccine coverage reaches a certain critical level, then the 
population (or herd) immunity will be sufficient to shield even susceptible (unprotected to 
the infection) individuals (Anderson RM & May RM, 1991;Nelson KE & Masters 
Williams C, 2007). 
To achieve elimination or eradication of a disease, selective immunisation can also be 
employed to supplement mass vaccination campaigns when a subgroup of the population is 
considered to be particularly at risk. For example, a combined measles-rubella vaccine was 
offered to all UK schoolchildren as part of a "catch-up" campaign in 1994 following a 
rubella outbreak, despite the fact that a routine immunisation programme with the 
combined measles, mumps and rubella (MMR) vaccine was in place since 1988 (Vyse AJ 
et aI., 2002;Vyse AJ et at., 2006). 
1.3 Infectious disease surveillance 
Since the end of the 19th century, many Western countries established surveillance systems 
for reporting cases of certain infectious diseases. Although these were initially set up as 
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early notification systems for outbreaks, the information collected has also been essential 
for epidemiological studies (Giesecke J, 2002). The main benefit of surveillance from an 
epidemiological perspective is the estimation of incidence i.e. the number of individuals 
acquiring the disease over a time period divided by the total population at risk. Incidence 
estimates can be used to examine the burden of diseases, their trends and the impact of 
intervention policies. Information on the number of disease cases can be collected in 
various ways such as physicians' reports on patients' diagnoses, diagnostic reports from 
microbiological laboratories or hospital records (Giesecke J, 2002). 
1.4 WHO targets for vaccine-preventable diseases in the European region 
As mentioned earlier, in Europe the infectious disease epidemiology is different to the 
developing world's. Many European countries have long-established vaccination 
programmes that reach over 90% population coverage for infections such as diphtheria, 
tetanus and pertussis (World Health Organization, 2009). However, the WHO estimates 
that approximately 32,000 people are still dying every year from vaccine-preventable 
diseases in Europe (World Health Organization Regional Office for Europe, 2008). 
Following the success of poliomyelitis elimination in Europe (Vilayleck MS, 2002), the 
WHO Regional Office for Europe set up targets for the elimination of other vaccine-
preventable diseases such as measles and rubella. Back in 1998, the plan was to interrupt 
indigenous measles transmission by 2007, and reduce the incidence of congenital rubella 
syndrome (CRS) in the European region by 2010 « ] cases ofCRS per 100,000 live 
births) (Centre for Disease Control and Prevention, 2004). In 2005, these targets were 
updated to include measles and rubella elimination by 2010 (Spika JS, 2006). Given that 
the 2010 deadline was not reached, it has now been postponed to 2015 (Steffens I et al., 
2010). 
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A brief description of the clinical symptoms and the epidemiology of eight vaccine-
preventable diseases (measles, rubella, mumps, pertussis, diphtheria, varicella zoster virus, 
hepatitis A and hepatitis B) in the European region are given below. Such a description is 
necessary, since the analysis carried out for this thesis was based on data on these 
infections, collected as part of a European project. 
Measles 
Measles is characterised clinically by fever, cough, coryza (running nose), and 
conjunctivitis (red eyes), followed by body rash. Complications occur in 40% of the cases, 
ranging from pneumonia and other respiratory infections, to diarrhoea and eye disease 
which can often lead to blindness (Nelson KE & Masters Williams C, 2007). 
The measles vaccine has been part of childhood vaccination programmes for at least 20 
years in Europe, with an overall estimated coverage rate of 94% (Martin R et aI., 2009). 
Although mortality has been greatly reduced in Europe (12 reported deaths in the European 
Union countries in 2005), measles remains a public health concern with a high number of 
cases and outbreaks reported in several European countries in 2006 and 2007 (Muscat M et 
al .. 2009;Eurosurveillance editorial team, 2007). 
Rubella 
Rubella (otherwise known as German measles) is a generally mild disease. mainly 
characterised by body rash. However, complications might occur when acquired by adults 
and especially women during pregnancy (World Health Organization, 2008c). Given that 
congenital rubella infection can lead to miscarriage, fetal death or the birth of an infant 
with CRS (symptoms include hearing loss, eye abnormalities, congenital heart disease and 
mental retardation), the rubella vaccination programmes were initially oriented towards 
women of childbearing age (Nelson KE & Masters Williams C, 2007). With the 
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introduction of the MMR vaccine, the immunisation strategy was altered to transmission 
prevention via childhood vaccinations. However, unless there is very high vaccine 
coverage, childhood immunisation can paradoxically lead to an increase in susceptible 
adults, and therefore, an increase of CRS due to a decrease of virus transmission and an 
accumulation of susceptible adult females (Nardone A et aI., 2008). 
Mumps 
Mumps, or infectious parotitis, is a disease that affects the salivary glands. It is generally a 
childhood disease, however, it can also occur in adulthood where complications are more 
likely to occur (World Health Organization, 2008b). 
Despite the relatively high coverage of MMR vaccine, mumps outbreaks have recently 
been recorded in a number of European countries (Schwarz NG et al .. 201O;Vyse A et al., 
2007). Some of these outbreaks are taking place in highly immunised populations 
(Brockhoff HJ et ai., 201O;Vandermeulen C et al., 2009). Such outbreaks challenge the 
effectiveness of the vaccines offered (protective effect of vaccine as estimated by post-
license observational studies) and the appropriateness of the diagnostic methods 
(Vandermeulen C et aI., 2009;Vyse AJ et aI., 2006). 
Pertussis 
Pertussis (otherwise known as whooping cough) is caused by the bacterium Bordetella 
pertussis, and its main characteristics are mild respiratory symptoms. It affects mainly 
children and infection during infancy can cause severe symptoms and death. In some 
European countries adult cases are an increasing problem (de Melker H et al., 1997). In the 
past, pertussis was a very common disease, however, the introduction of routine 
vaccination programmes, as early as the 1950s and I 960s for some Western European 
countries, has succeeded in greatly reducing the incidence (World Health Organization, 
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2005). Moreover, since mid-1990s, different types of vaccines (acellular pertussis 
vaccines) have been introduced in some European countries such as Sweden (Hallander 
HO & Gustafsson L, 2009) and the UK (Andrews N et al., 2010). Despite the high vaccine 
coverage, pertussis notifications have slowly been increasing in a number of European 
countries the last few decades. The reduction of pertussis transmission has not been fully 
established yet due to the variety of vaccination programmes (Hallander HO & Gustafsson 
L, 2009;Wearing HJ & Rohani P, 2009). 
Diphtheria 
Diphtheria is caused by the bacterium Corynebacterium diphtheriae, and affects mainly the 
upper respiratory system. Although most cases are mild or asymptomatic, a high fatality 
ratio (> 10%) has been reported in recent outbreaks (World Health Organization, 2006). 
After the introduction of diphtheria vaccines from the 1940s the number of cases reported 
in Europe was reduced from more than 100 per 100,000 population in I 940s to just 623 in 
total in 1980 prompting the WHO to set up a target of disease elimination in the region by 
2000 (Galazka AM et aI., 1995;WHO Regional Office for Europe, 1996). However, 
following an epidemic that occurred in the 1990' s in the newly independent states of the 
former Soviet Union, this target was postponed indefinitely (Hardy IR et ai., 1996). 
Reasons for the epidemic might include deterioration of socioeconomic conditions, a large 
group of susceptible adults, a decrease in vaccine coverage and a migration increase 
(Galazka A & Tomaszunas-BIaszczyk J, 1997). There seem to be large discrepancies in the 
proportion of the population susceptible to diphtheria between different European countries 
(Edmunds WJ et ai., 2000;Kolodkina V et aI., 2006). 
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Varicella Zoster Virus (VZV) 
Varicella (or chickenpox) is a mild childhood disease but can lead to complications if 
acquired by adults, neonates (severe neonatal varicella) or pregnant women (congenital 
varicella syndrome). In addition to the initial infection, VZV remains dormant within the 
nervous system, and may later in life cause herpes zoster, which often has serious 
complications, particularly in the elderly and immunocompromised (having the immune 
response attenuated, usually as a result of disease, malnutrition, or immunosuppressive 
therapy) (Pinot de Moira A & Nardone A, 2005). 
Many European countries have recently introduced VZV vaccination campaigns targeting 
specific risk groups, such as neonates, premature infants, pregnant women and 
immunocompromised. Others are currently considering introducing VZV vaccination as 
part of a routine immunisation programme in children (Pi not de Moira A & Nardone A, 
2005). However, a number of modelling studies have shown that such an immunisation 
strategy might result in an increase in herpes zoster and have instead suggested targeting 
the high incidence elderly group (van Hoek AJ et at., 2009). Although VZV has been part 
of routine childhood immunisation in the USA since 1995, the impact of this programme 
on herpes zoster incidence has not been assessed conclusively (Reynolds MA et aI., 2008). 
Hepatitis A Virus (HA V) 
Hepatitis A is an acute liver disease caused by HAV, and although it is asymptomatic in 
the great majority of the cases (especially in children) and has low mortality, it is an 
important source of morbidity in South and East Europe (Cianciara J, 2000;World Health 
Organization, 2000). 
Recent epidemiological studies suggest a decrease in HA V infections due to improvements 
in socioeconomic and hygiene conditions, and in some cases as a result of effective 
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vaccination. The decline of infection particularly during childhood means that there may 
be higher susceptibility in adulthood in the future where the symptoms are more severe. 
The WHO position on hepatitis A vaccines emphasises that the endemicity status of the 
country should guide the vaccination policy (Anastassopoulou CG et al., 2009). In general, 
Eastern and Southern European countries have higher incidence rates than Western or 
Northern countries, therefore more widespread immunisation programmes are needed in 
the former (Jacobsen KH & Koopman JS, 2004). 
Hepatitis B Yirus (HBY) 
Hepatitis B is a disease that affects the liver and may cause both acute and chronic disease 
(World Health Organization, 2008a). Similarly to HAY, the epidemiology of HBV varies 
across Europe, with higher incidence rates occurring in Eastern and Southern Europe. 
Given the mortality burden from HBY in Europe (7,000 deaths a year) the WHO called all 
countries to introduce universal HBV vaccination. By the end of 2004,43 out of 52 
countries in the European region had universal vaccination programmes in place (Nardone 
A et al., 2009). 
1.5 Epidemiology using serological data 
In order to assess the progress towards the targets set by the WHO, and to optimise the 
immunisation strategies for the above diseases in Europe, vaccination programmes need to 
be evaluated and improved to amend any perceived weaknesses. More specifically, 
susceptible cohorts need to be identified and potentially targeted with additional "catch-
up" campaigns. Vaccination programmes may be optimised by comparing their 
effectiveness among countries implementing a variety of immunisation strategies. 
As mentioned before, incidence estimation is one of the main aims of surveillance systems 
as defined by WHO. Other objectives include collecting information on clusters of disease, 
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vaccine-related adverse events, immunisation coverage and possible accumulation of 
susceptible individuals (WHO Regional Office for Europe, 2009). Incidence estimates can 
be combined with vaccine coverage to monitor the effectiveness of a vaccination 
programme, or to estimate prevalence i.e. the proportion of individuals diagnosed with the 
disease at a specific time. However, a weakness of surveillance systems based on clinical 
cases is that they cannot identify non-symptomatic cases which for some pathogens 
account for a high proportion of infections. 
An alternative approach is to estimate seroprevalence i.e. the proportion of individuals 
tested positive for past infection based on serology (a more extensive definition and 
discussion is given in the next Chapter) (Mosby, 2009). The population seroprevalence can 
be estimated through the collection and testing of a sample set of serum samples 
(alternatively, other body fluids can be used such as saliva or urine) that are representative 
of the population. The process of collecting and testing samples from individuals at risk 
aiming to determine susceptibility to a disease is called serosurveillance, and the 
corresponding studies serosurveys. The conduct (design and analysis) of serological 
studies on individuals and populations that are used to monitor or study diseases, is 
referred to as seroepidemiology (Dorland, 2000). 
The impact of seroepidemiological studies on designing new vaccination schemes and 
improving current policies has been demonstrated many times in the past. Using 
seroepidemiology, it is possible to estimate vaccine coverage when no other information is 
available, vaccine effectiveness (reduction in the incidence of a disease among individuals 
who have received the vaccine compared to the incidence in unvaccinated individuals), 
waning immunity over time or to identify susceptible cohorts (Giesecke J, 2002;Nelson KE 
& Masters Williams C, 2007). These estimates can be used to evaluate and compare 
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different vaccination strategies using mathematical modelling, in order to to build more 
robust vaccination policies. 
Examples of UK vaccine policies that have been influenced by serosurvey studies include 
the introduction of MMR in 1987, the measles and rubella (MR) "catch-up" campaign in 
1994, the introduction of the second MMR vaccine dose in 1996 and the decisions not to 
implement universal immunisation programmes for HBV and VZV (Brisson M & 
Edmunds WJ, 2003;Farrington CP, 1990;Osborne K et aI., 2000). 
The work carried out for this thesis is an extension of earlier work carried out as part of a 
large European seroepidemiological study. The aims and methods of that study are 
explained in brief below. 
1.6 The European Sero-Epidemiology Network (ESEN) project 
Many countries in Europe have serological surveillance schemes for evaluating their 
national vaccination programmes (Pi not de Moira A & Nardone A, 2005;Pebody RG et al., 
2007;Brisson M & Edmunds WJ, 2003;MeerhoffT et al., 2004;Neal S & Efstratiou A, 
2007). Coordination and harmonization of the national serological surveillance systems of 
vaccine preventable diseases in Europe could provide important information for tackling 
infectious diseases in the region, achieving the targets set by the WHO. This was the aim 
of the European Sero-Epidemiology Network (ESEN), a European project established in 
1996 (Osborne K et at., 1997). 
Eight European countries (Denmark, Finland, France, Germany, Italy, Netherlands, 
Sweden and UK), as well as Australia, participated in the project and seroprevalence was 
estimated for the following infections: measles (de Melker H et at., 200 I ), mumps 
(Nardone A et at., 2003), rubella (Pebody RG et at., 2000;Pebody RG et at., 2001), 
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diphtheria (Edmunds WJ et al., 2000;Edmunds WJ et at., 2001) and pertussis (Pebody RG 
et al., 2000). The project was co-coordinated by the Health Protection Agency (HPA), 
Centre for Infections (CfI) (previously known as Public Health Laboratory Service 
(PHLS» based in Colindale, London. 
1.7 Limitations of serosurveys 
Two major limitations were identified and addressed before the beginning of the project. 
One obvious problem was each country's serosurvey representativeness. Collecting 
potentially thousands of specimens using random sampling had practical difficulties, 
especially for some of the smaller participant countries with insufficient resources and 
limited population size to sample from. Consequently, countries used different methods for 
collecting the specimens, mostly by utilising serum that was left over from specimens 
submitted to the laboratories for diagnostic purposes and others by carrying out population-
based serosurveys (Osborne K et al., 2000;Osborne K et at., 1997). 
A potentially more serious limitation was that direct comparisons of serological 
measurements between national serosurveys were not possible since each national 
laboratory tested their own country's samples lIsing a variety of assays and techniques 
(Osborne K et al., 2000). Different laboratory methods can introduce additional sources of 
variability, namely between-laboratory and between-assay variability and hence, non-
comparable serological outcomes. The option of developing a set of guidelines for 
serological procedures (i.e. same assays and techniques) was not possible since many 
commercial assays were not available everywhere and laboratories preferred to use the 
techniques in which they had developed expertise. 
33 
1.8 The method of standardising serological results 
In order to overcome the problem of between-laboratory and between-assay variability and 
achieve comparable outcomes, a method of standardising quantitative serological outcomes 
was developed (Osborne K et al., 2000). For each infection, a reference laboratory tested a 
small panel of sera designed to cover negative, low and high positive results, and these 
were subsequently sent and tested by each country's national laboratory. The panel results 
for each country were regressed against the reference laboratory's results, and a 
standardisation equation was generated for each country that could transform national 
serosurvey results into common units. Once the serological results had been transformed 
into common units then a direct comparison between different countries' results was 
considered valid (Andrews N et aI., 2000;Giammanco A et aI., 2003;von Hunolstein C et 
ai., 2000). 
1.9 The European Sero-Epidemiology Network 2 (ESEN2) project 
The European Sero-Epidemiology Network 2 (ESEN2) project, funded by the European 
Commission in 200 I, was based on the original ESEN project. ESEN2 shared the same 
aim as the original project i.e. to standardise the serological surveillance of vaccine-
preventable infections in order to improve vaccination policies across Europe. 
An additional study objective of the ESEN2 project was the establishment of an active 
European network of experts in laboratory techniques and epidemiology for the 
surveillance of vaccine preventable infections. Moreover, the serological results, as 
mentioned earlier, apart from providing information with respect to the current risk of 
infection amongst the population could also be used for assessing the cost-effectiveness of 
vaccination programmes using mathematical modelling. 
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Apart from the infections included in the original ESEN project, the co-ordination of 
surveillance was extended to another three, namely VZV, HA V and HBV (eight infections 
in total). The number of participant countries was also increased to 22 (Figure 1.1) 
(includ ing two countries outside the European region , Australia and Israel), in comparison 
to the 8 countries included in the original project (Nardone A & Miller E, 2004). Most 
countries did not test all the eight infections included in the ESEN2 project but only those 
that were considered to be of national public health interest. 
Figure 1.1 A map of Europe highlighting the ESEN2 participant countries 
1.10 Other international seroepidemiology studies 
It is known that vaccination strategies can be more effective when coordinated under an 
orchestrated international effort. Examples of this are the immunisation campaigns against 
polio and smallpox that have succeeded in eliminating the former from the European 
region, and eradicating the latter worldwide (Nelson KE & Masters Williams C, 2007). 
Unfortunately, there have been very few seroepidemiological projects on an international 
level to guide coordinating efforts with their findings. Some recent projects are an 
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examination of Parvovirus B 19 infection in five European countries (Mossong J et at., 
2(07), a prospective study of pregnant women of Human T-Lympotropic viruses between 
seven European countries (Taylor GP et al., 2(05) and an investigation of the 
seroepidemiology of herpes simplex virus type I and 2 in the population of eight European 
countries (Pebody RG et at., 2(07). 
In conclusion, action at a national level may not be sufficient for the eradication or 
elimination of vaccine preventable diseases. Instead, a coordinated strategy at an 
international level is needed. Information gained from international seroepidemiological 
studies can be used to both improve vaccination programmes on a national level and design 
more efficient immunisation strategies at an international level. 
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Chapter 2: Serological assays, vaccines and 
seroprevalence 
37 
2.1 The immune system 
The body's immune ,\')'stem provides a defence against pathogens i.e. invasive organisms 
such as viruses, bacteria and fungi which may cause disease (Davies DH et aI., 1999;The 
Gale Group, 2008), The immune system can be divided into the innate or non-specific 
immune system, and the adaptive or specific immune system. The innate immune system is 
the "first line of defence" against infections and is designed to work within minutes after a 
pathogen attacks the body. It consists of mechanical barriers such as skin and mucous 
membranes, ciliated cells and mucus in the respiratory tract and the washing action of tears 
and urine. The innate immune system also consists of chemical barriers, such as lipids, 
lipoproteins and peptides in the skin, lysozyme in tears, several proteins in the oral cavity 
and the acidic pH in the stomach that are toxic to pathogens (Nelson KE & Masters 
Williams C, 2007). 
The adaptive immune response - a more sophisticated immune response - is triggered once 
the innate immune system fails to eliminate the threat of infection. Unlike innate immunity 
which does not distinguish between pathogens, the adaptive immune system is designed to 
recognise and remove specific antigens (any (foreign) substance that generates anti-
reaction) (Giesecke J, 2002). More specifically, receptors that are present on cells of the 
immune system can recognise small subregions of the antigen called epitopes. Different 
receptors in the adaptive immune system can recognise highly unique epitopes, and 
therefore, specific antigens. The cells of the adaptive immune system that are responsible 
for recognition of specific antigens are a type of leukocyte (Greek word for "white blood 
cells"), called lymphocytes, which are subdivided into T cells and B cells. When the 
receptors bind to the antigen, the Band T lymphocytes are activated, triggering the 
immune response (Nelson KE & Masters Williams C, 2007). 
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After the immune system has been activated and the antigen has been cleared, some Band 
T cells will become memory cells. These rapidly mobilise upon re-exposure with a 
previously encountered antigen (Nelson KE & Masters Williams C, 2(07). 
A simple description of the immune system response is shown in Figure 2.1. Initially, the 
pathogen encounters the innate immune system. This might prove sufficient to prevent 
infection. If the first line of defence fails to eliminate the infection, the adaptive immune 
system reacts with an antigen-specific response. In the case of re-infection. immunological 
memory to a specific antigen can be reactivated to produce a stronger and faster immune 
response (Mims C et aI., 1998). 
Figure 2.1 Innate and adaptive immune systems 
e.g. skin, tears etc 
Cellular immune response 
T ~hocytes and other cells 
e.g. lipids, proteins etc 
- recovery 




















Source: Based on a figure from "Medical Microbiology" (Mims C et al .• 1998) 
Adaptive immunity can be grouped into cell-mediated or cellular immune response, and 
humoral immune response. In the cellular immune response, T lymphocytes and other 
types of cells recognise and destroy antigens. The humoral immune response involves the 
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production of specific proteins from the cells of B lymphocytes called antibodies (or 
imnzunof.:lobulins) that bind to the antigen. This binding incapacitates the antigen and also 
stimulates removal of pathogens by macrophages and other cells (Giesecke J, 2oo2;Nelson 
KE & Masters Williams C, 2007). 
There are five different varieties of antibodies (known as isotypes), each with different 
structures and roles: IgM, IgG, IgO, IgA, and IgE. IgM provides the majority of antigen-
based immunity during the early stages of infection while IgG accounts for the majority of 
antibody-based immunity at a later stage of the infection (Nelson KE & Masters Williams 
C, 2oo7;Hardelid P, 2008). 
2.2 Diagnostic tests 
Biological assays (or more specifically, in this case, serological assays) are used to 
measure the existence, the amount and the type of antibodies in an individual's blood. 
However, before carrying out a serological test, the serum needs to be extracted from the 
blood i.e. the liquid that separates after the blood is allowed to completely clot (Saunders, 
2007). The process of serum separation is achieved by leaving tubes of blood samples at 
room temperature for a while so they clot. and afterwards placing them in a centrifuge 
machine. A picture of samples placed in a centrifuge machine is given in Figure 2.2. After 
the samples have been centrifuged, the red blood cells, which are denser, settle at the 
bottom. The floating serum is then extracted into new tubes using a Pasteur pipette (Figure 
2.3) (Prolmmune Limited, 2009). 
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Figure 2.2 Test tubes in a centrifuge machine 
Source: Wellcome image 
Figure 2.3 Scientist u e a multi-channel Pasteur's pipette 
Source: Wellcome image 
Once the eru m ha been extracted, the immune tatus can be determined either by te ting 
for a specific antigen or fo r anti gen-specific antibodie . Moreover, a ays can be de igned 
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to test for a specific antibody isotype e.g. IgG or IgM (Nelson KE & Masters Williams C, 
2007). Two commonly used assay methods are the enzyme-linked immunosorbent assay 
and the neutralisation test which are discussed briefly below. 
(a) The enzyme-linked immunosorbent assay test 
The enzyme-linked immunosorbent assay (ELISA) otherwise known as the enzyme 
immunoassay (EIA) is used to detect antibodies. Each well in a microtitre or assay plate, 
like the ones shown in Figure 2.4, is coated with a small amount of purified antigen. Once 
the serum has been extracted from the blood sample it is added to the well. If the serum 
contains any antibodies with specificity to the antigen in the well, they will bind to the 
antigen. The well is then washed and any material other than the bound antibodies is 
removed. The antibodies that are added next are linked to enzymes that can colour-flag the 
substance once a chromogenic enzyme substrate has been added. The resulting colour 
marks the quantity of antibodies present in the serum sample (Giesecke J, 2002). 
Figure 2.4 shows an assay plate following an ELISA test. The coloured cells indicate a 
positive result (in this case chlamydial infection). 
42 
Figure 2.4 An ELISA plate with 96 wells 
Source: Well come images 
The difference in colour that indicates the concentration of antibody can be quantified 
using a spectrophotometer (Figure 2.5). The re ulting measurement that is ba ed on the 
the amount of light absorbed by the sample is called absorbance or optical density (OD) 
(Giesecke J, 2002). 
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Figure 2.5 Spectrophotometer for measuring the intensity of colour for an ELISA test 
Source: Wellcome images 
The OD measurement are tran formed automatically to International Units per millilitre 
(IU/ml) by the a say reader using caJibration equation. The quantity of antibodies is 
expre ed by IU/ml. The 00 tran formation method and reason why thi is nece sary are 
explained in detail in Chapter 9. 
The method described above i a ummary of a variety of techniques that use enzyme-
linkage, and are all different variation of the ELISA assay method described above. 
Antigens can be detected directly from the pecimen, or once an organism is cultured 
outside the body i.e. in vitro. ELI A assays manufactured by a number of companies were 
used during the ESEN2 project. 
The neutralisation test (NT) i u ed for determining the presence or ab ence of pathogen 
Serum amples are mixed with the viru and ub equently incubated in the pre ence of a 
susceptible cell type. If antigen- pecific antibodie exi t in the serum, they will bind to the 
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virus, thereby blocking viral infection in the susceptible cells. The level of infectivity is 
then measured (Nelson KE & Masters Williams C, 2007). 
Since the NT is only able to detect the presence or absence of infection, quantification of 
such results is only possible with the use of serial dilution. The assay is initially conducted 
with the undiluted serum sample (dilution I: I). In the case of a "positive" result the 
sample is further diluted (i.e. dilution I: 2). If the sample is still positive, further serial 
dilutions are carried out until a negative result is achieved. The highest dilution producing 
a positive reaction is called the titre (Giesecke J, 2002). For the ESEN2 project, the NT 
was the preferred assay by most laboratories to measure specific diphtheria toxin 
antibodies. 
An example of the NT is shown in Table 2.1, where a sample was tested positive (dilution 
I: (28), and was subsequently further diluted (dilution I: 256). The titre is defined as 128 
which is the inverse of the last dilution at which a positive result was observed. 
Table 2.1 Example of serial dilution 
Dilution serum result 
1: 8 + 
1: 16 + 
1: 32 + 
1: 64 + 
1: 128 + 
1: 256 
Although the titre takes the value of the highest positive dilution, in theory the sample may 
become negative at any time between the highest positive and the negative dilution. For the 
example given in Table 2.1, this would mean that the sample may have become negative at 
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any dilution level between the interval (128, 256] and therefore, the true titre lies in 
between these two values. Although in practice this is seldom a problem, an example in 
which an adjustment was made to specify the true titre is presented in Chapter 5. 
Serial dilutions can quantify binary assay results resulting in a "semi-quantitative" format. 
An example of a frequency distribution is given in Table 2.2 where the Luxembourg 
national laboratory tested 146 sera against diphtheria antigen using the NT assay. Note that 
the measurements shown are not from a random population sample but were selected in a 
way to include measurements ranging from negative to high positive. 
Table 2.2 Distribution of 146 sera from Luxembourg tested against diphtheria using 













Due to the exponential nature of serological data, it is common practice to transform such 
results using logarithms. A logarithmic transformation of base 10 was applied to all 
serological data for the ESEN2 project, and this was also the practice for the analysis 
presented in this thesis. 
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2.3 Vaccines 
To be effective, a vaccine needs to produce considerable humoral and cell-mediated 
immune responses and provide protection for several years; if not for a lifetime. 
Essentially there are two main types of vaccines: (a) Live organisms that have been 
artificially weakened (attenuated) and (b) inactive organisms that are either whole or 
fractioned. 
(a) Live attenuated vaccines 
Attenuated bacteria and viruses are infective but non-pathogenic, and are produced by 
culturing pathogenic strains in vitro or in unnatural hosts, aiming to discover strains with 
restricted virulence growth in humans. Live attenuated vaccines provide strong immunity 
that tends to persist for a long time after vaccination, due to immunological memory, and 
have the advantage of producing both humoral and cell-mediated-immunity. A 
disadvantage of such vaccines is the likelihood of adverse effects, since they are poorly 
tolerated by immunocompromised individuals. In addition, live vaccines must be carefully 
stored and refrigerated to maintain their activity. Examples of live attenuated vaccines are 
measles, mumps and rubella (Nelson KE & Masters Williams C, 2007;Davies DH et at., 
1999). 
(b) Inactivated vaccines 
Inactivated vaccines use viruses and bacteria that have been killed by heat or chemicals. 
Otherwise inactivated vaccines may use purified components of the organisms (Nelson KE 
& Masters Williams C, 2007). The advantage of these vaccines is that they don't need to 
be refrigerated. The disadvantage is that they do not produce an antibody response as 
strong or as long lasting as live vaccines. As a result, several booster doses may be needed 
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to reinforce the antibody response (Davies DH et al., 1999). An example of an inactivated 
vaccine is the hepatitis A vaccine (Nelson KE & Masters Williams C, 2(07). 
Apart from the traditional vaccine types described above, over the last two decades there 
has been much interest in a new type of vaccine, the recombinant vaccine. This involves 
the genetic manipulation of organisms to create either active or inactive vaccines (Nelson 
KE & Masters Williams C, 2007). 
2.4 Prevalence and incidence definitions 
As defined in the previous Chapter, prevalence is the number (or proportion) of current 
cases of a disease in a given population at a specific time (Mosby, 2009). Seroprevalence, 
on the other hand, is the number (or more usually, the proportion) of individuals with a 
serological marker of infection at a specific time. Thus, seroprevalence is defined like 
prevalence, but its interpretation in terms of disease or infection can be quite different, 
depending on the marker. The serological markers considered in this thesis are quantitative 
measurements that have been dichotomised as positive or negative. 
As mentioned earlier, IgM antibody type appears in the serum for a limited period of time 
following the infection, and therefore, its presence indicates recent infection. IgG antibody 
is used as evidence of recent or past infection since it sometime peaks later but remains in 
the serum for a long period of time (Giesecke J, 2002). 
Figure 2.6 shows the rubella IgG and IgM levels after the onset of symptoms. Both IgG 
and IgM levels rise about the same time but IgM levels rapidly decrease to their previous 
levels after approximately a month. Therefore, a positive IgM provides evidence of recent 
(or current) infection, whereas a positive IgG can either mean current or past infection. 
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Source: PhD thesis titled ''The seroepidemiology of rubella in pregnant women in 
North Thames" (Hardelid P, 2008) 
For the antigens included in the ESEN2 project the serosurveys were tested against IgG 
specific antibodies. An exception was HBV which is associated with a number of different 
antigens (Mims C e/ ai., 1998). Samples were tested for antibodies against Hepatitis B core 
antigen (anti-HBc), Hepatiti s B sLllface antigen (anti-HBs) as well as Hepatitis B surface 
antigen (HBsAg). Interpretation of these assays is more complex and is beyond the scope 
of this project. 
As mentioned earlier, for many infections, naturally-induced high IgG antibody levels 
remain in the blood for many years after the infection, waning little with time, and for 
many pathogens, natural infection can be assumed to provide lifelong immunity (Vyse AJ 
et ai., 2006). Therefore, given this assumption is valid, testing for IgG antibodies results in 
seroprevalences that cover both recent and past infections. 
Incidence and prevalence (and seroprevalence) are related. Incidence can be estimated by 
comparing seroprevalence estimates in time (Giesecke J, 2002). For example, incidence 
estimates can be produced by comparing the seroprevalence estimates between the original 
ESEN project, and ESEN2 that was carried out a few years later. Under appropriate 
assumptions, incidence estimates can also be obtained from a single seroprevalence survey 
(Farrington CP, 1990). 
2.5 Estimating population prevalence using serosurveys 
Population seroprevalence estimates can be achieved after grouping the serological results 
into positive (current or past infections) or negative (susceptible). These can be obtained by 
applying a cut-off to the quantitative serological measurements. There are different 
methods for estimating such cut-offs, and well-conducted seroepidemiological studies are 
expected to include details of how they were calculated (Giesecke J, 2002). 
The example in Figure 2.7 shows the distribution of antibody titres as separate 
components, one corresponding to current / past infections, and another to non-infected 
individuals. These distributions are only hypothetical since the true status of the 
individuals is unknown. Serological measurements higher than the cut-off value were 
classified as positive whereas those lower as negative. 
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Mixture modelling is a method that has been used in the past to estimate population 
prevalence from serological data (Gay NJ, 1996). The principle is based on a mixture of 
component distributions for distinct underlying population groups. Using this method it is 
possible to distinguish between high IgG levels attributed to current or past infections, and 
low antibody levels attributed to non-infected and therefore, susceptible individuals. The 
proportion of individuals falling in each component can then be estimated. Using the same 
example as above (Figure 2.7), the proportion of past / recent infections will be equivalent 
to seroprevalence. Mixture models will be discussed in detail in Chapter 7. 
2.6 Estimating seroprevalence for a population under an existing vaccination 
programme 
Estimation of seroprevalence becomes more complex when part of the population has been 
vaccinated. This is subject to several factors such as the vaccine type (e.g. live or 
inactivated), the vaccine dose, the individuals' characteristics (age, socioeconomic status, 
state of the immune system, genetic factors etc) and the vaccine schedule (timing and 
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number of doses). Antibody responses to vaccination are often lower than those resulting 
from natural infection. Moreover, vaccine-induced IgG levels may wane with time, with 
the degree of decrease varying greatly between different vaccine types and antigens 
(Giesecke J, 2002;Vyse AJ et ai., 2006). Potentially, this means that part of the vaccinated 
population may become susceptible to an infectious disease after a period of time. 
Outbreaks among popUlations with high vaccine coverage that were previously considered 
to be protected confirm this. Such examples include the recent mumps outbreak among the 
Jewish community of New York, the pertussis outbreak in the Netherlands and the 
diphtheria outbreak in the ex-Soviet Union states during the I 990s (de Melker H et ai., 
1997;Hardy IR et ai., I 996;Centers for Disease Control and Prevention, 2010). 
Figure 2.8 depicts three hypothetical titre component distributions for a population with an 
existing vaccination programme. Between the components of past / current infections and 
non-infected individuals, a third component reflects the group of vaccinated individuals. 
As before, mixture modelling allows for an estimation of the proportion of individuals 
falling into each component. In this case a seroprevalence definition would include both 
groups of current / past infections and vaccinated individuals. 
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2.7 Correlates of protection 
The measurable quantities in the immune system that correlate with protection against an 
infection or disease are called Correlates of Protection (CoP). The identification of such 
proxy measures is significant for vaccine development, since they are employed to 
estimate the proportion of seroconverters as a result of vaccination (i.e. the proportion of a 
vaccinated group that acquires protection after vaccination), and hence, the reduction in the 
disease incidence following vaccination, called vaccine efficacy (VE) (Note the difference 
between the terms VE and vaccine effectiveness mentioned earlier; the former is estimated 
from clinical trials and therefore does not include the vaccine's indirect effect i.e. its ability 
to reduce the spread of infection in the popUlation). Often vaccines have excellent efficacy 
records based on empirical observations, without a clear understanding of the immune 
system mechanisms of protection (Lambert PH et ai., 2005;Plikaytis BD & Carlone GM, 
2005;Qin Let aI., 2007). 
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For the diagnostic assays included in the ESEN2 project (mainly ELISA and NT), 
antibodies were used as CoP. Research in the past has shown that for most (but not all) 
vaccines, prevention of infection correlates well with specific antibody response. An 
example of such a study was published in 1990, including schoolchildren tested for 
measles prior to an outbreak. It was shown that in general, antibody titres above a specitic 
value correspond to protection. although occasionally cases occur in individuals who have 
previously been infected (Chen RT et al., 1990). For some infections there are no known 
serological correlates of protection. This is arguably the case, for example, for pertussis 
infection. 
The relationship between protection and antibody production is often more complex than 
simply the level of serum antibodies. For example, it may be important for antibodies to be 
present at the site of virus replication, or have the ability to affect multiple strains of a virus 
or viruses that may potentially mutate (Plotkin SA, 20 I 0). Moreover, immunological 
memory should be generated in such a way that in the case of infection recurrence a 
sufficient number of antibodies will concentrate rapidly around the site of the pathogen 
(Lambert PH et al .• 2005). 
In conclusion, one of the assumptions used in the ESEN2 project was that of a high 
correlation between antibody response and protection. This assumption will be assumed to 
hold for this thesis hereafter. Although this assumption is believed to generally hold for the 
antigens included in the project (with the exception of pertussis), the relationship between 
antibody response and protection may not be so strong for some antigens such as mumps 
where outbreaks have been recorded for highly immunised populations (Centers for 
Disease Control and Prevention, 20 I 0). 
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2.8 Seroprevalence is not always equivalent to proportion protected 
As mentioned in the previous Chapter, the main aim of the ESEN2 project was to identify 
susceptible cohorts in the population, or inversely, to recognise the proportion of 
population "protected" against a particular disease. For an unvaccinated population the 
proportion of past / recent infections should equal seroprevalence, assuming life-long 
immunity following infection. However, there are a number of different factors that can 
affect the performance of diagnostic assays, which means that seropositivity and protection 
may not always be equivalent. 
The performance of an assay test can be assessed by calculating sensitivity and specificity. 
Sensitivity is defined as the proportion of individuals that have high antibodies to be 
recognised as such by the test, whereas specificity is the proportion of individuals that have 
low antibodies to be recognised as such by the test (Ades AE, 1990). By re-estimating the 
assay cut-off, either of these quantities can be increased at the expense of the other i.e. it is 
not possible to improve both sensitivity and specificity simultaneously. A key issue on 
defining an assay cut-off that achieves an optimal balance between sensitivity and 
specificity depends on whether the assay is designed to be used for individual diagnosis or 
for epidemiological purposes. This will be discussed in detail in Chapter 8. 
Apart from the cut-off definition there are other factors that determine immunity which the 
marker may not capture. Antibody cross-reactivity is defined as the ability of antibodies to 
react with more than one antigen (Male D et aI., 2006). Cross-reactivity can become a 
problem with respect to diagnostic assays, since it can produce evidence of antibody 
reaction, even when little or no antibodies exist for a specific pathogen. Although cross-
reactivity can be evaluated for assays such as ELISA, it may be possible that it is an issue 
for some diagnostic tests and antigens included in the ESEN2 project (Ndumbe PM & 
Lvenisky RJ, 1985). 
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Finally, previous studies have shown that antibody levels wane with time, depending on 
the antigen and whether the response is induced by natural infection or vaccination. As 
mentioned earlier for natural infections, antibody levels stay generally stable with time, 
however vaccine-induced immunity often wanes rapidly (Vyse AJ et aI., 2006). This can 
produce a number of measurements that are borderline between negative and positive, 
without it being possible to distinguish whether these individuals are truly protected. 
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Chapter 3: Aims and objectives 
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3.1 PhD project rationale 
This thesis is largely based on the ESEN2 project, from where it drew its general aim and 
material. However, it needs to be viewed as an extension of the ESEN2 project. since -
with the exception of the formalisation of the standardisation methodology shown in 
Chapter 4 that was used during the project - the work carried out for this thesis was beyond 
the scope of the project. 
As was also mentioned in Chapter I, it is possible to identify susceptible groups within the 
population by using serological data. In the short term, these groups can be specifically 
targeted by booster campaigns so as to prevent future outbreaks and limit the spread of the 
infection. In the long term, serological information can be used to evaluate and improve 
vaccination programmes. International studies based on population serological data allow 
for comparisons of the levels of immunity in different populations to be made along with 
the assessment of different vaccination strategies. 
As mentioned in Chapter I, the ESEN2 project aimed to achieve comparable 
seroprevalence estimates across Europe. Validating the methods used during the ESEN2 
project for harmonising serological outcomes is a crucial aspect of this overarching aim. 
Furthermore, it is important to compare the method employed for ESEN2 with alternative 
seroprevalence estimation techniques aiming to achieve improved methods that could 
potentially be used in future seroepidemiological studies. 
3.2 Overall aim 
The overall aim of this thesis was to formalise, validate and further develop the 
methodology used for the ESEN2 project for harmonising serological results, and to 
propose alternative methods for achieving comparable population seroprevalence estimates 
across Europe. 
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3.3 Specific objectives 
Specific objectives of this work are the following: 
1. To develop a statistical-based algorithm for implementing the standardisation 
methodology. 
2. To further develop the standardisation algorithm by taking into account issues such as 
censored data. 
3. To assess the impact of the standardisation method on seroprevalence. 
4. To examine and quantify the sources of variability arising from laboratory testing such 
as the between-laboratory and between-assay variability. 
5. To compare the standardisation methodology with an alternative method of 
seroprevalence estimation (mixture modelling). 
6. To assess the effect of the assay cut-oils on seroprevalence estimation and to suggest 
methods for re-estimating cut-offs suitable for seroepidemiology. 
7. To investigate the impact of plate-to-plate variability on seroprevalence estimation. 
3.4 Statistical methods 
A number of statistical techniques have been used throughout the thesis. However, their 
implementation will not be presented in a separate "methods" Chapter. Instead each 
statistical tool will be introduced when appropriate. 
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A list of the statistical tools introduced in the next Chapters is given below: 
Censored regression 
Different types of censored regression models were used to obtain standardisation 
equations as an alternative to the regression models used for the ESEN2 project (Chapter 
5). 
Multiple imputations 
Standardisation equations were obtained from models using a method of multiple 
imputations to account for censored data (Chapter 5). 
Non-parametric test for censored data 
A non-parametric test was used to indicate whether standardisation was valid to use in 
certain cases of censored serological data (Chapter 5). 
Mixture models for seroprevalence estimation 
Different types of mixture models were used, varying the distribution of the underlying 
components, to estimate seroprevalence from the non-standardised serosurvey results 
(Chapter 7). 
Mixture models for cut-off estimation 
A method was developed based on mixture models that included cut-off re-estimation for 
obtaining seroprevalences (Chapter 8). 
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Mixture models for investigating plate-to-plate variability 
Different methods based on mixture modelling were used to investigate and adjust the 
effect of plate-to-plate variability on population seroprevalence (Chapter 9). 
A summary of the Chapters to follow, along with a description of how the statistical 
methods described above were used, is given in the following Sections. 
3.5 Developing further the standardisation methodology 
As explained in Chapter I, the method of standardisation was used in the original ESEN 
project to transform each country's quantitative serological results into a comparable 
outcome, based on standardisation equations derived from testing a panel of sera by each 
national laboratory (Andrews N et al., 2000;Nardone A & Miller E, 2004). 
As part of this thesis, the standardisation methodology used for the original ESEN project 
to account for issues such as outliers, censored data and selecting between different types 
of standardisation equations was formalised, and a statistical-based algorithm was 
established (Chapter 4). This algorithm was subsequently used throughout the ESEN2 
project for standardising the serological results into common units. 
One aspect of the methodology that was further investigated was the effect of censored 
observations on the standardisation equation. For many serological assays no quantitative 
results were reported if they were outside the assay detection limits. Such observations 
were treated as censored and were taken into account during the ESEN2 project analysis 
using a method of simple substitution. The validity of the simple substitution method, as 
well as other methods such as censored regression and multiple imputation, were 
investigated using simulations. A non-parametric test was proposed for censored data on 
the x-axis (Chapter 5). 
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3.6 Impact of standardisation on seroprevalence 
Once a standardisation equation had been selected. it was used to transform thc scrosurvey 
data tested within each national laboratory into common units as dcfincd by thc refcrcncc 
laboratory assay. The transformation of the serological results was a way to correct for the 
between-laboratory and between-assay variability. The impact and scale of the different 
sources of variability on national seroprevalence were assessed by comparing the 
standardised with the non-standardised estimates (Chapter 6). 
3.7 Mixture models 
An alternative method for estimating population seroprevalence is the application of 
mixture models. Using this method. the standardisation of serological results can be 
bypassed altogether since mixture models can be applied directly on the non-standardised 
results. Several types of mixture models were fitted, and a comparison between 
standardisation and mixture model seroprevalence estimate results was carried out. The 
advantages and disadvantages of each method are discussed in Chapter 7. 
3.8 Assay cut-offs 
For the ESEN2 project, once the serosurvey results had been standardised, they were 
classified into positive or negative according to a cut-off point. As a consequence of this. 
the definition of the assay cut-off was very important. since it influences the classification 
of samples, and therefore, the estimated national seroprevalence. For the purposes of the 
ESEN2 project, the assay cut-off as defined by the assay manufacturer of the reference 
centre was used. In Chapter 8, the validity and impact of these cut-offs on the national 
seroprevalence are examined. Alternative methods for cut-off estimation are also examined 
based on ROC curve analysis and mixture modelling. 
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3.9 Plate-to-plate variability 
Using standardisation it is possible to adjust for between-laboratory and between-assay 
variability. However, a certain amount of variability would still be present, even if samples 
were tested using a unique assay within the same laboratory. Some of the unexplained 
variability could be attributed to the fact that not all the samples were tested 
simultaneously but batches of them were placed and tested on different plates. In Chapter 
9, the methods currently used for adjusting for plate-to-plate variability are validated. Also 
their impact on estimating population seroprevalence is examined and a method to adjust 
for this variability using mixture modelling is shown. 
3.10 Statistical software 
The main statistical software that was used for the data manipulation and analysis was 
Stata (StataCorp. Stata statistical software: releases 10.1, 11.0 and 11.1. College Station, 
Tex.: Stata Corporation, 2001). The censored regression models, the non-linear regression 
equations and the mixture models were all fitted using the maximum likelihood estimation 
command ml in Stata. Some general types of censored regression models programmed in 
Stata are given in Appendix I(A). An example of a programme for multiple imputations is 
shown in Appendix I(B), whereas a mixture model example is given in Appendix I(C). 
Note that Stata uses the Newton-Raphson algorithm for optimisation. 
The optimize command in R statistical software was used for cut-off estimation in Chapter 
8 (The R Development Core Team. R: A language and environment for statistical 
computing. Vienna, Austria, R Foundation for Statistical Computing. Version: 2.10.1) 
(Brent R, 1973). An example of a cut-off estimation programme in R is given in Appendix 
1(0). 
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For all the models fitted and presented in this thesis a number of different starting values 
were tried, in order to check the validity of the convergence. Despite changing the starting 
values, the models fitted generally converged to the same point which supports the 
robustness of the maximization procedure. Prior to fitting complex models such as the 
mixture model shown in Chapters 7,8 and 9, simpler, more robust models were fitted and 
their estimates used as starting values for the more complicated models. 
In addition, the same models were fitted using alternative commands or software to check 
the model fit. For example, linear censored regression models were fitted using both the ml 
command and the built-in cnreg command in Stata (part of the official software up to 
version I 1.1). 
All figures included in the thesis were constructed using Stata, whereas Microsoft Excel 
was used for the tables. 
3.11 Data source 
The data that are presented throughout this thesis were collected as part of the ESEN2 
project. Permission has been granted to the author by the members of the ESEN2 group to 
use this data. 
3.12 Publications arising from the thesis 
The author started working on the ESEN2 project in January 2002 (the project officially 
started in 2(01), whereas registration for the PhD thesis commenced two years later, in 
January 2004. The work carried out for the purposes of this thesis is closely related to that 
of ESEN2. Although the methodology for the ESEN2 project was mainly defined at the 
beginning of the project, subsequent work was influenced in some degree by the findings 
of this PhD thesis. 
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A peer-reviewed paper was published based on material presented in Chapter 2. Two 
further papers were published as part of the ESEN2 project, but were influenced by work 
carried out for this thesis (Appendix II). Parts of the thesis were also presented in a number 
of conferences and seminars. 
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Chapter 4: Standardisation of serological results 
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4.1 Comparability of national seroprevalence estimates 
The ESEN project aimed to compare and assess different vaccination strategies across 
Europe by identifying susceptible cohorts. In order to achieve this, age-specific 
seroprevalence needed to be estimated for each country which meant that comparable 
serological results were essential. 
Although there was an effort to use the same assays at different national laboratories, this 
was not possible in practice because commercial assays were not available everywhere, 
and laboratories preferred to use assays they were most familiar with. Given the variety of 
assays used in the end, the resulting serological outcomes were not comparable between 
national laboratories. Furthermore, even in cases where the same assays were used the 
results were often still non-comparable due to differences in laboratory techniques and 
operating procedures. 
One solution that would have enabled direct comparisons among serological results from 
the different national serosurveys, would be to test all samples in the same laboratory. 
Unfortunately, this was not possible during the ESEN projects given that large numbers of 
samples that needed to be tested. Moreover, one of the objectives of the projects was to 
develop a laboratory and epidemiology network of experts. As a result, it was necessary to 
develop a method for standardising serological results. 
The algorithm described in this Chapter was used to standardise the ESEN2 serological 
results and is based on the methods initially used for the original ESEN project (Andrews 
N et al., 2000). The algorithm takes into account issues such as the type of equation to be 
selected for standardisation, extreme observations that need to be investigated and results 
outside the quantitative range of the assay (Kafatos G et ai., 2005). 
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4.2 An example comparing seroprevalence 
An example is given to demonstrate the incompatibility of the serological results (and 
hence, of the seroprevalence estimates) arising from the differing laboratory methods. Age-
specific seroprevalence for VZV was estimated for Italy and the Netherlands after their 
laboratories used assay methods of their choice to test the national serosurveys. 
In the Netherlands, the serosurvey conducted in 1998 included the collection of 1176 age-
stratified samples. The assay method used was Human (Instruchemie bv). The resulting 
quantitative measurements were classified into positive or negative according to a cut-off 
of 0.3 IU/ml as set up by the assay manufacturer. The Italian national serosurvey consisted 
of 2446 age-stratified samples collected in 1996. An Enzygnost assay was used with assay 
cut-off 0.05 IU/m!. 
After testing the samples and grouping the resulting quantitative measurements into 
positives and negatives, the seroprevalence of VZV was estimated for each age group. 
Figure 4.1 shows the age-specific seroprevalence for Italy and the Netherlands. The 
seroprevalence for Italy was estimated to be much lower than the Netherlands for all age 
groups. However, it is unclear whether the difference observed represents a true 
seroprevalence difference resulting from genetic or environmental factors or whether it is a 
result of the different assay methods used. 
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Figure 4.1 Age-specific seroprevalence estimates of VZV antibody for the 
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A way to overcome the issue of non-comparable outcomes is to standardise quantitative 
serological results into common units. The method consists of constructing a small panel of 
sera by a reference country that can then be sent and tested by each national laboratory. 
Based on the panel results, regression equations can be selected to standardise each 
national serosurvey's results into common units. 
4.3 Panel construction 
At the start of the ESEN2 project, for each antigen, a reference laboratory prepared a 
standardisation panel consisting of approximately 150 samples. There were no formal 
sample size calculations for this, but it was chosen in a way to ensure that there were 
enough samples throughout the quantitative range of the assay from negative and equivocal 
(or low positive), to positive samples. Although a smaller sample size would probably be 
sufficient for most assays, a larger sample size was used to ensure there were enough 
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samples even for poorer assays with high variability. A list of the reference laboratories for 
each antigen is given in Table 4.1. 
Table 4.1 Reference centres and assay methods used for testing the standardisation 
panels for each antigen 
Antigen Reference laboratory Country Assay method 
Measles Robert Koch Institute (RKI) Germany Enzygnost ELISA 
Mumps Robert Koch Institute (RKI) Germany Enzygnost ELISA 
Rubella Robert Koch Institute (RKI) Germany Enzygnost ELISA 
Pertussis University of Palermo (UoP) Italy In·House, ELISA 
Diphtheria Istituto Superiore di Sanita (ISS) Italy DA-DELFIA 
Varicella Zoster Virus Instituto de Salud Carlos III (ISCIII) Spain Enzygnost ELISA 
Hepatitis A virus National Retrovirus Reference Centre Greece Abbott (AxSYM) 
Hepatitis B virus National Retrovirus Reference Centre Greece AxSYM AUSAB 
The reference laboratory tested the panel at least twice, and the geometric mean of these 
test results was taken to reduce the test-to-test variability for the reference centre. The 
panel was subsequently sent to each participant laboratory where it was tested by the assay 
method of their choice (Andrews N et al., 2000). 
4.4 Comparison of first and second panel test results 
The standardisation panels were also tested twice by the participant laboratories. The aim 
of the first test that was carried out at the beginning of the project was to ensure that all 
assays performed adequately. Any major problems with the assay methods used were 
detected and amended at this stage of the project. 
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The panel was tested for a second time at a later stage, halfway through testing the 
serosurvey, and these second panel results were used for the selection of the 
standardisation equation. 
The two test results allowed potential changes of the serological measurements over time 
to be investigated. This was examined using the following three methods: 
(a) A scatter-plot was produced to investigate the relationship between the two sets of 
results. 
(b) A paired t-test was used to test for the presence of a systematic bias. 
(c) A Bland-Altman plot was constructed to show potential systematic bias and identify 
possible outliers. The differences between the two test results were plotted against their 
means following logarithmic transformation. Assuming the mean difference between the 
test results is estimated as li" and the standard deviation of the differences as 8" ' we 
would expect most differences to lie between the interval ,I" -1.968" and p" + 1.968" 
(Bland JM & Altman DG, 1986). 
In an example comparing the first and the second VZV panel tests for Finland, the slope 
estimate of the regression line was 0.99 with a 95% confidence inten;al (el) oflO.96, 1.02] 
which includes the line of equivalence. The Bland-Altman plot showed that the mean 
difference was close to zero, so there was little evidence of overall bias (figure 4.2a). 
Figure 4.2b shows an example of HA V panel test results for Belgium, where the difference 
between the two tests was found to be significant. The regression slope did not include the 
line of equivalence (estimate = 1.03; 95% CI: [1.0 I, 1.04]). The Bland-Altman test showed 
that the second test gave consistently higher measurements than the first, and also that the 
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differences seem to increase for high values. The regression slope for the Bland-Altman 
test was estimated as -0.03 (95% CI: [-0.04, -0.02]). 
Figure 4.2 Comparison between first and second panel tests 
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The analysis comparing first and second tests of the panel often showed statistically 
significant differences as it was shown in the HA V example above, However, unless there 
had been a change in assay methodology, or a problem with the first test of the panel, these 
differences were usually small and reflected normal run-to-run assay variability, Such 
differences would not greatly affect the standardised results. In case of the differences 
being large and there being no clear problems with the first test, a third testing of the panel 
was undertaken. 
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4.5 Selecting standardisation equations 
Once the second panel was tested by both the reference centre and the testing laboratory, 
their loglo-transformed results were regressed (testing laboratory results were regressed 
against the reference laboratory results), and an equation was produced to be used for 
standardising the serosurvey results. 
be defined as: 
v = g(x)+c = R(J + RIX +P,x~ + ... + p,xk +c, '" , I I IJ, /.1 I ... , Ii,' I 
Equation 4.1 
where i = 1, ... , n index the sampled observations, y; is the response variable, X; the 
explanatory variable and c; the error term for k + I parameters. The error is assumed to be 
identically and independently normally distributed with zero mean and constant variance 
The fitted values are given by: 
Equation 4.2 
where Po' PI " .. , A are the parameter estimates estimated by maximum likelihood. 




As an example, the VZV panel was tested by both the Belgium and the Spanish reference 
laboratory using Enzygnost ELISA assays. The Belgian results were regressed against the 
Spanish data using a quadratic model determined by the prediction equation of the form: 
Equation 4.4 
which in this example becomes: 
where i = I, ... , 119, x; are the logro-transformed measurements given by the reference 
laboratory and y; are the predicted logro-transformed Belgian results. 
A number of issues needed to be considered for estimating standardisation equations. 
These are the following: 
(a) The type of equation selected. In the example above a quadratic equation was used but 
other types may be considered, which means that a robust selection method is necessary. 
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(b) Extreme observations need to be flagged as outliers and corrected if wrong (e.g. due to 
errors occurring during data entry or laboratory procedures) or otherwise excluded from 
further analysis. 
(c) An issue common with serological assays is the existence of a detection range within 
which observations are given in a quantitative form. Any measurements outside this range, 
say (DL, Du), are depicted as "< DL" or "> Du" if they are below or above, respectively. 
For example, the Spanish laboratory tested their panel for VZV using an assay with 
detection range between 0.002 and 6.62 IU/mI. This meant that quantitative results were 
returned for 124 samples (85%), 19 samples (13%) were recorded as "< 0.002" and 5 (3%) 
as "> 6.62 IU/ml". 
The following three Sections explain in detail how these issues were taken into account in 
the analysis that was carried out as part of the ESEN2 project. 
4.6 Outlier investigation 
After plotting each country's outcomes against the reference laboratory's results, one or 
more observations were sometimes considered extreme compared to the rest of the data. 
These potential outliers were investigated, and any errors that occurred during the panel 
testing, data entry or data manipulation were corrected. If any extreme measurements could 
not be attributed to any obvious error, it was assumed that an error had occurred during the 
laboratory testing, and they were omitted from further analysis. A statistical procedure was 
defined to decide which results had to be excluded. 
Once a linear regression equation of the type shown in Equation 4.1 was fitted, the 
standardised residuals Zi were calculated as shown in Equation 4.5. 
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Equation 4.5 
where 0- is the maximum likelihood estimate of the standard deviation (j (Armitage P & 
Berry G, 1994). 
Any observations with Zi outside the range of ±3 (approximately I % of the data) were 
considered outliers and were excluded from further analysis. This step was repeated with a 
more relaxed exclusion criterion of ±4. A two-step analysis was chosen to avoid a high 
number of iterations. A wider range was used on the second iteration to minimise the risk 
of too many samples being dropped as outliers. The maximum number of points dropped 
as outliers was set as 5% of the total samples. In cases where more points were flagged as 
outliers, the more extreme 5% of the data were dropped. However, such a large number of 
outliers did not occur in any of the panel comparisons on the ESEN2 project. 
An example using the measles sample results of Lithuania regressed against the German 
reference centre's results is given (both laboratories used Enzygnost ELISA assays). A 
quadratic equation was initially fitted and the standardised residuals were calculated. The 
standardised residual was outside the ±3 range for one observation and is highlighted in 
Figure 4.3(a). This observation was omitted and the model was re-fitted. Using a wider 
criterion for the standardised residuals of ±4, there was one additional observation that was 
borderline defined as outlier and was also omitted (highlighted in Figure 4.3(b). 
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Figure 4.3 Outlier investigation for Lithuanian measles results regressed against the 
Germany reference centre 
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4.7 Selection of regression model 
When selecting a regression model to be used for standardisation, the main aim was to 
choose a line that fits the data well. In addition to this, there was particular interest in the 
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area surrounding the negative / positive cut-off point. It was essential to obtain a good tit 
there, since serosurvey samples with serological results around the positive / negative cut-
off are the main candidates for misclassification. 
Evaluating the model fit 
Once the regression model was fitted, the strength of the line relationship or the proportion 
of data eX\l\ained b'y \ne model was quantified b)' the coeffrcielll of determination R2 
defined as: 
L(Y;-YY 
R2 = 1--::'=" ---L(Y; -y)2 ' 
Equation 4.6 
where y is the mean of the data. 
Based on data from the original ESEN project and the inherent variability of different 
assays, an R2 of 0.80 or higher was considered to be "satisfactory" for the standardisation 
to take place. However, R2 as low as 0.75 were also considered, especially for mumps or 
pertussis assays, for which there is higher variability due to weak correlates of protection 
(Andrews N et a/., 2000;Giammanco A et aI., 2003;Kafatos G et at., 2005). 
Type of regression model 
A straight and a quadratic line equation were compared and, for parsimony, the simplest 
was sought i.e. simple linear regression was used unless there was significant evidence at 
the 5% level that the quadratic term was providing a better fit. In a few cases where there 
was a clear lack of fit around the critical area of the positive-negative cut-off, other models 
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were considered such as a cubic or sigmoid model (an example of a sigmoid model is 
given below). 
Figure 4.4 shows an example of Slovakian measles panel results tested using a Virotech 
ELISA assay regressed against the German reference centre's results that used an 
Enzygnost ELISA assay. Both the linear and the quadratic curves are shown. Since the 
quadratic term was not significant, the simple linear regression model was chosen as the 
standardisation equation (linear regression t-test; p = 0.16). 
Figure 4.4 Comparison between linear and quadratic curves for the standardisation 
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In another example, the Czech Republic HA V panel is plotted against the Greek reference 
centre's results (Figure 4.5(a)). Unfortunately, the panel appears to have very few 
measurements around the assay cut-off of 0.01 IUlml or -2 on the 10glO-scale where the fit 
matters most. This means it is quite difficult to estimate with precision the shape of the line 
around this area, and this could result in a high number of misclassifications when 
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applying the standardisation equation to the national serosurvey data. In this case the 
quadratic term is significant (p < 0.00 I). However, with the little information that is 
provided, it is clear that neither the linear nor the quadratic curves fit the data well around 
the crucial cut-off points. Hence, a sigmoid curve of the following type was proposed 
instead: 
)'=(1.+ p. +c 
I I ·1"+,'" ) i ' +e' , 
Equation 4.7 
where a, p, y, JE 9\ are constants and Gi - N(0,(J2) (Figure 4.5(b». Note that for the 
function y(x) = (J. + p., the lower horizontal asymptote is lim (y(x») = (I. and the 1+ e-(:,+,)·t) .,-+~ 




Figure 4.5 Comparison of different regression lines for the HA V panel tested by the 
Czech Republic and Greece laboratories 
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4.8 Effect of results outside the assay detection range 
As mentioned earlier, many serological assays do not return quantitative results outside a 
specific range bound by detection limits. Although this has little effect for a patient's 
diagnosis, it can be a disadvantage for seroepidemiological studies, where all information 
is important. Such limited observations, where the only information available is whether 
their true value is below or above the detection range, are called cl'Il.WJrn/ data. Censored 
data are formally defined and discussed extensively in the next Chapter. 
During the ESEN2 project, laboratories were encouraged to report quantitative results 
during the standardisation panel testing, however, in practice, this was not always possible. 
For analysis purposes, any results below the assay detection range (Df., Du) were 
substituted by DL/ 2 whereas any data above were replaced by 2Du (Andrews N el al., 
2000;Giammanco A et ai., 2003;von Hunolstein C el aI., 2000). 
In order to measure the effect of these conventions on the fitted line, two models were 
fitted, before and after excluding these observations. The model including results outside 
the detection range can be expressed as the function y(x;), whereas the model that 
excludes these results as Yc(x). Given that the main interest is around the positive / 
negative cut-off point (say 60), the absolute difference was estimated between the two 
models on that point (i.e. IY(60 ) - yc(60 )1) where .y(c5() is defined as: 
Equation 4.8 
where Po' p) , P2 , ... , A are the parameter estimates of the model including censored data. 
Similarly yc(60 ) is defined as: 
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Equation 4.9 
where fico, ftel"'" ftn are the regression parameter estimates after excluding any censored 
data. 
To make the model difference Iy(<>o) - yc(<>o)1 comparable between different assays, it was 
divided by the range of the observations Yi, i.e. max(Yi) - min(Yi)' The resulting quantity, 
that will be referred to as cut-off ratio (COR), measures the effect the censored data has on 
the regression line and is defined as follows: 
Equation 4.10 
In the cases where the cut-off ratio was less than 0.05, there was little difference between 
the two regression lines and therefore the model based on the substituted censored 
observations was used. For COR> 0.075, the results outside the detection limit clearly 
influenced the model at the positive / negative cut-off, and hence, they were excluded from 
the analysis. Where the COR was between 0.05 and 0.075, the complete dataset was used 
unless the line excluding the censored data clearly improved the fit in the region of the 
positive / negative cut-off. 
The impact of the results outside the detection range of the assay on the standardisation 
equation is shown in two examples. For the example given in Figure 4.6, the results of the 
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Belgian VZV panel testing for VZV were regressed against the Spanish reference centre's 
results. Spanish measurements below the detection range reported as "< 0.002 IVlml" were 
substituted by 0.00 I, whereas those reported as "> 6.6 IUlml" were suhstituted by 13.2. A 
quadratic equation was fitted twice, once using only the quantitative data, and once using 
all the data after substituting the censored observations. The difference between the two 
fitted lines on the cut-off point of 0.05 IU/ml was not considered important (COR = 0.04) 
and hence, the equation including all the observations was selected. 
Figure 4.6 Influence of censored results on the regression line - VZV panel results for 
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In another example, the results of the Slovakian panel testing for anti-HBs (MONOLISA 
antiHBs 3.0) were regressed against the Greek reference centre's results (AxSYM AUSAB 
assay). Seventy-five samples (45%) were below the assay detection range of the Slovakian 
assay and were reported as "< 0.1 units", whereas 15% of Greece assay were reported as 
"< 0.05". From Figure 4.7 it is evident that there are not enough quantitative results 
reported by Slovakia around the cut-off point. The censored data were substituted by 
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"0.05" and "0.025" for the Slovakian and the Greek assays, respectively. The difference 
between the equation using only the quantitative results and the one using all the data after 
substituting censored observations at the reference centre's cut-off point (l0 units), was 
COR = 0.122. Therefore, the equation based only on the quantitative result was selected as 
the standardisation equation (Figure 4.7). 
Figure 4.7 Influence of censored results on the regression line - HBV panel results for 
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4.9 Standardisation algorithm 
The methods used for dealing with outliers, selecting the type of equation and censoring 
measurements were all combined into one algorithm. The reason for this was that the 
methodology needed to be automated for the large quantities of data included in the 
ESEN2 project. 
The flow-chart (Figure 4.8) presents a summary of the standardisation algorithm. Initially, 
potential outliers were flagged, investigated and either corrected or excluded from the next 
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steps of the analysis based on the more complex model (quadratic). The outlier 
investigation was carried first as any changes of the extreme points could affect the 
standardisation equation estimates. Linear and quadratic curves were then fitted and 
compared in order to select the type of the standardisation equation. Finally, the impact of 
censored data on the standardisation equation was assessed and if found to be influential, 
these data were also excluded. 
Figure 4.8 Flow-chart summarising the standardisation algorithm 
Fit quadratic. Remove samples 
ifstandardisedresiduals> 131 
1 
Fit quadratic. Remove samples 
ifstandardisedresiduals> 141 
1 
Fit linear and quadratic models. 
Test the quadratictenn·. 
1 
Fit the model induding only results 
within the detection range. Use COR 
to choose between the two models. 
] 
1. Outlier investigation 
2. Type of model 
3. Effect of results outside the 
detection range 
* Note that in exceptional situations where both the linear and the quadratic curves were 
clearly not appropriate an alternative model was preferred (e.g. cubic or sigmoid). 
4.10 Back-standardisation 
There were occasions when it was not possible to standardise a country's results because 
the serosurvey was tested before the distribution of the panel. An alternative method of 
standardisation was then used named back-standardisation. 
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Following the serosurvey testing, approximately 150 samples were selected from the 
serosurvey after stratifying the results according to titre to ensure that the whole range 
from high positive to low negative were represented. The samples were sent to the 
reference laboratory to be re-tested. The standardisation was then performed in the same 
way as for the standardisation panel. 
4.11 Standardised vs. non-standardised seroprevalence estimates 
To demonstrate the impact of the standardisation equation on estimating seroprevalence 
the previous example of the measles panel tested by Lithuania and Germany is revisited. 
After applying the standardisation algorithm, a fitted quadratic equation of the same type 
as shown in Equation 4.4 was chosen to standardise the serosurvey outcome: 
). = - 0.29 + 1.05x + 0.12x2 , 
• t I I 
where i = 1,. .. , 148, Xi are the 10glO-transformed measurements given by the German 
laboratory and y; are the predicted 10glO-transformed Lithuanian results. 
Figure 4.9 shows that a quadratic relationship gives a satisfactory description of the data. 
However, it is clear that any serosurvey samples classified as "negative" by the Lithuanian 
assay but measured close to the Lithuanian positive / negative cut-off of 0.15 IU/ml 
(shaded area) could be re-c1assified as "positive" by the reference assay following the 
application of the standardisation algorithm. 
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Following the serosurvey testing, the testing laboratory results can be transformed into the 
same scale as the reference laboratory's results. For a quadratic equation. a testing 
laboratory measurement Yo can be transformed to reference centre units Xo as follows: 
Equation 4.11 
A A 
where fio' fil and fi2 are the regression parameters estimated from Equation 4.4. 
Using Equation 4.11, a Lithuanian measurement yo was transformed into the same unit 
scale as the reference laboratory's measurement Xo as follows: 




As an example, a measurement of 0.1 IVlml (or -Ion the logw-scale) which was below the 
0.15 IVlml cut-off by the Lithuanian assay and was initially classified as negative, would 
be transformed to 0.18 IVlml (or -0.73 on the 10glO-scale), and therefore, reclassified as 
positive. 
Figure 4.10 shows the seroprevalence estimates before and after standardisation. A number 
of samples that have been re-classified have been taken from individuals aged between 3 
and 6 years and also 8 and 29 years. The high number of borderline measurements for 
these age groups may reflect the lower antibody response and waning immunity with time 
following vaccination. 
Figure 4.10 Seroprevalence estimates for Lithuania measles results 
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As a second example, the Italian and Dutch serosurveys presented in Section 4.2 are 
revisited. As it shown in Figure 4.11, there is little difference in seroprevalence estimates 
89 
following standardisation. This means that seroprevalence differences can be attributed to 
genuine seroepidemiological disparities instead of difference between laboratory methods. 
Figure 4.11 Age-specific seroprevalence estimates of VZV antibody for the 
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4.12 Conclusions 
This Chapter presented a collection of methods developed to generate equations for 
standardising serological outcomes tested in different laboratories into comparable units. 
Separate techniques for dealing with issues such as selecting the type of equation, outliers 
and measurements outside the assay detection limits, were brought together into one 
automated algorithm to be used for the ESEN2 project (Kafatos G et ai., 2005). Once the 
serological outcome was standardised using this automated routine, comparable 
seroprevalence estimates were produced. 
There are a number of reasons as to why seroprevalence estimates differ following 
standardisation and sample re-c1assification. This can be due to variability of the 
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serological measurements occurring when samples are tested by different assays or 
laboratories. In addition, higher variability can be expected from assay tests of specific 
antigens which may be due to cross-reactivity as explained in Section 2.8. An attempt to 
quantify the impact standardised results have on seroprevalence estimation and to examine 
the impact of the factors above will be presented in Chapter 6. 
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Chapter 5: Cens()Ted Serological Data 
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5.1 Assay detection limits 
As discussed in the previous Chapter, one important issue that affects standardisation 
equations is that many serological assays are constrained by detection limits (DL). One 
reason for setting a detection range could be the failure of instruments to detect levels 
below or above certain values (say DL and Du, respectively). A lower threshold is common 
for immunoassays such as the ELISA that require antigen concentrations sufficient for 
binding antibodies (Schisterman EF et aI., 2006). Low concentrations may not be reliably 
differentiated from the background noise, and hence, not accurately measured. An upper 
detection limit may occur in dilution assays in cases of extremely high antibody response, 
when testing for antibodies at an additional dilution is not considered worthwhile (Barnhart 
HX et at., 2005;Schisterman EF et aI., 2006;Whitcomb BW & Schisterman EF, 2008). 
For the ESEN2 project, during the testing of the standardisation panel, laboratories were 
asked to provide quantitative measurements even outside the assay range. For data below 
DL, this sometimes meant having higher measurement error due to the background noise 
(Whitcomb BW & Schisterman EF, 2008;Lim J, 2006). However, it is always good 
practice to obtain such measurements, since the thresholds assigned to distinguish between 
values with and without background noise may not be appropriate for seroepidemiological 
studies (Whitcomb BW & Schisterman EF, 2008). As mentioned previously, many 
laboratories were not able to produce quantitative measurements throughout the assay 
range. 
The analysis of biological assays constrained by thresholds is an area that has been 
developing rapidly during the last five years, with numerous peer-reviewed papers and 
techniques published. The aim of this Chapter to review some of these methods and to use 
them to generate standardisation equation estimates that are comparable to the ones 
obtained by the ESEN2 methods. 
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5.2 Types of censored data 
In statistical terms, a set of data is called censored when observations are known only to be 
greater (or less) than some value (Bland M, 2000). This is the case with serological data 
when quantitative measurements (the exact values of which may be known or unknown) 
outside the assay DL are reported as fixed values. A distinction needs to be made between 
censored and truncated data, the latter occurring when values outside a certain range are 
entirely omitted (Breen R, 1996;Greene WH, 2003;Maddala GS, 200 I). 
There are different types of censored data, however, the following three categories are 
considered here: 
(i) Right-censored, where all that is known is that the data are higher than a 
specific value. In terms of serological assays, these are the measurements 
reported as "> Du " (Zhang Z & Sun J, 2010). 
(ii) Left-censored, data where all that is known is that the data are less than a 
specific value. In terms of serological assays, these are the measurements 
reported as "< DL ". Although assays can be bounded from both sides. left-
censoring appears more commonly, and therefore. the analysis will be mainly 
concentrating on these scenarios (Baccarelli A et al .. 2005;Bamhart HX et al .• 
2005;Zhang Z & Sun J, 2010). 
(iii) There is a third type of censored data which includes measurements where all 
that is known is that they lie within an interval (Zhang Z & Sun J. 2010). This 
type of censoring will be discussed in more detail later in this Chapter. 
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5.3 Deletion and simple substitution methods 
There are a number of different methods that have been proposed for dealing with censored 
biological assay data. The simplest is the deletion method that omits the censored 
observations from the analysis resulting in a truncated dataset. This has obvious 
disadvantages given there is loss of infonnation (Baccarelli A et al., 2005;Jain RB et al., 
2008;Schistennan EF et al., 2006). 
Another easy-to-apply method involves analysing the dataset after substituting censored 
observations by a single value. This method is called simple substitution. Various recipes 
have been proposed for estimating the substituted value. For left-censored data, they 
include substituting censored data with 0, DL, DL/ 2, DL / J2 or 2DL/ 3 (Baccarelli A et 
al., 2005;Bamhart HX et af., 2005;Daniels RD & Yiin JH, 2006;Jain RB et al., 
2008;Krishnamoorthy K et aI., 2009;Richardson DB & Ciampi A, 2003;Schisterman EF et 
al., 2006;Lubin JH et ai., 2004). Substitution with 0 (which is not applicable to the log-
transfonned data presented here) has been found to overestimate the slope when fitting a 
straight line. On the other hand, replacing with DL seems to produce the opposite effect i.e. 
underestimation of slope (Helsel DR, 2005;Lubin JH et al., 2004). Substitution with 
DL / J2 is appropriate if the data follow a nonnal distribution (e.g. log-transformed 
serological data), and DL/ 2 can be applied for highly-skewed data (e.g. non-transformed 
serological data) (Jain RB et al., 2008). These substitutions have been found to work and 
are particularly useful for low proportions of censored data. 
As mentioned in the previous Chapter, standardisation equations were estimated by both 
deletion and simple substitution methods (DL /2 and 2Du for left- and right-censoring, 
respectively) prior to log-transfonnation. To recapitulate, given the importance of good fit 
around the positive / negative cut-off point, the estimated equations by the two methods 
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were compared at that point. The simple substitution method was generally used, apart 
from situations where the difference between the methods at the point of interest was large 
and the deletion method was preferred (Chapter 4) (Kafatos G et al., 20(5). 
An example of left-censoring from the ESEN2 project is as follows: Israel's HAY panel 
results, reported as IUlml, were plotted after they were log-transformed against the Greece 
reference centre's results that had a positive I negative cut-off of 0.0 I IUlml (-2 on the 
10glO-scale). Of the 142 samples tested by both laboratories after excluding the outliers, 39 
(27%) were reported as "< 0.005" IUlml by Israel. 
Using the ESEN2 standardisation methodology, two quadratic regression equations were 
produced using deletion and simple substitution by Dl. I 2, after assuming the data followed 
a log-normal distribution (i.e. replacing the censored observations by loglO(0.005 I 2». For 
this example, simple substitution was chosen for the appropriate standardisation equation 
instead of deletion, since the difference between the two lines at the reference centre's 
positive I negative cut-off was not large (COR = 0.019, using Equation 4.10). Although for 
higher measurements the two fitted lines gave similar fitted values, this was not the case 
for lower measurements, where the model using simple substitution was affected by the 
substituted observations (Figure 5. I). 
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A comparison of standardisation equation estimates for the deletion and the simple 
substitution methods was carried out. The cut-off values for Israel ( yc( -2) and y(-2) for 
deletion and simple substitution, respectively) were estimated, after substituting the 
reference assay cut-off of -2 (on the loglO-scale), as in Equations 4.8 and 4.9: 
,..,.. "'.., ,. }'(-2) = fio + fil (-2) + fi2 (-2)- = -0.39 + 1.1 O( -2) + 0.1O( -2)- = -2.18 
and 
,.. A ..... .., .., 
yc (-2) = fico + fiC! (-2) + fic2 (-2)- = -0.38 + 1.08( -2) + 0.11 (-2>- = -2.08. 
where Po' PI' pz were the parameter estimates for the simple substitution and Pco, PC! 
PC2 for the deletion method. 
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Table 5.1 shows a comparison between the regression and cut-off estimates using the 
different methods. The standardised cut-off was estimated highest after suhstituting hy lh ( 
.V( -2) = -2.0 I ). This is expected, since the censored observations, due to their high value, 
pull the lower end of the equation upwards towards O. The standardised cut-off was 
estimated lowest after substituting by Dd2 ( y( -2) = -2.18 ). This is due to the low values of 
the data used for substitution that pull the lower end of the equation downwards. 
Table 5.1 Standardisation equation estimates using simple substitution and deletion 
methods (95% CIs in brackets) 
Method Po PI Pz cut-off 
Deletion -0.38 (-0.45, -0.31) 1.08 (1.04, 1.13) 0.11 (0.07, 0.16) -2.08 
simple OL -0.41 (-0.46, -0.35) 1.08 (1.04, 1.11) 0.14 (0.12,0.16) -2.01 
Substitution OLI2 -0.39 (-0.45, -0.33) 1.10 (1.07,1.14) 0.10 (0.08,0.12) -2.18 
DL l..fi 
-0.40 (-0.45, -0.34) 1.09(1.06,1.12) 0.12 (0.10,0.14) -2.10 
2DLI3 -0.40 (-0.45, -0.34) 1.09 (1.06, 1.13) 0.12 (0.10,0.14) -2.11 
5.4 Simulations for regression equations 
The different methods were validated using a simulation technique similar to a parametric 
bootstrap (Efron B & Tibshirani RJ, 1993). Censored data were generated randomly from 
the reference centre's results using a model of the general form shown in Equation 4.1 
where Po, PI, ... , Pk and (J were regarded as known since they had been chosen in advance. 
Such models to be used for simulation-generating scenarios will be referred to as true 
models. 
The process is described as follows: 
98 
1. Based on the number of samples included in the reference panel (say n), a set of random 
data was generated from a distribution with mean II = ° and variance (i, i.e. N(O, 0-2 ), to 
obtain the residuals. 
2. Assuming the generated data represent a set of residuals ii' where i = I, ... , n, a set of 
measurements for the testing laboratory y; (the laboratory that is regressed against the 
reference laboratory) was generated using the equation 
Equation 5.1 
3. A detection range (DL, Du) was applied to the simulated data by assuming that any 
observations below the range were replaced by "< DL " and any observation above by " 
4. For the simulated dataset, regression equations were fitted, producing a set of estimates 
for each of the methods described above i.e. jJ~o ,jJ~1 , ... , jJ~k where C denotes the method 
used (deletion or any of the simple substitution methods - Note the change of notation up 
to this point since the subscript C denoted the deletion method only). Together with the 
regression estimates, the cut-off value for the testing laboratory y~ (00 ) , where 00 denotes 
the reference assay cut-off, was estimated using Equations 4.8 and 4.9. 
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5. The process was repeated multiple times (say M) and the mean of the estimates for each 
. I ~pA' I ~pA' I ~/\.· t't' parameter was calculated, I.e. -  COj ,-~ Cli' ••• ,-~ I n , ,as well as the cut-o 
M i=1 M j=1 M I_I 
. I ~ • (' ) pomt -~yc ()o . 
M j=1 
The amount of uncertainty in estimates arising from the variability between the simulated 
datasets is quantified by two different methods: 
(a) The percentile interval. This includes the 2.51h and 97.51h percentiles of the simulated 
estimates as the lower and upper limits, respectively. 
(b) The coverage probability. This is the proportion of simulation runs for which the 
confidence interval for each of the estimated parameters p;·o, P;I' ... ' P;k at that run 
contains the true model parameters Po. Pl. ... , Pk. 
The performance of a method C is then evaluated by comparing the mean of the estimates 
of the parameters to their true values, by checking whether the true values lie in the 
percentile intervals and whether the coverage probability is close to its nominal value. 
5.5 Comparison of deletion and simple substitution methods using simulations 
The simulation process described above was applied to the Israel HA V panel example 
comparing the deletion with a number of simple substitution methods. 
I. Based on the number of samples included in the Greek reference panel, 148 random 
samples were generated from a normal distribution model with mean Jl = 0 and standard 
deviation (T = 0.26 to be used as residuals t~. 
I 
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2. The measurements of the testing laboratory were then generated from a true model of 
the form y = -0.4 + I. Ix + 0.12x2. Using Equation 5.1 the simulated measurements were 
generated from y; = - 0.4 + I.lxj + 0.12xj2 + E,* . 
3. Any simulated measurements below 0.005 IU/ml were assumed to be below assay DL 
and were (a) dropped from the model or substituted by (b) 0.005, (c) 0.005 I 2, (d) 
0.005 I J2 , (e) (2 13)xO.005 (measurements shown prior to 10glO-transformation). 
4. For each of these datasets a regression equation was fitted. 
5. The data were simulated 1,000 times and the average of the estimates was taken. The 
coverage probability was chosen to describe the uncertainty around the regression 
parameters, whereas the 95% percentile interval was selected for the cut-off estimate. 
Figure 5.2 shows the model comparison between deletion and substitution by 0.005 and 
0.005 I 2. Data from one set of simulations is shown as an example. The regression 
equation after substituting with 0.005 12 gave estimates closer to the truth for antibody 
measurements around the cut-off of interest (-2 on the log IO-scale), and lower when 
compared to the other two methods. 
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Figure 5.2 Comparison between simple substitution and deletion methods a fter I 000 
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The means of the parameter estimates with their corre ponding c verage probabi I itie for 
the 95% confidence intervals are shown in Table 5 _2. The positi ve In ga ti ve c ut -off i a lso 
presented together with its corre ponding 95% perc nlile int rval. For the lru m de l 
y = -0.4 + I.l x + O.12x2, the cut-off was y(-2) = 2. 12 (Equations 4 .8 and 4.9). imple 
ubstitution with DLI 2 gave coverage probabilities close to the nomina l va lue and a cut-off 
estimate very close to the truth ( y~ (-2) = -2. 13). The th r two mcth ds with hi gh 
coverage were substitution with DL I J2 and 2DLI 3. 
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Table 5.2 Mean parameter estimates and 95 % coverage probabilities generated from 
the model y = -0.4 + l.lx + 0.12x2 with (J = 0.26 
Method Po PI P2 cut·off' 
true model -0.40 1.10 0.12 -2.12 
Deletion -0.42 (90.6%) 1.08 (81.2%) 0.15 (39.6%) -1.96 (-2.03, -1.89) 
simple DL -0.43 (83.5%) 1.09 (88.1%) 0.15 (26.7%) -2.00 (-2.06, -1.96) 
Substitution DL/2 -0.41 (93.2%) 1.10 (93.0%) 0.12 (94.8%) -2.13 (-2.19, -2.06) 
DL In 
-0.42 (89.0%) 1.10 (92.7%) 0.14 (69.3%) -2.07 (-2.13, -2.01) 
2DL/3 -0.42 (89.9%) 1.10 (92.3%) 0.13 (76.2%) -2.08 (-2.14, -2.02) 
* 2.51h and 97.5lh percentiles given instead of coverage probabilities 
The example shown above and the generated simulations examine the scenario where the 
Israel panel results were reported as censored if below 0.005 IU/ml. This resulted in 27% 
of censored data. However. the methods presented are expected to vary in performance 
according to the proportions of data being censored. Simulations were thus performed in 
the same way as explained above, varying the point where the data were censored. 
Figure 5.3 shows a comparison of the cut-off estimates between the different methods. For 
up to 15% of data censored substitution with 2DLI 3 and Dl. 1.J2 produced cut-off 
estimates closest to the truth compared to other methods. followed by substitution with Dd 
2. For 20% to 25% of data censored, substitution with DL 12 produced the best estimates. 
A maximum of 25% of the data were censored in the simulated datasets, given that it 
would make no sense to have censored observations above the standardised cut-off value 
of -2.12 (from Table 5.2). 
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Figure 5.3 Comparison cut-off estimate between simple substitution and deletion 
methods for different proportions of data censored generated from the model y = -0.4 
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The method comparison was repeated after generating simulations from a simple linear 
regression model of the form y = -0.4 + 1.lx with a = 0.26. Assuming censoring of data 
below 0.005 IV/ml, the model using deletion gave better estimates than the simple 
substitution methods (Figure 5.4). According to the standardisation algorithm for such a 
scenario, the regression based on deletion would have been selected to obtain the 
standardisation equation, due to the large differences between this method and the simple 
substitution regression on the cut-off point (Chapter 4). The large differences between the 
two methods may be partly due to the fact that the 0.005 threshold value is close to the 
assay cut-off. 
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Figure 5.4 Comparison between simple substitution and deletion methods after 1,000 
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4 
For the true model y = -0.4 + 1. 1 x, the cut-off was y( -2) = -2.6. For up to 20% of the data 
being censored, subst itution with DLi 2 gave a consistently better estimate at the point of 
cut-off in comparison to the other methods. However, for 25% of the data being censored, 
a ll methods produced biased results , with the deletion method having the closest estimate 
to the truth (Figure 5.5). 
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Figure 5.5 Comparison of cut-off estimate between simple substitution and deletion 
methods for different proportions of data censored generated from the model y = -0.4 
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5.6 Censored regression 
Censored regression analysis is a statistical tool for incorporating observations limited by 
censoring on the response variable. It is a generalisation of the normal regression, and if 
the number of censored data is small, then censored regression tends to give similar 
estimates to normal regression. Censored regression was initially introduced as an 
extension of the probit model for an econometrics application by Tobin, and was later 
referred to as "Tobit regression" (Lubin JH et aI., 2004). Several types of censored 
regression models exist, however, since the Tobit model is the simplest and most 
commonly used amongst them, it will be used throughout hereafter, and will simply be 
referred to as censored regression. There are different ways of estimating the parameters of 
such models using ordinary least squares (OLS) and maximum likelihood (ML) techniques 
(Breen R, 1996;Jain RB et aI., 2008). The latter will be used in this Chapter, since the 
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estimators with ML techniques appear to have some advantages when compared to the 
OLS method (Breen R, 1996). 
Consider a model of the general form as shown in Equation 4.1 where the equation of the 
line is summarised by: 
Equation 5.2 
where /30, /31, ... , /3k are k + I parameters. 
Suppose the observed response variable Yi consists of (a) n measurements of which the first 
f. are quantitative, (b) a number of left-censored observations Yi = DLi for i = (+ 1 .... , c 
where all that it is known is that the true value Yi< DLi and (c) a number of right-censored 
observations Yi = DUi for i = c + I, ... , n where all it is known is the true value)"i > D Ui . Note 
that the subscript i is added to the notation DL and Du to account for potentially different 
censoring bounds. Let alsof(y; g(Xj), a) be the probability density function (PDF) and 
F (y; g(x;), a) the cumulative distribution function (CDF) with equation of the line R(Xi) and 
standard deviation a. The likelihood for the censored regression model is: 
len 
L= nf(y;;g(x),a)x n F(y;;g(x),a)x n (l-F(y;;g(x),a». 
;=1 ;=( +1 i=c'+1 
Equation 5.3 
The log-likelihood is then: 
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In(L) = I In (J (Y,: g(x, ),0"))+ :t In (F ()',: g(x),a)) + f In (1- F (),,: g(x, ),17)) . 
;=1 1=( +1 
Equation 5.4 
The parameters included in equation g(x;) and the standard deviation a can then be 
estimated by using maximum likelihood estimation (Lubin JH et al., 2004). 
5.7 Method of Multiple Imputation (MI) 
Apart from deletion, simple substitution methods and censored regression, other methods 
have been proposed in the literature for dealing with censored observations. A method 
often quoted is Multiple Imputation (MI). The main reason for using MI would be to obtain 
explicit values for the censored data that can be used in further analysis. Given that the 
main aim is to estimate regression parameters, the censored regression method discussed 
above should be sufficient (Lubin JH et ai., 2004). However, given that a variety of MI 
methods are being used in the literature to obtain regression estimates from censored data, 
it seems necessary to compare it to the other methods. A simple application of the MI 
method consists of the following steps: 
I. For a model of the type defined in Equation 4.1, use censored regression to obtain initial 
parameter estimates Po, PI , ... , Pk and B. 
2. A set of residuals i;' can then be generated from N(O, 8 2 ) using Equation 5.1. 
3. After restricting the data to the censored observations i = f + I, ... ,n (including left- as 
well as right-censored data), a set of imputed quantitative measurements y;' can be 
obtained for the censored data. 
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4. Using the original dataset with the addition of the imputed observations obtained from 
Step 3, a regression model of the general form shown in Equation 4.1 can be fitted and MI 
estimates P~, P; , ... , P; and a ¥ can be achieved. 
5. The procedure can be repeated multiple times resulting in estimates jJ~j' P;j , ... , P~ and 
a': where j = I, .. , m denotes the number of imputations. The means of these estimates i.e. 
j 
I m h. I m hIm h 
- IfJ~j ,-IfJl'j , ... ,-IfJ;j are the MI estimates. The number of imputations does not 
m j;1 m j;1 m j;1 
need to be large, with a recommended value between 3 and 5, and will need to be larger 
only if a larger proportion of the data is missing. For the examples shown below, m = 10 
was used to fully account for the imputation variance, as has been done in previous studies 
(Lubin JH et al., 2004). 
As with censored regression, several variations of the MI method have been proposed in 
the past. One of these methods, proposed by Lubin, includes bootstrapping for obtaining 
the initial parameter estimates PO' PI , ... , A and a to be used for the imputations (Lubin 
JH et at., 2004). Other methods include Markov Chain Monte Carlo (MCMC) adapted for 
MI (Schafer JL, 20 I 0). The procedure explained above, a very basic application of MI, is 
the one that will be examined throughout this Chapter. 
5.8 Confidence intervals for MI estimates 
By combining the two variance components, the within- and between-imputation variance, 
it is possible to obtain a pooled variance and hence, confidence intervals around the MI 
estimates (Krishnamoorthy K et aI., 2009). 
Suppose we are interested in calculating the variance of the MI estimates: 
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Equation 5.5 
where K = 0, I, ... , k denotes the number of parameters and m the number of imputations. 
The within-imputation variance is defined by: 




The between-imputation variance can be defined as: 
Equation 5.7 
The pooled variance for each estimate is given by combining the within-imputation 
variance in Equation 5.6 and the between-imputation variance in Equation 5.7 as follows: 
Equation 5.8 
where the term (] + ~) compensates for the finite number of imputations. 
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Confidence intervals may be obtained from: 
Equation 5.9 




(Carpenter J & Goldstein H, 2004;Schafer JL, 2010). 
5.9 Example and simulations 
Equation 5.10 
Using the same example as above, the HAY Israel panel results were regressed against 
data from the Greek reference centre using a censored regression model by maximising the 
log-likelihood in Equation 5.4: 
10.1 142 
In(L) = ~)n (f (y,: g(x),lJ)) + I In (F(y,; g(x),lJ)), 
,=1 '=104 
where g(x,) = Po + PIX, + P2X,2 for i = I, ... , 142 observations of which 39 were left-
censored andf(.) and F(.) are the normal PDF and CDF, respectively. 
For obtaining the MI estimates the following steps were implemented: 
III 
I. The estimates Po = -0.33, PI = 1.13, P2 = 0.04, 8 = 0.24 were obtained from censored 
regression. 
2. A set of residuals ( was generated from a normal distribution N(O. 0.24\ 
3. For the censored observations included in the sample (i.e. 39 samples were reported as 
"< 0.005" IVlml) a set of imputed measurements was generated using 
Y,' = -0.33 + 1.13x; + 0.04X;2 + ( . 
4. A quadratic regression model was fitted on the imputed dataset. 
5. The process was repeated 10 times and the average of each estimate was taken as the MI 
estimate. 
Confidence intervals were calculated around the MI estimates after combining the within-
and between-imputation variance as shown in Section 5.8. 
The resulting regression equations using the different methods are depicted in Figure 5.6. 
The censored regression method was compared to the MI method and the simple 
substitution using D/.I 2. In this example, the censored regression and MI gave regression 
equations similar to each other, whereas the regression using simple substitution method 
was highly influenced by the censored observations at the lower end. 
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Figure 5.6 Regression curves for Israel HA V panel using simple substitution, 
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The estimates with their corresponding 95% confidence intervals are shown in Table 5.3. 
A comparison of the cut-off value for Israel after substituting the 0.01 IU/ml cut-off for the 
Greek reference centre using the different methods, showed similar estimates for MI and 
censored regression, whereas the estimate was higher for simple substitution. Note that the 
MI confidence intervals are wider than the other methods since they incorporate two 
different sources of variation, the variability between- and within-imputations. 
Table 5.3 Standardisation equation estimates for Israel HA V panel using simple 
substitution, censored regression and MI (95% CIs in brackets) 
A 
method Po PI P2 cut-off 
substitution with DL / 2 -0.39 (-0.45, -0.33) 1.10 (1.07,1.14) 0.10 (0.08, 0.12) -2.19 
censored regression -0.33 (-0.39, -0.26) 1.13 (1.09,1.17) 0.04 (0.01, 0.07) -2.43 
multiple imputation -0.32 (-0.80, 0.15) 1.12 (0.65, 1.60) 0.04 (-0.43, 0.52) -2.40 
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The different methods were also compared using simulations. As above, random data were 
generated 1,000 times from a "true model" y = -0.4 + I . Ix + 0 . 1 2x~ with a standard 
deviation (J = 0.26. The regression estimates were then obta ined us ing the censored 
regression and MI methods. The regression eq uation ca n be viewed in Figure 5.7 below. 
The equations as estimated by the two methods are c lose to the true model. 
Figure 5.7 Comparison between censored regression and MI methods from 1,000 
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Table 5.4 shows the mean parameter estimates following the simulations using simple 
substitution, censored regress ion and MI methods, together with the 95% coverage 
probabilitie . The esti mated cut-off value for I rael is a lso reported together with the 95% 
percentile intervals. The parameter estimates were all clo e to the true model. The cut-off 
estimate was sli ghtly higher for the MI method, however, the 95% percentile interval 
included the true estimate. Note that the MI gave 100% coverage probability due to the 
wider confidence inte rval s. 
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Table 5.4 Parameter estimates and 95 % coverage probabilities generated from the 
model y = -0.4 + 1.lx + 0.12x2 with (T = 0.26 using censored regression and MI 
A 
method Po PI P2 cut-off" 
true model -0.40 1.10 0.12 -2.12 
substitution with DL / 2 -0.41 (93.2%) 1.11 (93.0%) 0.12 (94.8%) -2.13 (-2.19, -2.06) 
censored regression -0.40 (94.2%) 1.10 (93.9%) 0.12 (95.1%) -2.12 (-2.21, -2.05) 
multiple imputation -0.40 (100.0%) 1.09 (100.0%) 0.13 (100.0%) -2.07 (-2.17, -1.99) 
* 2.5'h and 97.5,h percentiles given instead of coverage probabilities 
The cut-off value as estimated by the different methods is shown in Figure 5.8 for different 
proportions of data censored. Censored regression gave cut-off estimates closest to the 
truth followed by simple substitution and the MI imputation methods. 
Figure 5.8 Comparison of cut-off estimate between the censored regression and MI 
methods for different proportions of data censored generated from the model y = -0.4 
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Simulations were generated after changing the reference assay cut-off from -2 to -I (on the 
10glO(lUlml) scale) aiming to censor a higher proportion of data. Substituting this to the 
true model y = -0.4 + 1.lx + O.12x2 gave a cut-off of y( -I) = -1.38. For up to 30% of the 
data censored, censored regression, simple substitution (with D[./ 2) and MI all gave cut-
off estimates close to the truth, with the first two being slightly better. For 35% to 40% of 
the data censored, the multiple imputation method provided the least biased estimate 
followed by censored regression, whereas the simple substitution and deletion methods 
produced estimates far away from the true cut-off (Figure 5.9). These findings agree with 
the literature, which suggests that simple substitution methods produce biased estimates 
when more than 25% of the data is censored (Lubin JH et ai., 2004). 
Figure 5.9 Comparison of cut-off estimate between the censored regression and MI 
methods for different proportions of data censored generated from the model y = -0.4 
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5.10 Investigation of regression assumptions 
The methods shown here rely to some extent on the assumptions of multiple linear 
regressIOn. 
The most important of these are the following: (i) the residuals must follow a normal 
distribution, (ii) the error term [; should have a constant variance (homoscedasticity), and 
(iii) a further issue is performance within non-linear regression models. The validity of 
these assumptions was investigated using simulations. 
0) Normality assumption 
A number of statistics that examine whether the normality assumption holds for a censored 
regression model have been suggested in the past (Greene WH, 2003;Holden D, 2004). 
However, for this Chapter, robustness to the normality assumption was investigated by 
simulating data using a non-normal residual distribution. Specifically, a gamma 
distribution reI", r) was fitted for the distribution of residuals, where I" was defined as the 
shape parameter and r as the scale parameter. Note that the distribution was shifted to 
centralise around zero by subtracting its mean I,r. 
Simulations were generated from the model y = -0.4 + I.Ix + 0.I2x2 with a = .J l,r 2 = 0.26 
and )" = 2 for the gamma residual distribution. A comparison between the simple 
substitution and the censored regression methods can be viewed in Figure 5.10. Both 
curves are close to the true line. 
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Figure 5.10 Comparison between simple substitution and censored regre ion 
methods from 1,000 simulations generated from the model y = -0.4 + I.1x + O. J 2rz 
with (J = 0.26 when the normality assumption does not hold (1 = 2) 
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Table 5.5 . hows the e timated paramete rs for the simple substitution, censored regre sion 
and MI methods afte r 1,000 simulati ons. All methods produced cut-o ff es timates c lose to 
the true mode l's cut-off with the MI method be ing s lightly more bi ased . 
Table 5.5 Parameter estimates and 95 % coverage probabilities generated from the 
model y = -0.4 + I.Ix + 0.12x2 with (J = 0.26 using simple substitution and censored 
regression when the normality assumption does not hold (1 = 2) 
method Po PI pz cut-off 
true model -0.40 1.10 0.12 -2.12 
substitution with DL / 2 -0.41 (92.5%) 1.11 (93.1 %) 0.12 (94.7%) -2.13 (-2.20, -2.07) 
censored regression -0.40 (94.6%) 1.10 (95.4%) 0.12 (93.3%) -2.13 (-2.22, -2.06) 
multiple imputations -0.40 (100.0%) 1.09 (100.0%) 0.12 (100.0%) -2.08 (-2.19, -1.99) 
'" 2.5'h ~ nd 97.5'h percentiles given instead of coverage probabil iti es 
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Figure 5.11 shows the cut-off value estimate for different proportions of data censored for 
that scenario after varying the shape parameter. The MI, censored regression and DL / 2 
methods, all gave cut-off estimates close to the truth. The robustness of the censored 
regression method for small deviations from the normality assumption has been 
demonstrated in a previous study (Lynn HS, 2001). 
Figure 5.11 Comparison of cut-otT estimate between censored regression and MI 
methods for ditTerent proportions of data censored generated from the model y = -0.4 
+ 1.1x + 0.12x2 with (J = 0.26 when normality assumption does not hold (varying A) 
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(in Homoscedasticity 
As mentioned above, one of the assumptions of censored regression is the homogeneity of 
the variance (homoscedasticity). However, there may be an additional source of 
uncertainty that only applies to values outside the assay DL, and more often to low 
concentrations. This may lead to higher residual variability for these measurements 
(heteroscedasticity), and therefore, violation of the assumptions for censored regression. 
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Although the impact of heteroscedasticity on censored regression estimators has been 
investigated in the past, analyses have focused on very specific models. The proportion of 
data censored seems to be one of the main factors determining the degree of estimators' 
bias (Greene WH, 2003). 
One way to take heteroscedasticity into account is to treat measurements below and above 
DL differently by fitting "hybrid" models, such as the hybrid lognormal, that produce 
different error variances depending on whether the observation is within the DL or not. 
However, to construct such a model, it is essential to initially establish whether the same 
error variance exists across the whole distribution of the assay. This may be provided -
although not always possible - by obtaining quantitative results for some measurements 
outside the DL (Daniels RD & Yiin JH, 2006;Whitcomb BW & Schisterman EF. 2008). 
The effect of heteroscedasticity on the regression estimates was examined as follows: The 
different methods of handling censored data were evaluated after doubling the amount of 
variation for lower concentrations. Using the same example as above, data were generated 
from the model y = -0.4+1.Ix+0.12x2 with a standard deviation (1 = 0.26 for 
measurements above the reference cut-off value of log 10(0.0 I) and (1 = 0.52 for 
measurements below 10glO(0.0l). 
Figure 5.12 shows the estimated curves using the simple substitution and the censored 
regression models after 1,000 simulations. Although both curves are very close to the true 
model there is some discrepancy at the lower end of the equation where there is higher 
amount of variability. 
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Figure 5.12 Comparison between simple substitution and censored regression 
methods from 1,000 simulations generated from the model y = -0.4 + I.Ix + 0.12x2 
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Table 5.6 hows a compari son between simple substitution, censored regre s ion and MI 
estimates followin g simulations . The s imple ubstitution and cen ored regre sion methods 
produced cut-off estimate closer to the truth_ 
Table 5.6 Parameter estimates and 95 % coverage probabilities generated from the 
model y = -0.4 + I.Ix + 0.12x2 with l1 = 0.52 and l1 = 0.26 for measurements below and 
above logJo(O.OI ), respectively 
method 
true model -0.40 
substitution with OLl I 2 -0.42 (95.3%) 
censored regression -0.41 (95.3%) 














-2.06 (-2.14, -1.98) 
-2.04 (-2.13, -1.96) 
-1.97 (-2.07, -1.88) 
The results of the simulations, presented in Figure 5.13 below, show that simple 
substitution and censored regression produced the closest cut-off estimates to the truth. 
However, all methods produced biased estimates for more than 20% of the data censored. 
Figure 5.13 Comparison of cut-off estimates between the censored regression and MI 
methods for different proportions of data censored generated from the model y = -0.4 
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(iii) Non-linear regression models 
Different types of equations were used to describe the relationship between the reference 
centre's and the testing laboratory's standardisation panel results. In some cases, however, 
straight line or quadratic models failed to provide a good fit around the critical area of the 
positive I negative cut-off. 
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The example below demonstrates the use of a non-linear regression model. For this 
example the Cypriot rubella panel results were plotted against the German reference centre 
results. The positive I negative cut-off for the reference centre was 4 IUlml (0.6 on the 
logJO-scale), and the detection range for Cyprus was [I, 200] (in IU/ml) with 31 left-
censored (21 %) and 3 right-censored results (2%). 
Since both the linear and the quadratic curves clearly did not provide a good fit, a 
regression sigmoid model was fitted using maximum likelihood of the form: 
ft 
g(x,) = (X + I -1"+," I ' +e' , 
Equation 5.11 
where i = I, ... , 149 denotes the panel samples and 0., ft, y and <5 are the model parameters. 
Using the ESEN2 standardisation methodology, regression based on deletion was chosen 
to obtain the standardisation equation, given the large differences between the two lines on 
the cut-off point (COR = 0.(99). 
After substituting Equation 5.11, it is possible to obtain estimates for the equivalent 
regression type after taking censoring into account. Model estimates using the different 
methods are shown in Figure 5.14. For higher measurements the different models gave 
similar results. However, for less than I logJO(reference IU/ml), the deletion method gave 
higher results than censored regression and MI methods since it ignored the potential effect 
of left -censored data. 
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The parameter estimates with their corresponding 95% confidence intervals are given in 
Table 5.7. The method of deletion produced very different regression estimates from the 
other methods. The cut-off estimate (Yc (0.6) = 0.24) was much higher than for the other 
methods. 
Table 5.7 Standardisation equation estimates using simple substitution and deletion 
methods (95% CIs in brackets) 
a ft A J method 'Y cut-off 
0.05 2.14 -4.68 3.90 
deletion (-0.07,0.18) (1.99, 2.29) (-5.64, -3.72) (3.15, 4.65) 0.24 
substitution with DL I 2 -0.27 2.45 -5.05 4.36 
and 2Du (-0.34, -0.20) (2.35, 2.55) (-5.09, -4.19) (3.63, 5.09) -0.07 
-0.20 2.38 -4.86 4.19 
censored regression (-0.30, -0.11) (2.26, 2.50) (-5.71, -4.01) (3.49, 4.89) 0.01 
-0.17 2.35 -4.50 3.90 
multiple imputation (-0.51,0.18) (2.00,2.70) (-5.35, -3.68) (3.27,4.54) 0.07 
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The methods used were validated through simulations. As be fore, random data were 
ge ne rated 1,000 times using the refere nce pane l results. The true model wa se t a 
2.5 . h Y = -0.3 + WIt a standard devi ation (/ = 0. 16. Substituting a cut-off o f 
I + exp( -( -4) - 3.5x) 
0.6 to the true model gave y(0 .6) = 0.03 . Fo llowing each simulati on, regress io n eq uati ons 
were estimated using the methods of deletion, simple substitutio n, censored regression and 
MI afte r ce nsoring all measure ment below log lo(l ) and above log lo(200) ru/ml. 
Figure 5. 15 shows how the models based on de letion, censored regres ion and MI compare 
to the true model the data was generated from . The censored regression and MI curves 
re main very close to the true line, whereas the model based on dele tio n dev iates at the end 
of the lines, espec iall y at the lower e nd where there is a hi gher numbe r o f left-censored 
data. 
Figure 5.15 Comparison between censored regression and the deletion methods after 
1,000 simulations generated from y = -0.3 + 2.5 with (/ = 0.16 
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The parameter estimates for the different methods are shown in Table 5.8. The cut-off 
estimate was close to the truth for all methods with exception of the deletion method 
(y~(O.6)=O.16). 
Table 5.S Parameter estimates and 95 % coverage probabilities generated from the 
model y = -0.3 + 2.5 with (J = 0.16 using simple substitution, censored 
1 + exp( -( -4) - 3.5x) 
regression and MI methods 
method 0. P )' ~ cut-off" 
true model -0.30 2.50 -4.00 3.50 0.03 
deletion -0.00 (10.1%) 2.13 (7.9%) -5.07 (42.9%) 4.21 (51.5%) 0.16 (0.06, 0.24) 
substitution with -0.35 2.59 -3.93 3.42 0.00 
DL/ 2 and 2Du (93.5%) (81.2%) (95.5%) (94.4%) (-0.07,0.08) 
censored -0.33 2.53 -3.96 3.48 0.02 
regression (96.4%) (95.9%) (95.6%) (94.9%) (-0.08,0.11 ) 
multiple imputation -0.30 (97.7%) 2.47 (98.0%) -4.03 (67.0%) 3.57 (75.2%) 0.03 (-0.07, 0.12) 
* 2.5 th and 97.5 th percentiles given instead of coverage probabilities 
5.11 Interval censored regression 
The serological results shown in the examples above were reported quantitatively within a 
detection range, since most of the ESEN2 project assays were designed in this way. 
However, it is not uncommon for assays to report results in a "semi-quantitative" format 
due to the way the samples were diluted. Often this special feature of the data is ignored, 
and such measurements are treated as continuous in the analysis for reasons of simplicity. 
An alternative method proposed here is to treat these semi-quantitative measurements as 
interval censored data. Then appropriate techniques, such as the interval censored 
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regression method, can be applied which allow for bias adjustment generated from this 
type of data (Lyles RH et al., 2001 ;Zhang Z & Sun J, 2010). 
Suppose that a sample of size N + n consists of a set of m intervals with sizes N .. N2,. .. , Nm 
(~N; = N ). Then a measurement Yij, where i = I, ... , m andj = I, ... , N;, belongs to the 
interval [min( y), max(y)) . Also, let N + 1, ... , c be left-censored data and c + I, ... , n be 
right-censored data. 
Then the log-likelihood shown in Equation 5.4 can be generalised as: 
m N, 
In(L) = LLln[ F( max(y;);g(x;),O") - F( min(y;);g(x;),O") J+ 
;=1 j=1 
+ I In[F(Yk;g(xk),a)]+ Iln[I-F(Yk;g(xk),a)]. 
k=.V+1 k=ctl 
Equation 5.12 
An example is given where the NT-Yero assay was used by the Finnish laboratory for 
testing the diphtheria panel. Each sample was tested by dilution and, if found positive, it 
was further diluted until a negative result was obtained. This means that the titre lies 
between two dilutions but its exact value is unknown. In addition to the interval censoring, 
results below the 0.004 dilution were reported as "< 0.004" and hence, were treated as 
left-censored. The Italian reference centre tested their panel with DA-DELFIA which 
produced quantitative measurements and had a cut-off of 0.01 IU/ml or -2 on the 10glO-
scale. Using the standardisation algorithm, the simple linear regression based on the simple 
substitution method was chosen. 
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Figure 5.16 and Table 5.9 show the comparison between the regression equations when 
ignoring interval censoring i.e. using deletion and simple substitution. and when adjusting 
for it using an interval censored regression model. The interval censored regression method 
gave a slightly higher slope. and therefore, a higher cut-off estimate ()'( -2) = -2.36). 
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Table 5.9 Model estimates using deletion, simple substitution and interval censored 
regression methods (95% CIs in brackets) 
~ 
method Po cut-off 
deletion -0.24 (-0.32, ·0.15) 0.98 (0.89, 1.07) -2.20 
substitution with Dd 2 -0.23 (-0.32, -0.15) 1.01 (0.95, 1.08) -2.25 
interval censored regression -0.00 (-0.10, 0.09) 1.18 (1.09,1.26) -2.36 
The different methods were compared using simulations. Once measurements for the 
Finnish laboratory were generated from the true model, they were divided into groups to 
resemble serological data from dilution series (Table 5.10). Any measurements:'5 0.004 or 
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> 1.024 were treated as censored. Note that the data were 10glO-transformed prior to the 
analysis. 
Table 5.10 Dilution groups for quantitative data 
quantitative data groups titres 
(0.004, 0.008) 0.008 
(0.008, 0.016) 0.016 
(0.016, 0.032) 0.032 
(0.032, 0.064) 0.064 
(0.064,0.128) 0.128 
(0.128, 0.256) 0.256 
(0.256,0.512) 0.512 
(0.512, 1.024) 1.024 
Figure 5.17 shows the random data that were generated from a true model y = -0.2 + x 
with (J = 0.3 and classified into dilutions after 1,000 simulations (the results of one 
simulation are shown). The regression estimates were obtained using deletion, simple 
substitution and interval censored regression methods. The interval censored regression 
seems closer to the true line than the other two methods. 
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Figure 5.17 Comparison between deletion, simple substitution and interval censored 
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Table 5. 1 I shows the model estimates using deletion, simple substitution and inte rva l 
censored regress ion together with their 95% coverage probabilities. The e timated cut-off 
va lue for Finland was also reported together with the 95% perce ntile inte rval s. The inte rval 
ce nsored regre ion method produced a cut-off estimate closer to the truth than the other 
methods. 
Table 5.11 Parameter estimates and 95 % coverage probabilities generated from the 
model y = -0.2 + x with (J = 0.3 
method Po fl. cut-oW 
true model -0.20 1.00 -2.20 
deletion -0.46 (0.1%) 0.89 (23.5%) -2.24 (-2.33, -2.16) 
simple substitution -0 .34 (13.6%) 0 .99 (95.2%) -2.32 (-2.40. -2.24) 
interval censored regression -0 .20 (95 .9%) 1.00 (95.2%) -2.20 (-2.30. -2.10) 
* 2.5,h and 97 .5 ,h percentiles given instead of coverage probabi lities 
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5.12 Method comparison when censoring occurs on the independent variable 
During the ESEN2 project, laboratories were asked to provide quantitative results when 
testing the standardisation panel. However, this was not always possible and some 
laboratories reported censored data. The reference centres provided quantitative results for 
all antigens apart from VZV where a small number of samples were reported as below the 
assay DL. For such a scenario the methods of deletion and simple substitution were used as 
described above, despite the fact that the censoring occurred on the independent variable 
(Kafatos G et al., 2005). 
Non-parametric methods have been proposed for dealing with x-censored data based on 
Kendall's tau statistic. Kendall's line is obtained by calculating the median of all possible 
pairwise slopes. Although this method has since been further developed and today a 
number of variations exist, the disadvantage, apart from being computer intensive, is that it 
only applies for straight lines (Akritas MG et al., 1995;Helsel DR, 2005;Lim J, 2006). 
As an alternative to Kendall's line, a non-parametric test is proposed here to decide 
whether the regression equation estimates after excluding the x-censored data can be 
considered unbiased. The method can be described as follows: 
(i) Fit a regression equation of the type shown in Equation 4.1 based only on the 
quantitative data (i.e. omit the x-censored values). 
(ii) Obtain the 90% prediction interval (PI) for y at the point where x-values are censored. 
(iii) Test whether the number of censored x-values outside the 90% PI is consistent with 
the expected number following a binomial distribution. 
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If the number of censored x-values is within what would be expected. then the regression 
model based on the deletion method can be considered valid. 
An example is given where the Irish VZV standardisation panel of 14X samples is plotted 
against the Spanish reference centre's results. The Irish lab reported all-quantitative results, 
whereas the Spanish reference centre reported 18 samples (12%) below 0.002 IU/ml. The 
positive / negative cut-off was 0.05 IV/ml (-1.3 on the loglO-scale) as given by the 
reference centre. 
Figure 5.18 shows the fitted line y; = 1.81 + 0.63x; (i = I •... , 148) together with the 90% 
PI. There are 5 samples above the 90% PI. Given that there are 18 censored observations 
for x, it would be expected that 18xO.05 = 0.9 samples would be above the 90% prediction 
interval. Using a binomial test, the observed censored data above the prediction limits 
(5/18) are significantly different than those expected (p = 0.002), which suggests a 
potential change of direction for the fitted line below DL. Therefore, the fitted line using 
the deletion method may not be appropriate to use as the standardisation equation in this 
lower range. 
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The idea behind this nonparametric method, is to test whether fitting that particular type of 
equation (linear, quadratic or other) based on the deletion method, is reasonable for the 
censored dataset shown_ Given that the x-variable is censored, it is not possible to know 
the shape of the regression equation in the censored area, i.e. whether it follows the same 
equation as in the area where quantitative measurements are available. 
By testing whether the number of samples above the prediction interval is within normal 
expectations, the possibility that the data in the censored area follow a different type of 
equation is examined. Note that for the above example, the main interest is in the data 
above the prediction interval (and not so much below), because these are more likely to be 
inconsistent with the rest of the equation. There are two main possibilities for the x-
censored values: either there is a linear relationship or the data level-off. The latter would 
mean that a different type of equation could be more suitable than the linear, since it would 
fit better the y-values in the censored area. There is a third possibility of generally higher 
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variability at low levels. In this case we would expect similar numbers of x-censored data 
below and above the prediction intervals. 
5.13 Conclusions 
The results of the simulations showed that for up to 20 - 25% of censored data, simple 
substitution and deletion methods generally gave estimates close to the truth at the crucial 
point of positive / negative cut-off. This is probably sufficient for the panel test 
comparisons carried out during the ESEN2 project, since small proportions of data were 
reported as censored in most cases. However, in scenarios with more than 25% censored 
observations, the simple substitution and deletion estimates become biased whereas 
censored regression and MI methods continue to give accurate estimates (Lubin JH et al., 
2004). 
Although the simulations confirm that the methods used in the ESEN2 project to take into 
account censoring were valid, a case has been made for using the censored regression 
method instead in the future. The censored regression method can be easily applied, since 
it is readily available in most statistical software (cnreg command in Stata), although it may 
be necessary to write a maximum likelihood routine for non-linear regression models 
(examples of such routines are given in Appendix I(A». When regression assumptions 
were violated, censored regression continued to give acceptable cut-off estimates as shown 
by the simulation examples. 
The MI method has the advantage of being a more robust method for high proportions of 
censored data (>25%). However, it is often not a straight-forward method to implement, 
and some variations of this method can be computer intensive. The usage of censored 
regression is also advised by Lubin (amongst others), who claims that " ... multiple 
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imputation is necessary only if explicit values are needed for measurements below DL" 
(Lubin JH et al., 2(04). 
Two novel methods were proposed for different types of censored data. Interval censored 
regression models were suggested for assays with dilution series. In the simulation 
example shown, the interval censored regression method gave a cut-off estimate closest to 
the truth. For x-censored data, a non-parametric method was proposed for testing whether 
the regression model estimates using the deletion method can be considered valid to 
describe the relationship between the assay tests. 
Another method which was not examined in this Chapter includes the replacement of 
measurements below the DL with a constant equal to the expectation of the censored data, 
in order to obtain unbiased estimates (Akritas MG et af., I 995;Richardson DB & Ciampi 
A, 2003;Schisterman EF et ai., 2006;Lubin JH et af., 2004). Substitution with 
E(Y; I Y; < D,,) is easy to implement, and it has been found in the past to produce better 
estimates than the simple substitution with D1J 2 (Lynn HS, 2001). However, the 
drawback of substituting with E(Y; I Y; < DL ) is its dependency on distributional 
assumptions (Lubin JH et ai., 2(04). 
As mentioned above, there have been a number of papers during the last 5 years examining 
different methods to account for censored observations when estimating regression 
coefficients. Although some of the methods described in this Chapter are not new, it was 
important to apply them to these particular sets of serological data, since they have been 
found in the past to give different results under different scenarios. 
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In conclusion, the simple substitution and deletion methods as presented in the previous 
Chapter, and used for the ESEN2 project, seem to be working satisfactorily. However, for 
a future ESEN project, censored regression could provide better estimates. 
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Chapter 6: Comparison between standardised and 
non-standardised serological results 
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6.1 Serosurvey construction and national sero-profiles 
As part of the ESEN2 project, each participant laboratory was asked to collect and test its 
own national serosurvey. Each country was advised to collect around 3,500 samples 
stratified by age and sex. In this way, at least 200 samples would be obtained for each age 
group, a number which, according to the sample size calculations, would mean a 95% 
confidence interval width of 4% to 6% for seroprevalence estimates. 
In practice, smaller serosurveys were collected of minimum size 1,000 - 1,500 samples or 
100 samples per year stratum (gender was occasionally ignored). Although a population-
based serosurvey would be ideal to minimise selection bias, this was only carried out by a 
few countries due to logistical difficulties and high expense. Most participant countries 
collected serum specimens from residues remaining after the completion of 
microbiological or biochemical investigations (Osborne K et ai., 2000;Osborne Kef aI., 
1997). However, the representativeness of national serosurveys is beyond the scope of this 
thesis. 
Following the collection of the serosurvey, each national laboratory tested the samples 
using an assay of their choice. During the ESEN2 project, a standardisation algorithm was 
developed as a means to compare serological results tested in different national 
laboratories (Chapter 4). This was necessary in order to overcome the issue of variability 
between assays and laboratory methods (Andrews N et ai., 2000;Kafatos Get aI., 2005). 
Once the serosurvey results had been standardised, seroprevalence was estimated for each 
country by age group (Andrews N et ai., 2000;Kafatos G et ai., 2005). Theoretically, any 
discrepancies between standardised and non-standardised results could be explained within 
the context of variability, due to the variety of laboratory techniques and assays (Chapters 
2 and 4). 
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The main aim of this Chapter is to assess the impact of standardisation on population 
seroprevalence or national sero-profiles. The hypothesis is that if the bias corrected by 
standardisation does not greatly affect seroprevalence, then there might be a case against 
the benefits and necessity of standardising. A second aim is to identify the source of any 
differences between standardised and non-standardised seroprevalences. 
6.2 Classification into negative, positive and equivocal results 
Serological assays are used primarily for individual patient diagnosis. For this purpose, a 
simple binary outcome, either negative (unprotected against infection) or positive 
(protected against infection), should be sufficient. As discussed in Chapter 2, many of 
these assays return a continuous outcome which can subsequently be classified into 
positive or negative, by applying a cut-off point in accordance with the assay 
manufacturer's specifications. 
During the previous Chapters, it has been assumed that for each assay a unique cut-off 
point exists that classifies samples into positive and negative. However, this is not strictly 
true since many assays have two cut-off points instead of one. Using these, quantitative 
measurements can be classified into negative, positive and equivocal or low positive 
results. 
In the following example, the serosurvcy that was carried out by Spain in 1996 as part of 
the ESEN2 project is presented. The serosurvey involved collecting and testing 3,605 
samples for VZV using an ELISA assay (Enzygnost VZV, Dade Behring, Germany) (de 
Ory F et al., 2(06). Two cut-off points were specified by the assay manufacturer: 0.05 and 
0.1 IV/mt. According to these, 522 samples were classified as "negative", 14 samples were 
classified as "equivocal" and 3,069 as "positive". The loglO-transformed distribution of 
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IU/ml by four different age groups together with the cut-off range can be viewed in Figure 
6.1. 
Figure 6.1 Frequency distribution of VZV Spanish results by age group 
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Since the aim of the ESEN2 project was to estimate seroprevalence in the population, a 
single cut-off point was required. 0.05 IU/ml was chosen i.e. the lower cut-off point 
specified by the assay manufacturer (de Ory F et af., 2006)_ Merging equivocal with 
positive results is a practice commonly applied to serological data, and it was used for a 
number of different antigens and assays throughout the ESEN and ESEN2 projects 
(Andrews N ef al., 2008;de Melker H et af., 2001 ;Pebody RG et af., 2000;Tischer A et ai., 
2007;Andrews N et aI., 2(00). In this thesis, any future reference to a single assay cut-off 
will mean that such merging has taken place where necessary. 
As far as the above example is concerned, there was little difference in seroprevalence 
estimates when the equivocal results were merged with positive or negative samples or 
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were ignored altogether, since few observations in this serosurvey were classified as 
equivocals. 
6.3 Obtaining standardised and non-standardised sero-profiles 
For the purposes of the ESEN2 project, the standardisation algorithm was applied to the 
serosurvey results for each country resulting in common units. These measurements were 
classified as either "negative" or "positive" according to the reference centre's assay 
manufacturer. The national seroprevalence was then calculated by estimating the 
percentage of positive samples for each country and age group. 
A serosurvey case of 1,592 sera was tested by the Israel national laboratory for VZV using 
the same assay as the Spanish reference laboratory (Enzygnost VZV, Dade Behring, 
Germany). After a panel of 133 samples were tested by both laboratories, a quadratic 
equation was selected to transform Israel's results into comparable units according to the 
Spanish reference centre's assay specifications (de Ory F et ai., 2006). The standardisation 
curve and the reference centre's positive I negative cut-off (i.e. 0.05 IUlml or -1.3 on the 
10glO-scale) are given in Figure 6.2 below. 
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The equation -", = -O.08+x, +O.14x; (i = I, ... , 133) was selected to standardise the Israel 
serosurvey results as shown in Equation 4.11. Figures 6.3(a) and 6.3(b) show the 
distribution of serological results prior to and after standardising for three age groups (1-9, 
10-19 and more than 20 years). 
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Figure 6.3 Distribution of Israel's VZV serosurvey results by age groups 
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Following standardisation, continuous measurements may be classified into negative or 
positive results. Figure 6.4 below presents a comparison between the standardised and non-
standardised outcome. 
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Figure 6.4 Sero-profile for Israel's VZV results before and after standardisation 
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The difference between standardised and non-standardised results suggests that a number 
of samples valued near the negative / positive cut-off point may be classified differently by 
the national and the reference laboratories, especially among 15-25 year olds, 
A qualitative comparison of the data is presented in Table 6.1. There was a discrepancy of 
23 samples (i.e. 1.5% of the data) that were tested as positive by the Israel assay but were 
re-c1assified as negatives following standardisation, 
Table 6.1 Comparison between standardised and non-standardised results classified 
as negative and positive 
standardised classification 
negative positive Total 
local negative 162 0 162 
classification positive 23 1407 1430 
Total 185 1407 1592 
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The discrepancy may be further investigated by re-introducing the "equivocal" 
classification. Equivocal samples were defined as 0.05 to 0.1 IU/ml according to the Dade 
Behring assay manufacturer but were regarded as positives for the purposes of 
seroprevalence calculation. Table 6.2 shows the qualitative comparison grouped into 
negative, equivocal and positive results. Twenty-eight of the 5 I samples that were 
classified as equivocal were classified the same following standardisation. Twenty-three 
samples were re-classified as negatives. 
Table 6.2 Comparison between standardised and non-standardised results classified 
as negative, equivocal and positive 
standardised classification 
negative equivocal positive Total 
local negative 162 0 o 162 
classification equivocal 23 28 o 51 
positive 0 21 1358 1379 
Total 185 49 1358 1592 
Figure 6.5 below shows Israel's VZV results by age, classified into negative, equivocal and 
positive before they were standardised. It was mainly the equivocal results for ages 17 to 
24 years, of which there was a high number, that were re-classified following 
standardisation. Given that for Israel there was no routine vaccination programme 
established at the time the serosurvey was tested, it is possible that the equivocal results 
represent waning antibody immunity following childhood infection (Pinot de Moira A & 
Nardone A, 2005). Note that in this case, the standardisation helped to identify a 
potentially important epidemiological finding which may otherwise have been missed. 
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Figure 6.5 Non-standardised results for Israel VZV serosurvey by age group 
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6.4 Between-laboratory and within-laboratory variability 
As was brie fl y mentioned in Chapter 4, variability between erologica l results can be 
ca tegori sed into the fo ll owing two types: 
(a) or sera that are tes ted within a laboratory using a specific assay, variabi lity in tes t 
res ults wi ll be referred to a wiThin-laboratory va riability. Thi may occur, either due to 
s light changes in the conditio ns in which the te t took place or due to diffe rent individual s 
carrying out the test. Diffe rences between a ay plate mayal 0 be responsible for this 
variabili ty but thi s will be exa mined in hapter 9. 
(b) For the purposes of the ESEN2 project national ero urvey were te ted in different 
laboratories. Thi introduced a different . ource of variation that will be referred to as 
between-laboratory variability. Thi s type of variation may occur a laboratories use 
s li ghtly different procedur and / or diffe rent a ay. Since between-laboratory variability 
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is systematic (e.g. an assay being more sensitive than others), it can also be referred to as 
bias. 
In most situations between-laboratory variability would be expected to be higher than 
within-laboratory variability. Standardisation provides a method of correcting such bias. 
6.5 Impact of standardisation on sero-profiles 
Assuming no failure of the standardisation methodology, the difference between 
standardised and non-standardised seroprevalence estimates serves as a measurement of 
the within- and mainly between-laboratory variability. In other words, the larger the bias 
between laboratory results the greater the difference between standardised and non-
standardised outcomes. 
However, the exact nature of this variability is not clear. It is very likely a combination of 
variability generated from different assay methods, and differences in laboratory 
techniques and procedures. The level of the variability may also be expected to vary 
between different antigens and age groups. 
In order to provide a measure of the variation between standardised and non-standardised 
seroprevalence estimates, the difference in seroprevalence estimates across age groups, 
EPj, for age groupsj = I, .... i;, was defined as follows: 
EP = I" -1jJ, J rJ J 
Equation 6.1 
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where (jJ and {I refer to the seroprevalence estimates before and after standardisation, 
respectively. Then the extreme seroprevalence difference EP is the value of EPj , for which 
IEP) is at maximum. 
In addition, the mean of overall absolute seroprevalence difference or simply mean 
seroprevalence difference MP was defined as: 
Equation 6.2 
Note that in order to calculate the mean seroprevalence difference the data were re-grouped 
into yearly age groups to ensure that all groups were of equal length. 
For instance, in the Israel VZV results (Figure 6.4), the extreme seroprevalence difference 
was observed for the 19 years age group i.e. EP = -13%. The mean seroprevalence 
difference was MP = 2% . 
Tables 6.3 (a)-(O show the assay methods by antigen used in each laboratory, the local 
assay cut-off values and the extreme and mean seroprevalence differences following 
standardisation. In addition, the tables indicate whether the back-standardisation method 
was used (the back-standardisation method was explained in Section 4.10). 
Seroprevalence was only estimated for measles, mumps, rubella, diphtheria, VZV and 
HA V. Pertussis serosurveys were excluded from the analysis since there are questionable 
serological correlates of protection. For the purposes of the ESEN2 project, pertussis titres 
were examined after they were categorised according to their titre measurement 
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(Giammanco A et al .. 2(08). HBV serosurveys were also excluded because seroprevalence 
estimation was more complex, requiring the testing of antibodies against several different 
antigens (Section 2.4). 
Table 6.3 Comparison of standardised and non-standardised seroprevalence 
estimates by laboratory and assay method used 
(a) Measles 
assay back-standardisation local age group 
country method' method used cut-off (yrs)** EP(%) MP(%) 
Australia DB no 0.15 10 -4.4 0.9 
Belgium HC no 27 11 71.0 52.1 
Bulgaria HC no 27 30-39 16.5 9.4 
Cyprus ER no 0.25 14 26.7 10.2 
Czech Republic SK no 0.2 1-4 -5.4 2.4 
Germany DB no 0.15 reference 
Hungary VR no 0.15 20-29 -6.7 0.9 
Ireland Biotech no 0.9 5-9 3.1 2.2 
Israel DB yes 0.15 8 -2.0 0.4 
Latvia HU no 0.4 10-19 14.6 5.6 
Lithuania DB no 0.15 20-24 18.5 3.8 
Luxembourg DB no 0.15 no difference 
Malta VR no 0.15 5-9 0.4 0.2 
Romania DB no 0.15 11, 14 2.6 1.0 
Slovakia VT no 9 25-29 -3.6 0.6 
Slovenia DB no 0.17 20-24 4.5 1.5 
Spain DB yes 0.15 3 -1.6 0.2 
Sweden In-house yes 0.12 8 9.5 4.1 
UK DB no 0.15 11 10.2 1.6 
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(b) Mumps 
assay back-standardisation local age group 
country method- method used cut-off (yrsr- EP(%) MP(%) 
Belgium HC no 27 17.9 2.9 
Bulgaria HC no 27 3 -34.1 20.2 
Cyprus ER no 20 10 22.0 12.5 
Czech Republic SK no 200 -20.0 5.5 
Finland DB no 230 13 -3.1 1.3 
Germany DB no 230 reference 
Hungary VR no 70 5 2.0 0.4 
Ireland Capita no 0.9 8 ·2.1 0.4 
Israel DB yes 231 5 -18.6 5.7 
Latvia HU no 39 8.0 5.1 
Lithuania DB no 150 14 -4.8 1.4 
Luxembourg DB no 231 13 -9.0 2.7 
Malta VR no 150 6 22.5 8.9 
Romania DB no 150 25-29 -5.7 3.3 
Slovakia VT no 9 7 1.9 0.4 
Slovenia DB no 190 19 -11.0 2.9 
Spain DB yes 230 7 -13.0 5.0 
Sweden DB yes 230 2 -12.8 7.8 
UK DB no 230 12 -4.0 1.0 
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(c) Rubella 
assay back-standardisation local age group 
country method" method used cut-off (yrs)·" EP(%) MP(%) 
Auslralia DB no 5 30.2 8.1 
Belgium DO no 10 9,10 30.1 16.1 
Bulgaria PL no 27 5 6.0 1.9 
Cyprus Radim no 8 14 18.9 5.9 
Czech Republic DO no 8 10-14,15-19 2.2 1.3 
Germany DB no 4 reference 
Hungary DO no 10 5-9 7.7 5.1 
Ireland Biokil no 10 10 3.3 0.8 
Israel DB yes 4 4 -4.5 0.8 
Latvia PL no 0.4 -18.7 4.5 
Lithuania DB no 4 no difference 
Luxembourg DB no 6 no difference 
Malta Abbott no 5 40+ -1.1 1.0 
Romania DB no 4 3 -1.8 0.4 
Slovakia DO no 9 7 -1.9 0.4 
Slovenia DB no 4 14 -1.0 0.3 
Sweden In-house yes 8 no difference 
UK Microgen no 0.89 7.7 1.6 
(d) Diphtheria 
assay back-standardisation local age group 
country method" method used cut-off (yrs)"" EP(%) MP(%) 
Australia DAE yes 0.01 30-39 3.0 0.8 
Czech Republic NT no 0.01 50+ -5.9 2.2 
Finland NT no 0.01 reference 
Hungary Passive Haem yes 0.Q1 50+ -20.8 4.4 
Ireland NT no 0.016 no diflerence 
Israel DAE no 0.01 60+ -11.6 3.4 
Latvia ELISA (Hycor) yes 0.Q1 50+ -8.9 4.3 
Luxembourg NT no 0.01 no diflerence 
Slovakia NT yes 0.01 20-29 14.5 10.5 
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(e) VZV 
assay back-standardisation local age group 
country method' method used cut-off (yrs)" EP(%) MP(%) 
Belgium DB no 50 6,8, 13 -2.1 0.8 
Finland DB no 50 8 -4.2 0.2 
Germany DB yes 50 6 -0.8 0.1 
Ireland DiaMedix no 15 4 4.3 1.9 
Israel DB no 50 15-19 -13.0 1.8 
Italy DB yes 50 2 -2.8 0.6 
Luxembourg DB no 50 5 -1.4 0.5 
Netherlands HU no 0.3 10-14 -0.3 0.0 
Slovakia ER no 250 3 16.2 5.3 
Spain DB no 50 reference 
UK DiaMedix yes 15 10.3 5.3 
(f) HAV 
assay back-standardisation local age group 
country method' method used cut-off (yrsr' EP(%) MP(%) 
Belgium DiaSorin no 10 2 20.2 9.4 
Czech Republic Abbott (AxSYM) no 40+ -23.3 15.1 
Finland Enzygost no 10 no difference 
Germany Abbott (AxSYM) yes 
no difference 
Greece Abbott (AxSYM) no 10 reference 
Ireland DiaSorin no 10 7 18.1 9.1 
Italy DiaSorin no 10 4 -29.9 8.0 
Lithuania Enzygost no 10 20-24 
-39.9 17.1 
Malta Abbott (AxSYM) no 7 3.4 0.6 
Netherlands Abbott (AxSYM) yes 9,25-29 
-2.4 1.8 
Romania Abbott (AxSYM) no 10 7.2 0.8 
Slovakia DiaSorin no 20 2 0.9 0.3 
* Assay abbreviations: ER: Euroimmun; DAE: Double Antigen ELISA; DB: Dade Behring; DO: ETI-RUBEK-
G PLUS; He: Hycor; HU: Human; PL: PJateJia Rubella IgG; SK: Seiken; VR: Virion; VT: Viotech 
** Note that "age group (yrs)" denotes the age group(s) with the highest maximum seroprevalence difference_ 
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There were a number of laboratories where the mean seroprevalence difference was 0, 
whereas the highest MP resulted from testing the Belgian measles serosurvey (MP = 
52.1 %). The overall median M P was 1.6 with a corresponding interquartile range (IQR): 
[004,5.1 J (the arithmetic mean MP was 3.5; 95% CI:[2.5, 4.5]). The extreme 
seroprevalence difference was highest for Belgian measles serosurvey for II year-olds 
(E~, = 71.0%). 
6.6 Examples of differences between standardised and non-standardised 
seroprevalence 
Several examples are given in an attempt to illustrate the differences between standardised 
and non-standardised seroprevalence. The first example is that of the Italian serosurvey 
results for HAV. As shown in Table 6.3(f), the Italian laboratory used a different assay 
(DiaSorin) to the reference centre (Abbott (AxSYM». Although both assays had the same 
cut-off value (10 IUlml), a great number of samples were re-classified following 
standardisation, which meant that both the maximum seroprevalence and the mean 
absolute seroprevalence differences were large (EP4 = -29.9% and MP = 8.0%, 
respectively). 
Looking at the standardisation panel results produced by both laboratories, and the 
standardisation curve, the Italian assay gave higher measurements around the positive I 
negative cut-off (Figure 6.6). This means that, following standardisation, positive 
serosurvey samples just over the Italian cut-off (shaded area) were re-classified as 
negative. 
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T he estim ated seroprevale nces for Italian serosurvey results tested against HA V before and 
a ft e r these were standardi sed are shown in Figure 6_7_ It seems that there is a high numbe r 
o f low positi ve results for Ita ly for the under 25 year-olds, which transla tes into a 
seropreva lence diffe rence be tween standardised and non- tandardi sed results_ The refore, 
fo r thi s exa mple. seroprevalence difference can be attributed to laborato ry testing, 
although it is unclear whethe r (or how much) the difference i a re ult of the diffe rent 
a says, or is due to diffe rence between laboratory practices_ 
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Figure 6.7 Differences between standardised and non-standardised seroprevalence of 
Italian HA V results by age 
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The second example is that of the UK rubella serosurvey results for VZV. These were 
obtained using a different assay (Microgen with an assay cut-off of 0.8 units) to that used 
for the reference centre's samples (Dade Behring with a cut-off of 4 IVlml). Although on 
average the seroprevalence estimates did not differ much after standardisation (M P = 
1.6%), there was a high discrepancy between the estimates for the 1 year-olds (EP) = 
7.7%). 
Looking at the standardisation curve, any negative results for the UK that were just below 
the local assay cut-off (shaded area) were re-classified as positive following 
standardisation (Figure 6.8). 
155 
















o _______________________________ ~- :'---------- ------- ------- ---------------_. 
·1 L-____ ~----._----._----._--_.----_.----_,----_. 
·.5 o .5 1 1.5 2 2.5 3 
Germany (log1O-scale) 
1--- ---. -- testing lab cut·off - - - reference centre cut·off 1 
Given that the low negative UK results were re-c1assified as positives following 
standardisation, the standardised seroprevalence estimates are higher than the non-
standardised (Figure 6.9). This is the opposite effect to the previous example, where the 
standardised seroprevalence estimates were lower than the non-standardised. Note that in 
this example, the extreme seroprevalence difference is positive since the standardised 
estimate is higher. 
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Figure 6.9 Differences between standardised and non-standardised seroprevalence of 
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The third example is that of the Belgium serosurvey results for measles. Here there are 
large differences between standardised and non-standardised seroprevalence (EP 11 = 
71.0% and M P = 52.1 %). Figure 6. 10(a) shows that the difference between the two curves 
follows a similar pattern by age. Figure 6.1 O(b) shows the same data but multiplied by 10 
before taking logs. In this case, standardised and non-standardised seroprevalence match, 
which raises the question of whether the non-standardised data, tested by the Hycor assay, 
were reported on the right scale. 
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Figure 6.10 Differences between standardised and non-standardised seroprevalence 
of Belgian measles results by age 
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6.7 Variability due to different assays 
Comparisons of mean seroprevalence differences allow us to investigate different sources 
of variability. This may occur due to different laboratory techniques or the use of a variety 
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serological assays and it is important to understand how these varied for individual 
antigens and how they were affected by age. 
Assessing the variability that occurs between different assays was possible by contrasting 
seroprevalence between laboratories that used the same assay as the reference laboratory, 
and seroprevalence between laboratories using different assay types. In order to examine 
variability, the results were further summarised by classifying the mean seroprevalence 
difference into 3 groups: < 5%,5% - 10%, and> 10% (Table 6.5). 
Table 6.5 Mean seroprevalence difference between laboratories that used the same 






















Overall, 84% of the laboratories that used the same assays as the reference laboratories had 
a mean difference between standardised and non-standardised seroprevalence of less than 
5%. A significantly higher proportion of laboratories that used different assays to the 
reference centres had MP higher than 5% (p = 0.013). This suggests a smaller 
standardisation effect on seroprevalence for laboratories that used the same assay as the 
reference centre. 
6.8 Variability arising due to different antigens 
As shown before. there is a difference in mean seroprevalence by antigen which could 
explain part of the overall differences between standardised and non-standardised 
estimates. Table 6.6 shows that there were on average higher differences between 
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standardised and non-standardised seroprevalence for HA V (MP 2: 5% for 45% of the 
laboratories participating in the serosurvey), or mumps (44% of the participant laboratories 
had MP 2: 5%) compared to other antigens (less than 25% of the serosurveys had MP 2:5 
%). 
Table 6.6 Mean seroprevalence difference between antigens 
mean seroprevalence difference 
antigen <5% 5-10% >= 10% Total 
measles 14 (77.8%) 2 (11.1%) 2 (11.1%) 18 (100%) 
mumps 10 (55.6%) 6 (33.3%) 2(11.1%) 18 (100%) 
rubella 13 (76.5%) 3 (17.6%) 1 (5.9%) 17 (100%) 
diphtheria 7 (87.5%) 0(0%) 1 (12.5%) 8 (100%) 
VZV 8(80%) 2 (20%) 0(0%) 10 (100%) 
HAV 6 (54.5%) 3 (27.3%) 2(18.2%) 11 (100%) 
Total 58 (70.7%) 16 (19.5%) 8 (9.8%) 82 (100%) 
6.9 Variability due to different age groups 
For the youngest and oldest age groups (1-4 and 20+ year-olds, respectively) the maximum 
difference between standardised and non-standardised seroprevalence seems to be higher 
than in the other age groups (approximately 70% of the serosurveys had EP 2: 5% for these 
age groups - Table 6.7). The generally higher EP for these age groups are due to a high 
number of low positive results that were classified differently following the application of 
the standardisation equation. For those older than 20 years the reason may be waning 
immunity. 
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Table 6.7 Extreme seroprevalence difference between age groups 
extreme seroprevalence difference 
age group <5% 5·10% >= 10% Total 
1-4 6 (30%) 4(20%) 10 (50%) 20 (100%) 
5-9 12 (63.2%) 3 (15.8%) 4(21.1%) 19 (100%) 
10-19 9 (52.9%) 1 (5.9%) 7(41.2%) 17 (100%) 
20+ 4 (28.6%) 4 (28.6%) 6 (42.9%) 14 (100%) 
Total 31 (44.3%) 12 (17.1%) 27 (38.6%) 70 (100%) 
6.10 Failure of standardisation method 
As mentioned above, once the results of a serosurvey have been standardised, the resulting 
difference between standardised and non-standardised seroprevalence estimates can be 
attributed to within and between-laboratory variability. However, it may also be a result of 
a failure of the standardisation method. More specifically, large differences may indicate 
that laboratory procedures may have changed between the time of testing the 
standardisation panel and the serosurvey samples. Alternatively, it could be a result of an 
atypical set of samples used for the standardisation panel, which could have resulted in a 
biased standardisation equation. 
Theoretically, such potential failures should not occur when the back-standardisation 
method is being used since the panel is chosen from already-tested serosurvey (Section 
4.10). In practice, however. a different type of bias would arise from using back-
standardisation. This would be due to the deterioration of serum samples with time as the 
same serosurveys had sometimes been stored for more than 5 years before the beginning of 
the ESEN2 project. 
A comparison between standardised and non-standardised estimated seroprevalence 
obtained with and without back-standardisation is shown in Table 6.8. There was little 
difference between the two methods, with standardisation reporting a slightly higher 
161 
proportion of serosurveys with MP > 10% (9% and 6% for standardisation and back-
standardisation, respectively), but slightly lower for MP between 5% and 10% (19% and 
24% for standardisation and back-standardisation, respectively). 
Table 6.8 Mean seroprevalence difference between standardisation and back-
standardisation methods 
mean seroprevalence difference 
method <5% 5-10% >= 10% 
standardisation 46 (71.9%) 12 (18.8%) 6 (9.4%) 
back-standardisation 12 (70.6%) 4 (23.5%) 1 (5.9%) 
Total 58 (71.6%) 16 (19.8%) 7 (8.6%) 





The tables above show a descriptive interpretation of the seroprevalence difference 
between the standardised and non-standardised results. The mean seroprevalence 
difference was also analysed using a muItivariable regression model aimed at identifying 
the factors associated with large differences in seroprevalence estimates. 
Each of the 22 national laboratories participating in ESEN2 was involved in testing 
samples of between 2 and 6 antigens. Apart from the reference laboratories where no 
standardisation was necessary, the Belgian measles data were also excluded, since there 
was a question of integrity of the data (Section 6.6). The distribution of the mean 
seroprevalence differences for the remaining 81 serosurveys is shown in Figure 6.11. 
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In order to satisfy the normality assumptions the data were logl o-transformed . For 8 
serosurveys there was no difference between standardised and non-standardised results at 
any age group. The e were replaced by the lowest mean seroprevalence difference (MP = 
10g lO(0. 1 )), and were treated in the analysis as censored (Figure 6. 12). 
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A censored normal regression model was fitted to the log-transformed mean 
seroprevalence differences. The explanatory variables were the 22 laboratories, the 6 
antigens, whether the back-standardisation method was used and whether the laboratories 
used the same assay method as the reference laboratory. The model results (that the model 
estimates and their corresponding confidence intervals have been exponentiated for 
interpretation purposes) are shown in Table 6.9. Note that a likelihood ratio test was used 
to test whether the addition of a particular variable in the model provided a better fit (the 
likelihood ratio test is discussed in detail in Section 7.4). 
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Table 6.9 MuItivariable analysis of mean absolute seroprevalence differences 
Variable Level MP estimates 95%CI p-value 
antigens measles baseline 
mumps 2.58 (1.17,5.72) 
rubella 0.68 (0.30, 1.54) 
diphtheria 0.78 (0.24, 2.47) 
VZV 1.55 (0.53, 4.56) 
HAV 2.87 (1.02,8.07) 0.014 
variability due to assay same assay baseline 
different assay 1.32 (0.62, 2.82) 0.477 
back-standardisation no baseline 
yes 2.22 (0.77,6.35) 0.140 
national laboratories Italy baseline 
Australia 2.57 (0.27, 24.84) 
Belgium 3.46 (0.43,28.18) 
Bulgaria 7.37 (0.73, 73.89) 
Cyprus 9.41 (0.94, 94.40) 
Czech Republic 3.78 (0.46, 30.95) 
Finland 0.16 (0.02, 1.49) 
Germany 0.02 (0.00, 0.26) 
Hungary 1.60 (0.18, 14.22) 
Ireland 0.91 (0.12, 7.00) 
Israel 1.17 (0.15,8.94) 
Latvia 4.59 (0.52, 40.88) 
lithuania 1.57 (0.18,13.65) 
Luxembourg 0.22 (0.02, 1.97) 
Malta 0.91 (0.11,7.70) 
Netherlands 0.13 (0.01, 1.45) 
Romania 1.11 (0.13,9.90) 
Slovakia 0.92 (0.12, 6.76) 
Slovenia 1.49 (0.15,15.31) 
Spain 0.46 (0.04,5.71) 
Sweden 0.64 (0.06, 6.59) 
UK 1.76 (0.22,14.17) 0.003 
constant 0.61 (0.08, 4.37) 0.622 
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Antigens were significantly associated with mean seroprevalence difference (p = 0.014) 
and in particular, mumps and HA V had the highest MP estimates. There were significant 
differences between MP by different laboratories (p = 0.003). The Bulgarian and Cypriot 
laboratories had the highest MP estimates which were significantly higher than the German 
laboratory, where the smallest differences were observed. 
Using a different assay from the reference laboratory did not affect the number of samples 
re-classified following standardisation, and hence, the mean seroprevalence difference (p = 
0.48). Using back-standardisation seemed to generate higher mean seroprevalence 
differences, however, this finding was not significant (p = 0.14). 
The mean seroprevalence difference estimates for different antigens, and whether back-
standardisation was used, are also shown in Figure 6.13 below. The back-standardisation 
method seems to consistently give higher seroprevalence differences although the 
confidence intervals overlap. 
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Figure 6.13 Multivariable model results of mean absolute seroprevalence differences 
by antigen and whether back-standardisation was used (adjusted for laboratories and 
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A an alternative analy. i method, the mean seroprevalence differences were grouped into 
"<5 %" and "~5 1'0". A logistic regression model was fitted using the same explanatory 
variab les as in Tabl 6.8. There was significant association between the mean 
seroprevalence diffe rence and antigens (p = 0.009) with mumps and HAY having hi gher 
odds of mean seroprevalence difference of 5% or higher. There was no ev idence of an 
as ociation between more than 5% seroprevalence differences and testing in different 
laboratories (p = 0. 16). LI ing the back- tandardisation method (p = 0 . 18) or when using 
different assays than the refere nce centre (p = 0.62). Note that different MP clas i fications 
gave sli ght ly differe nt model est imates; there were generally s ignificant difference 
between antigen and borderline significant evidence for different laboratorie .. 
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6.12 Conclusions 
The main aim of this Chapter was to quantify the impact of standardisation on 
seroprevalence estimation. Overall, the median change of seroprevalence estimates 
following standardisation was 1.6 (lQR: [0.4, 5.1]) whereas the geometric mean was 3.5 
(95% CI: [2.5,4.5]). 
A secondary aim was to test the hypotheses of seroprevalence differences occurring due to: 
(a) different antigens, (b) using assays other than the reference one, (c) differences in 
laboratory methods even when using the same assay and (d) whether the back-
standardisation method had been used. 
The number of samples re-classified following standardisation varied greatly between 
antigens, with HA V and mumps showing the highest change on seroprevalence estimates. 
For both antigens, many serological assays performed poorly with high variability around 
the standardisation equations which meant that there was an increased risk for samples to 
be misclassified. Moreover, the changes in seroprevalence can be explained by between-
laboratory variability, with a high number of samples re-classified following 
standardisation for the Cypriot and the Bulgarian laboratories. 
As mentioned above, in theory, back-standardisation might provide a better technique 
because it ensures there are no differences between the standardisation panel and the 
serosurvey serological samples. This was not shown from the analysis results, where the 
sample's re-c1assification following standardisation was higher using back-standardisation 
(although this finding was not significant). The reason for this may be a different type of 
bias attributed to the deterioration of the serum samples with time. In the case of back-
standardisation it may be several years between the time the serosurvey is tested and the 
time the standardisation panel is chosen and tested. Hence, there is little benefit from using 
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back-standardisation, and therefore, it is only advised to be used as an alternative method 
to the standard method that was most commonly used during the ESEN2 project. 
In addition to variability and potential bias, another issue appears important when dealing 
with serosurvey estimates. The cut-off point above which the quantitative results of an 
assay are considered positive (i.e. individuals are protected) is currently defined by the 
assay manufacturer using a variety of methods. The choice of this cut-off is very important 
since it directly affects the classification of the assay results. This issue will be addressed 
in detail in Chapter 8. Chapter 7 will introduce mixture modelling as an alternative method 
of analysing serological results. 
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Chapter 7: Mixture models as an alternative method 
to standardisation 
170 
7.1 Introduction - A standardisation limitation 
As discussed in the previous Chapters, once the serosurvey results had been standardised to 
common units, these were classified as positive and negative in order to estimate the 
population seroprevalence. This classification was carried out in accordance to a cut-off 
point specified by the reference centre's assay manufacturer. The choice of this cut-off is 
very important since it directly affects the classification of the assay results of all 
participant laboratories. 
A detailed discussion on how these cut-offs were chosen by the assay manufacturers and 
alternative techniques for estimating such cut-offs, is provided in Chapter 8. The present 
Chapter will address the question of whether the method of standardisation and the 
definition of cut-offs can be bypassed altogether by the application of mixture models 
directly on the non-standardised serological results. Several types of mixture models will 
be presented, and a comparison between seroprevalences obtained by standardisation and 
mixture modelling will be carried out. The advantages and disadvantages of each method 
will be discussed. 
7.2 Background on mixture modelling 
The standardisation method was developed to compare seroprevalence estimates for the 
ESEN2 project. An alternative method for seroprevalence estimation that has been used in 
the past is mixture modelling, which has been described as "a statistical method that can be 
used to reveal component distributions in a heterogeneous population" (Dong Z, 1997). 
Mixture model methodology has been developing for the last 100 years, however due 
mainly to computational difficulties, it is only since the 1980s that considerable advances 
have been made in fitting these models, and in particular using the method of maximum 
likelihood (McLathlan G & Peel 0, 2000). As an illustration of these difficulties, in 1894 
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Karl Pearson had to solve a ninth degree polynomial using the method of "moments 
estimators" for a mixture model with two normal components. Since the development of 
modern computers, mixture models have become popular in many scientific areas using 
maximum likelihood to obtain parameter estimates (Dong Z, I 997;McLachlan G & Peel 0, 
2000). 
In terms of applications to serological data, a mixture model was first used in 1990 for 
estimating an assay cut-off that accurately classifies individuals' sera (Parker RA et aI., 
1990). That particular application of mixture modeling will be discussed in detail in 
Chapter 8. A mixture model was first used to estimate population seroprevalence directly 
from the data, rather than initially classifying individual samples into "positive" or 
"negative", in a parvovirus serosurvey carried out in 1991 (Gay NJ, 1996). Since then, 
amongst other studies, they have been used to model VZV (Vyse AJ et ai., 2004) and 
measles, mumps and rubella data (Vyse AJ et aI., 2006;Hardelid P, 2008). 
The mixture modelling method is presented below as it may be generally applied. This will 
allow for comparison with the standardisation algorithm to illustrate the major advantages 
and drawbacks of this methodology. 
7.3 A simple mixture model 
A generalised equation for the probability density function of a mixture model with 
components from the same family of distributions can be defined as: 
Equation 7.1 
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where trj is the probability that an observation comes from component j = I, ... , K 
( ~H, = ,). W;th;n componentj, x has dens;ty g(x; 0) where OJ are pam meters that vary 
between components (McLachlan G & Peel D, 2000). 
Since the serosurveys examined were age stratified, the mixture models used should be 
estimated within age groups, which means that the model in Equation 7. I becomes: 
Equation 7.2 
for i = I, ... , (age groups. 
A simple mixture model is applicable to serological survey data assuming: 
I. Two underlying distributions corresponding to two distinct popUlation groups, one for 
negative samples / susceptibles and one for positive / protected individuals. Letj = 0 
denote the negatives and j = I the positives, and set 7ril = 7ri, 7riO = I - 7ri. Hence, tri is the 
seroprevalence for age group i. 
2. The underlying component distributions are normal. 
3. The shapes of the underlying distributions (location and dispersion parameters) are 
common across age groups and therefore, do not change with age. 
Given these assumptions, Equation 7.2 becomes: 
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Equation 7.3 
where x denotes the loglO-transformed IU/ml, fN(x;J'-,(JJ, fN(X;P+,(J+) are the normal 
density functions for the negative and positive populations, respectively and 1C; stands for 
seroprevalence in age group i, 
The model parameters 11-, (J., Ph (J+ and 1C; of the Equation 7.3 can be estimated using 
maximum likelihood. The log-likelihood function used for such maximisation is obtained 
as a sum of terms: 
In(L,,;) = In (g; (x,,)), 
Equation7.4 
where Xh. II = I, ... , n; are the quantitative observations in age group i. 
For data below the assay detection range (left-censored), the log-likelihood becomes: 
Equation 7.5 
where F N is the standard normal cumulative distribution function and xc, c = 1, ... , f i are 
the left-censored observations in age group i. 
Similarly, for right-censored data, the log-likelihood is: 
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Equation 7.6 
where Xd, d = I, ... , mi are the right-censored observations in age group i. 
7.4 Model diagnostics 
Once a mixture model is fitted to the data, it is important to look at model tit and 
investigate whether model assumptions hold. There are several diagnostic criteria that can 
be used (a) to compare different models which are either nested or not and (b) to assess the 
overall fit of a model. Some of these are listed below. 
AIC and BIC 
One method for making comparisons between models is the Akaike Information Criterion 
(AIC) defined as 
AIC = -2In(L) + 2k , 
Equation 7.7 
where In(L) is the maximised log-likelihood of the model, and k denotes the number of 
parameters in the model. 
An alternative method is the Bayesian Information Criterion (BIC) defined as 
BIC = -21n(L) + k In(n), 
Equation 7.8 
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where n is the number of observations. 
In each case, the model with the lowest value of the chosen information criterion is 
selected. 
These approaches penalise models with high number of parameters, with BIC producing a 
greater penalty as compared to Ale (Morgan BJT, 2000). 
Likelihood ratio test 
AIC and BIC are often used to make comparisons between models since they are easy to 
derive. However, when the models to be compared are nested within each other, i.e. the 
more complex ones can be transformed into the simpler ones by applying a set of linear 
constraints on the parameters, then the likelihood ratio test or deviance test can be used 
instead. 
Suppose LI is the maximum likelihood of model I and L2 the maximum likelihood of 
model 2 that is nested within model 1 i.e. model 2 is a simplification of model 1. For 
testing the null hypothesis that model 2 is the true model, the likelihood ratio test statistic 
D is defined as: 
D'if,-dJ, =-2In(~)= -2(ln(£.,)-ln(I.,»). 
Equation 7.9 
Under the null hypothesis that model 2 is the true model, the statistic D follows an 
approximate chi-square distribution with d!2 - dJi degrees of freedom, where d!l, dh are the 
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degrees of freedom for the model I and model 2, respectively (Collett D, 1999;Kuha J, 
2004). 
Pearson Goodness-of-fit test 
There are different methods of testing the model fit, the most commonly used being the 
Pearson Goodness-oI-fit test (Kirkwood BR & Sterne JAC, 2003;Morgan BJT, 2000). An 
often quoted disadvantage of this method is that the data need to be grouped into bins prior 
to carrying out the test, and therefore, the results depend on how these bins have been set. 
However, having to define the bins may also be an advantage since it makes it possible to 
focus around the area of interest e.g. around the region where densities meet for the 
mixture models presented here (and hence, where miscIassification is most likely to occur). 
To test the null hypothesis that the data follow a specific distribution, assume the data have 
been divided into N bins. For a bin i defined by the interval [XL, Xu] the expected 
frequency is: 
Equation 7.10 
where n is the total number of observations and F is the cumulative distribution function. 
The Pearson test statistic is then calculated by: 
Equation 7.11 
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where 0; is the observed frequency. Under the null hypothesis that the model is correct, the 
test statistic follows an approximate chi-square distribution with N - m - I degrees of 
freedom where m is the number of estimated parameters. 
To show where the greatest differences between observed data and fitted distribution lie, 




Under the null hypothesis we would expect most of the residuals to fall within the range 
±2. The expected frequencies in each bin need to be sufficiently large (at least 5) for the 
chi-squared distribution to be correct, and hence for the test to be valid (Zar JH, 1999). 
Bootstrapping 
Another method used to assess the model fit at different points of the serological 
distribution is bootstrapping. The method is described as follows: 
1. Using the observed data y; (i = I, ... , n), a random sample y; can be drawn using 
sampling with replacement (bsample command in Stata). This is possible if each 
measurement selected randomly from n observations, is returned back to the sample before 
the next measurement is drawn. In other words, each measurement has a probability of 11 n 
of being selected in the first place and can be included in the sample multiple times. This 
process can be repeated until M random samples of size n have been drawn. 
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2. Mixture models can be fitted to each of these samples obtaining estimates 8,:; where h = 
1, ... , k indexes the model parameters andj = 1, .. , M the bootstrap sample to which the 
model is fitted. 
. f h I th . h 1 ~ eA , 3. The bootstrap estImate or tel parameter IS t en - L.. . 
M j=1 '. 
Finally, upper and lower percentile limits around the parameter estimates and other 
quantities. such as the density, can be presented. Using these bootstrap confidence 
intervals, it is possible to test the null hypothesis that the model is correct. 
Kolmogorov-Smimov Goodness-of-fit test 
An alternative test for continuous data that does not require the data to be binned is the 
Kolmogorov-Smirnov Goodness-of-fit test (Zar JH, 1999). The null hypothesis under this 
test is that the data are drawn from the fitted distribution. The test is based on the distance 
between the empirical cumulative distribution function (ECDF) and the fitted cumulative 
distribution function. 





where n(i) are the number of points less than Xi· 
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Equation 7.13 
The Kolmogorov-Smimov statistic Dn is then defined as the maximum of the distances 
D =maxlE (x)-F(x,.)I, 
" n I 
Equation 7.14 
where F(Xi) is the cumulative distribution function. 
The test statistic D can be compared to the Kolmogorov-Smimov test critical values Da.1I 
where (J. is the significance level. Note that the Kolmogorov-Smimov test is more sensitive 
near the centre of the distribution than its tails (Wilcox R, 1998). 
7.5 Example of a mixture model (naive model) 
The Belgium VZV serosurvey results are used to demonstrate the comparison between 
standardisation and mixture model methods. VZV was chosen rather than other antigens 
included in ESEN2 because no routine vaccination schedule exists. This greatly simplifies 
the mixture model since it can be assumed that there are only two underlying populations 
(individuals who had either previously been infected or never been infected). 
A mixture model was fitted to the 2,762 standardised results given by the Belgian 
laboratory. Thirteen samples of extremely low IU/ml results were classified as "censored" 
and were fixed at 0.003 IUlml (the lowest value in the dataset) or at -2.5 on the 10glO-scale. 
Similarly 3 sera of extremely high results were fixed at 5.8 IU/ml (or at 0.8 on the 10glO-
scale). 
As in Equation 7.3, two underlying populations (for negativel non-infected and positive I 
infected individuals) were assumed, both following normal distributions with common 
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location and di pe r ion parameter by age group. The Stata program for fittin g such a 
model i given in Append ix 1(C). 
The mixture di tributi on by age group following model esti mation (negative component : 
ft. = -2.05, a_ = 0.25 ; p iti e component: Jl+ = -0.26, a + = 0.45; prevalence estimates: 
;[, = 0.58, ;[2 = 0.92. ;[ J = 0.97, fi:4 = 0.99) is given in Figure 7.1 below. The mixture model 
appears to not quite fi t the ob e rved data within the tog lO IU/mt intervals (-0.5, 0) and (0, 
0.5 ), fo r age groups 1-5 and 6-9 years. 
Figure 7.1 Fitted model as uming constant mean and standard deviation for Belgian 
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7.6 Example of model diagno tics (na·ive model) 
To a e s the G dne - f-fi t o f th m de l d cribed in the previous Section, a Pearson 
chi - quare te t wa initia ll a rri d out. A mentioned earlier, this test depends on the 
I I 
definition of the bins and it requires sufficiently large expected frequencies in each bin in 
order to be valid. For these reasons, a procedure was defined prior to the analysis. 
Initially, the serological results were grouped into 220 bins of different widths. Table 7.1 
below shows some of these bins (IoglO-transformed data), the observed and the expected 
counts. Note that the expected values were estimated by age group, and therefore, the data 
were pooled over the 4 age groups. The Pearson residuals estimated as shown in Equation 
7.12 are also shown. These bins were used as long as the pooled expected frequencies were 
approximately between 10 and 15. 

































Using Equation 7.11 the test statistic was X2 = 276.3 for 211 degrees of freedom (p = 
0.002). The test provides evidence to reject the null hypothesis that the model is correct. 
By plotting the residuals against their corresponding fitted values it is possible to see 
whether there is a systematic pattern; such a pattern suggest a bad model fit. Figure 7.2(a) 
suggests that this is not the case and the residuals are randomly scattered, though there are 
some residuals outside the ±2 limits. 
182 
To find where the major differences between the observed data and the fitted mixture 
model lie, the Pearson residuals were plotted against log IV/ml. The critical area where it is 
important for the model to provide a good fit is around the area where the two underlying 
components meet. For this example, this is between -1.5 and 0.5 on the log IO-scale. Figure 
7.2(b) shows that there is generally a good fit in this area, despite the fact that there is the 
odd large residual in the age groups 6-9 and 10-19 years. 
Figure 7.2 Pearson residuals by age group for the naive model (excl. censored data) 
(a) Residuals vs. fitted values 
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The test was repeated after the data were grouped in 30 bins, concentrating on the area 
where the underlying distributions meet i.e. -2 to -0.8 on the 10glO-scale. Serological results 
within the area of interest were grouped into bins of different widths, as long as the pooled 
expected frequency was between 10 and 20. 
Table 7.2 shows the grouped serological results (IoglO-transformed data) pooled over the 4 
age groups. High residuals were reported between [-1.46, -1.33) and [-1.25, -LIS). The 
Pearson Goodness-of-fit test showed significant differences between observed and 
expected frequencies (X2 = 35.63; df = 21; P = 0.024). 
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Table 7.2 Serological outcome grouped in 30 bins for Pearson Goodness-of-fit test 
interval observed expected residuals 
[-2.50, -2.00) 167 155.96 0.88 
[-2.00, -1.97) 11 14.30 -0.87 
[-1.97, -1.93) 13 13.62 -0.17 
[-1.93, -1.90) 9 12.73 -1.05 
[-1.90, -1.86) 10 11.68 -0.49 
[-1.86, -1.83) 9 10.53 -0.47 
[-1.83, -1.75) 15 18.53 -0.82 
[-1.75, -1.69) 10 11.12 -0.33 
[-1.69, -1.59) 16 12.92 0.86 
[-1.59, -1.46) 16 11.83 1.21 
[-1.46, -1.33) 23 14.12 2.36 
[-1.33, -1.25) 15 13.38 0.44 
[-1.25, -1.20) 21 11.26 2.90 
[-1.20, -1.15) 22 14.10 2.10 
[-1.15, -1.12) 8 10.05 -0.65 
[-1.12, -1.09) 11 11.40 -0.12 
[-1.09, -1.06) 11 12.87 -0.52 
[-1.06, -1.03) 9 14.48 -1.44 
[-1.03,-1.01 ) 9 10.61 -0.49 
[-1.01,-0.99) 14 11.41 0.77 
[-0.99, -0.97) 11 12.26 -0.36 
[-0.97, -0.95) 19 13.14 1.61 
[-0.95, -0.93) 15 14.06 0.25 
[-0.93, -0.91) 13 15.02 -0.52 
[-0.91, -0.89) 10 16.01 -1.50 
[-0.89, -0.87) 21 17.03 0.96 
[-0.87, -0.85) 17 18.08 -0.25 
[-0.85, -0.83) 20 19.16 0.19 
[-0.83, -0.81) 16 20.26 -0.95 
[-0.81, 0.80) 2313 2315.13 -0.04 
Bootstrapping 
As an alternative method to the Pearson residual plot, bootstrapping was used to indicate 
where the differences between observations and fitted values lie_ One thousand samples of 
size 2,762 were randomly drawn, with replacement from the original dataset and the 2.5th 
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and 97.51h centi les were calculated for each age group. Figure 7.3 shows the fitted densitie 
together with the 95 % bootstrap interval. The fact that many observations I ie outside the 
interval s around the fitted line, underline the lack of good model fit. Although a bootstrap 
confidence interval can easi ly be produced for a simple mixture model , this becomes more 
difficult for complicated model s where the initial parameter values need to be carefully 
chosen for the model to converge correct ly. 
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Kolmogorov-Smirnov Goodness-of-fit test 
The Kolmogorov-Smirnov Goodness-of-fit test was also used as an alternative to the 
Pearson chi -square test. After exc luding a ll censored data, the te t showed s ignificant 
differences between the ECDF and the CDF of the fitted model. U ing Equation 7.14 the 
test stati stic was ca lculated as DO.05.2746 = O. ) 9 (p < 0.00). Figure 7.4 shows that the large 
differences between the ob erved and expected cumu lative distributions occurred between 
-0.5 and 0.3 for age groups 1-5 and 6-9 years. 
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Figure 7.4 ECDF plotted against mixture distribution CDF by age group 
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7.7 Varying mean and standard deviation by age group 
One of the assumptions of the model fitted above is that the parameters of the negative and 
positive components of the mixture distribution remain constant by age group. Specifically 
for VZV, very little information is known regarding the tendency of antibody levels to 
wane over time (Vyse AJ et ai., 2004). However, as it has been noted in the past for 
parvovirus B 19 serology, and might be applicable more generally to other vaccine-
preventable diseases, "the model for the density of results from seropositives ... needs to be 
sufficiently flexible to describe any decay in antibody levels" (Gay NJ, 1996). 
This may be achieved by allowing the shape of the underlying distributions to vary by age. 
In this case, the shape of the negative component is assumed to be fixed by age, however, 
the location and dispersion parameters of the positive components may vary to allow for 




where !/+i and CY+i are the mean and standard deviation, respectively, of the positive 
component for age group i. 
For the Belgium VZV serosurvey example, the data can be grouped into 4 age groups (i = 
1, ... ,4) i.e. 1-5,6-9, lO-19 and olderthan 20 years. This resulted in a 14-parameter-model 
(negative component: fi- = -2.05, 8_ = 0.26; positive component: fi+ 1 = -0.1 ], fi+2 = -0. ]9, 
P+3 = -0.27, ji+4 = -0.31, 8+1 = 0.46, 8+2 = 0.46, a +3 = 0.45, 8+4 = 0.43; prevalence 
estimates: Jl-1 = 0.57, Jl-2 = 0.92, Jl-3 = 0.97, Jl-4 = 0.99). 
The fitted model is shown in Figure 7.5 below. Although the model seems to fit the data 
better when varying the positive distribution component parameters by age group, it may 
not accurately incorporate the shape of the distribution. There are differences between the 
observed and fitted distributions between the 10glO IV/m] interval (-0.5, 0.5) for age groups 
1-5 and 6-9 years and (0, 0.5) for lO-19 years. In particular, for the age groups 1-5 and 6-9 
years, the positive component of the frequency distribution seems to be slightly skewed to 
the left. Moreover, there is not a good fit for the negative component of the 1-5 year-old 
group. 
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Figure 7.5 Fitted model varying the mean and standard deviation of the mixture 
model positive component by age group 
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Both the negative and po itive components of the mixture mode ls shown 0 fa r were 
a sumed to fo llow normal distributions. This may not ho ld so for the positi ve component, 
where there i antibody decay which may affect the fit in the key region where the two 
component densities meet. A more flexible mode l can be used in stead, such a a skew 
normal di tribution . The skew normal distribution is an extension of normal d istributi on 
a llowing for a "skewness parameter" . 
Assuming a normal dis tribution with constant mean and standard deviation for the negati ve 




for age groups i = I, ... , (,fSN being the skew normal density function 
,2f )F (,x-v) fSN(X;V,T,I,)=-;- N(X;V,T N /'-T- , 
Equation 7.17 
where v, T and A are the location, dispersion and skewness parameters, respectively. The 
distribution is right skewed for ), > 0, it is left skewed for }, < 0 and it is normal for }, = o. 
The mean 11 of the skew normal distribution can be expressed as 
Equation 7.18 
and the variance (i as 




(Azzalini A, I 985;Roncalli T & Lagache T, 2004). Note that in Equations 7.18 and 7.19, 1( 
denotes the mathematical constant. 
190 
In order to take into account the censored observations as shown in the log-likelihood 
estimation from Equation 7.5 and Equation 7.6, the skew normal cumulative distribution 
function was calculated as follows: 
Equation 7.20 
where F2(UI,U2) is a bivariate normal distribution with correlation p = -~ (Azzalini I +},2 
A, 1985;Roncalli T & Lagache T, 2004;Wijsman RA, 1996). 
For the VZV example, for i = I, ... , 4 age groups, the 18-parameter mixture model allowing 
for a skew normal positive component is shown in Figure 7.6 (negative component: 
it = -2.09, B= 0.22; positive component: VI = 0.49, l\= 0.36, V3 = 0.24, v4 = 0.00, i l = 0.83, 
estimates: Jrl = 0.59, Jr2 = 0.93, JrJ = 0.98, Jr4 = 0.99). Compared to the model shown in 
Figure 7.5, the underlying skew normal distribution improves the fit in the higher 
measurements (positive component) for age groups 1-5, 6-9 and 10-19 years. 
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Figure 7.6 Fitted model with a skew normal positive component varying its 
parameters by age group 
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Using Equation 7.9, the likelihood ratio test between the models before and after including 
skewness parameters is defined as: 
D,Ij,_,Ij. = -2{ In(~ ) - In(~ ) ) = - 2(-2138.4+2091.6) = 93.6 , 
where L2 i. the model likelihood without the skewness parameter (Equation 7.15), and LI is 
the model like lihood including the kewness parameters (Equation 7.16). Under the null 
hypothesis that ), = 0, the stati stic 0 follows an approximate chi-square distribution with 
diz - djl = 36 - 32 = 4 degrees of freedom , where diz and dfl are the degrees of freedom for 
the model, exc luding and inc luding the skewness parameters, respectively. The highly 
significant p-value (p < 0.00 I ) suggests that the model that includes the skewness 
parameters improves the model fit. 
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7.9 Model diagnostics (final model) 
After grouping the data into bins in the same way as shown in Table 7.1, the Pearson chi-
square test showed that there were borderline no significant differences between the data 
and the fitted distribution (X2 = 232.1; df = 201; P = 0.065). After re-grouping the data, 
concentrating around the area of interest (-2 to -0.8), there was borderline significant 
evidence to reject the null hypothesis that the mixture model is correct (X2 = 20.2; df = II; 
p = 0.043). 
Figure 7.7 shows there are no Pearson residuals outside the ±2 limits for high antibody 
measurements. Therefore, the skew normal distribution for the positive component fits the 
data better, as compared to the previous example shown in Figure 7 .2(b) where there were 
a number of residuals with extreme values particularly in age groups 1-5 and 6-9 years. 
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Although the Kolmogorov-Smimov test showed smaller differences between the observed 
and fitted data compared to the naive model shown above, these were still highly 
significant (DO.05.2746 = 0.10; P < 0.00 I). 
A comparison of the different mixture models is undertaken using AIC and BIC. A 
summary of the different models is given in Table 7.3. The mixture model using skew 
normal parameters fits the data better than the other two models. The additional number of 
parameters was taken into account since it had the lowest AIC and BIC values. 
Table 7.3 AIC and BIC for the mixture models fitted 
number of 
models parameters AIC BIC 
lor both components -
constant mean and sd by age group 8 4341.9 4389.3 
lor positive component -
varying mean and sd by age group 14 4304.9 4387.8 
for skew normal positive component -
varying all parameters by age group 18 4219.3 4325.9 
7.10 Seroprevalence estimation using standardisation 
In order to demonstrate the difference between standardisation and mixture model 
methods, seroprevaience was also estimated after the serological results were standardised. 
The Belgium national serosurvey data were tested using the Enzygnost VZV (Dade 
Behring, Germany) assay, an assay also used by the Spanish reference centre (de Ory F et 
al., 2006). The frequency distribution of the loglO-transformed results, together with the 
assay cut-off point (i.e. 0.05 IVlml or -1.3logJO IV/ml), are shown in Figure 7.8. 
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Figure 7.8 Assay cut-off point and frequency distribution of VZV Belgium results by 
age group 
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Once the tandardisation equation was applied to the serologica l results, these were 
classified into "positive" and "negative" according to the cut-off point of the reference 
centre' assay (O.OS fU/ml). A shown in Figure 7.9 there were small differences betwe n 
sta ndardised and non- tandardi sed seroprevalence est imates. 
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Figure 7.9 Comparison between standardised and non-standardised VZV 
seroprevalence estimates by age 
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7.11 Model comparisons 
The seroprevalence estimates for each age group, using standardisation and the different 
mixture models, are presented in Table 7.4. The 95% confidence intervals around the age-
specific seroprevalence estimates were estimated using the profile likelihood method. For 
each seroprevalence estimate, the maximum and minimum values for which the deviance 
was within 3.84 of the minimum, were calculated (Gay NJ, \ 996;Vyse AJ et ai., 2006). 
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Table 7.4 Seroprevalence estimates by age groups for standardisation compared to 
different mixture models, with 95 % CI 
age groups 
1·9 yrs 10·19 yrs 20.29 yrs 30·39 yrs 
methods positive component (n = 471) (n = 373) (n=ll09) (n = 809) 
non-standardised 57.1% 90.4% 95.4% 98.25 
results (52.5%, 61.6%)" (86.9%,93.1%)" (94.0%, 96.6%)" (97.0%, 99.0%)· 
standardisation 57.1% 89.0% 94.6% 97.3% 
(52.5%, 61.6%)" (85.4%, 92.0%)' (93.1 %, 95.8%)" (95.9%, 98.2%)" 
mixture models constant mean and 57.7% 92.0% 97.3% 99.2% 
sd by age group (51.3%, 64.0%) (87.4%, 95.4%) (95.6%, 98.5%) (97.9%,99.8%) 
varying mean and 57.4% 91.8% 97.3% 99.2% 
sd by age group (50.9%, 63.6%) (87.2%,95.3%) (95.5%,98.5%) (97.8%,99.8%) 
skew normal - varying 59.2% 93.4% 98.3% 99.3% 
parameters by age group (52.7%,65.5%) (88.9%, 96.6%) (96.9%,99.3%) (98.1%,99.9%) 
• 95% Binomial exact CI 
In general, differences in seroprevalence between the methods were small. The 
standardisation method seroprevalence estimates were lower, whereas the skew normal 
model estimates were slightly higher when compared to the other methods, especially for 
ages 1-9 and 10-19 years. 
7.12 Functional relationship of mean and standard deviation with age 
In accordance with ESEN2 project guidelines, the Belgium laboratory tested 
approximately 100 samples for each I-year age band less than 20 years of age. In addition 
to this, they tested approximately 200 samples for age groups 20-24, 25-29, 30-34 and 35-
39 (Nardone A e/ aI., 2007). The aim was to obtain accurate seroprevalence estimates for 
narrow age groups, especially at younger ages. 
In order to obtain seroprevalence estimates for the 23 age groups, a mixture model of the 
type shown in Equation 7.15 would need 2 parameters for the negative component, 46 for 
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the positive (23 for the mean and 23 for the standard deviation) and 23 for the 
seroprevalence estimates resulting in 71 parameters. Similarly a 94-parameter model 
would be needed for a skew normal positive component (Equation 7.16). However, such a 
model could not be fitted in Stata, since a high number of parameters caused convergence 
problems for the maximum likelihood algorithm (Gould W & Sribney W, 1999). 
Separate seroprevalence estimates may be achieved for each of the age groups by reducing 
the number of parameters for the positive component of the distribution. To obtain this, the 
mean and the standard deviation were assumed to follow functional relationships by age. 
This is something that has been done in the past (Hardelid P, 2008), however, the 
difference in this case was that the age-specific seroprevalence estimates were not assumed 
to follow a linear relationship, since they were the subject of interest. To determine these 
functional relationships, all samples classified as "positive" by standardisation were 
initially selected. The mean and standard deviation of these measurements were plotted by 
age (Figure 7. lO(a) and 7. lO(b». Both graphs suggest that a quadratic relationship may be 
more appropriate than a linear one to describe waning immunity as they provide a better 
fit. 
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Figure 7.10 Distribution of mean and standard deviation of IOglO IU/ml results by age 
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The model in Equation 7.15 then becomes 
Equation 7.21 
Despite the reduction in the number of parameters, it was still not possible to obtain 
convergence of the ML algorithm after age was divided into 23 groups. The reason for this 
was that for the older age groups there were very small numbers of negative samples, and 
therefore, the negative component of the distribution could not be easily estimated. Table 
7.5 shows the number of samples classified as "negative" by the standardisation method; 
for some age groups these were as low as 3 or 4. 
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Table 7.5 Frequency and percentage of negative samples per age stratum (according 
to how these were classified following standardisation) 
age group negative % Total 
58 61.1% 95 
2 61 64.9% 94 
3 43 45.7% 94 
4 22 23.4% 94 
5 18 19.1% 94 
6 17 18.1% 94 
7 12 13.0% 92 
8 8 8.5% 94 
9 4 4.3% 93 
10 3 3.3% 92 
11 4 4.3% 93 
12 7 7.4% 94 
13 8 8.5% 94 
14 5 5.4% 93 
15 5 5.3% 94 
16 5 5.3% 94 
17 6 6.4% 94 
18 10 5.7% 174 
19 7 3.7% 187 
20-24 4 2.0% 204 
25-29 9 4.5% 200 
30-34 3 1.5% 201 
35-39 6 2.9% 204 
Total 325 11.8% 2762 
To achieve convergence. some of the older age groups in Table 7.5 were grouped into the 
following 14 age groups: 1,2,3,4,5,6,7,8,9,10-12, 13-14, 15-19,20-29 and 30-39. 
7.13 Functional relationship of skewness parameter with age 
As shown above, a skew normal was considered a more flexible distribution to describe the 
shape of the positive component. To reduce the number of skewness parameters, a 
quadratic function for skewness was considered in addition to the functions used for the 
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location and dispersion parameters. This would transform Equation 7.16 into the 
following: 
Equation 7.22 
groups i = I, ... , (. 
Using the 14 age groups shown in Table 7.5, the estimated parameters of the fitted model 
were: 
Negative component: jJ= -2.11,8= 0.25. 
Positive component: vo= 0.56, VI = -0.03, l'2= 0.00, To= 0.88, TI = -0.01, T
2
= 0.00, 
~) = -4.20, 11 = 0.08, ~ = 0.00. 
Prevalence estimates: i l = 0.40, i2 = 0.36, i3 = 0.56, i4 = 0.82, is = 0.84, i6 = 0.89, 
i 7 =0.91, i x=0.95, i<)=0.98, i lO =0.99, ill = 0.97, i J2 =0.98, il3= 0.99 and i I4 =0.99. 
The model shown above was compared to a model with a nonnal underlying component 
for the positive group (instead of skew normal) using a likelihood ratio test. The skewness 
parameters were found to be significant (D4 = 99.8; P < 0.(01). Furthennore, the normal-
components model had higher AIC and BIC (AIC = 4243.5 and BIC = 4373.8) compared to 
the skew normal component model (AIC = 4149.7 and BIC = 4297.8) which suggested that 
the latter provided a better fit. 
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The mean and the standard deviation estimates by age group for the skew normal 
component as calculated by Equations 7.18 and 7.19 (using the location, dispersion and 
skewness parameters), respectively, are given in Figure 7.11. 
Figure 7.11 Fitted mean and standard deviation of IOglO IUlml results by age for the 























"''],,,~<,<o'\co~ ... '], ~ 
,,<::i ... "
age 
The Pearson residuals are plotted for the 14 age groups in Figure 7.12 below. There are a 
few of the residuals outside the ±2 range for age groups I to 9 years. These are within the 
range of -1.9 to -Ion the logro-scale. 
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Figure 7.12 Pearson residuals vs.logto IU/ml by age group 
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7.14 Seroprevalence comparison for 14 age groups 
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The seroprevalence comparison between local results classification, classification after 
standardisation. and the two mixture models described above for 14 age groups are 
depicted in Figure 7.13. The estimated population seroprevalence using the skew normal 
model is consistently higher than the standardised seroprevalence for ages 4 and older. The 
highest difference between the two estimation methods occurs at the 6 years age group, 
where seroprevalence is estimated as 82% and 89% by the standardisation and the skew 
normal mixture model, respectively. 
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Figure 7.13 Seroprevalence comparisons 
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7.15 Conclusions 
Besides using standardisation to estimate and compare population seroprevalence between 
samples tested in different national laboratories, an alternative approach is mixture models. 
Both these methods have a number of advantages and disadvantages. 
As far as standardisation is concerned, the definition of the reference centre's cut-off point 
has a big impact on the classification of the samples. A biased estimation of the cut-off 
point might lead to sample misclassification, and hence, biased seroprevalence estimates. 
The estimation of assay cut-offs points will be further discussed in Chapter 8. 
On the other hand, although standardisation is a time-consuming and costly process, it 
provides a final standardised dataset of serological data. Apart from estimating 
seroprevalence, standardised results may also be applied to direct comparisons between 
quantitative serological data. In addition, more complex analyses may be undertaken on the 
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individual serum results. such as multivariable logistic regression and other types of 
modelling. 
The main advantage of mixture models is that they overcome the drawbacks of fixed-cut-
offs by estimating seroprevalence directly from the data. This greatly simplifies the 
methodology since there is no need for the construction, distribution and testing of a 
standardisation panel. 
A disadvantage of the mixture models method is that there is an element of subjectivity on 
deciding the number and shape of underlying components. A more important disadvantage 
is the mixture models' dependency on the presence of separate peaks for the underlying 
populations. It is important to estimate the tails of the distributional components accurately 
around the area where the underlying distributions overlap, particularly in those situations 
where the components are not well-separated. Given that the shapes of underlying 
distributions are greatly affected by extreme measurements, the resulting estimates can be 
seriously biased. Hence, mixture model results should be interpreted with caution unless 
the underlying distributions are well separated. 
An example illustrating this point is provided by a mumps serosurvey. A total of 3,575 
samples were tested for mumps as part of the UK serosurvey carried out in 2000. The titre 
distribution of the standardised results, shown in Figure 7.14, has no separate peaks to 
indicate the underlying populations of those vaccinated or previously infected and those 
susceptible. Therefore, given that the underlying populations are not clearly defined, it is 
not possible to ensure that the positive and negative components are fitted correctly. 
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During thi s Chapter a simple exa mple was chosen to demonstrate the applicat ion of a 
mi xture mode l. However, as mentioned above, the construction of a mixture mode l is a 
subjecti ve process, with respect to shape and number of underlying component 
di tributions, which may potentially lead to model selection bias_ Efforts have been 
undertaken in the past to introduce rules aiming to limit the level of subjectivity (Vyse AJ 
el ai. , 2006;Biern acki C el ai. , 2000;Hardelid P, 2008) . However, despite these efforts, the 
e le ment of subj ectivity remains. The following quote is taken from Cormack: "Data-based 
model-selection is difficult and dangerou s_ The stati stical question is usually phrased in 
te rms of the ignificance leve ls at which a new parameter should be included in the mode l, 
or an ex isting parameter excluded. Measures such as Akaike 's crite rion are advocated as 
objective dec ision rules. I sugge t that biological under tanding of the data set also pl ays a 
part... " (Morgan BJT, 2000)_ 
A " biological understanding of the data" might include an appreciation , that for some 
antigens, measure me nt error might be an issue; for others, the presence of low positives (or 
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unprotected positives) owing to imperfect vaccines (as may be the case for mumps); 
waning antibodies with age; or lack of serological correlates of protection (as with 
pertussis), might all produce serological data for which it is not possible to separate 
negative and positive components. For such data, mixture modelling might lead to biased 
estimates, and so results need to be interpreted with caution. 
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The material discussed in Chapters 4, 5 and 6 aimed at the validation and further 
development of the standardisation methodology used in the ESEN2 project, in order to 
achieve common units, and hence, comparable seroprevalence estimates. Once 
standardisation had been achieved, the results were classified into positive or negative, 
according to a cut-off point. 
The estimation of an assay cut-off is very important, since it influences the classification of 
samples, and therefore, the national sero-profiles. The aim of this Chapter is to investigate 
the validity and impact of these cut-offs on the national sero-profiles, and to examine 
whether seroprevalence estimation can be improved by calculating alternative cut-offs. 
8.2 Assay cut-offs as specified by the manufacturers 
The cut-offs applied to the ESEN2 quantitative serological data were specified by the 
manufacturer of each reference country's assay. 
Before assessing the validity of negative I positive cut-offs it is essential to understand how 
these were determined by assay manufacturers. Traditionally, fixed cut-offs are estimated 
from a sample of sera assumed to be negative i.e. from individuals who had neither been 
infected nor vaccinated in the past. A commonly used cut-off has been the sample mean of 
the log-transformed titres of a group of known negative samples plus 2 or 3 standard 
deviations. This ensures high specificity, disregarding however, the effect this may have on 
sensitivity (for a definition of sensitivity and specificity see Section 2.8) (Baughman AL et 
ai., 2006;Maple PAC et al .• 2006;Tong DDM et ai., 2007;Vyse AJ et aI., I 999;Parker RA 
et al., 1990). 
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As was briefly mentioned in Chapter 7, mixture modelling has been used in the past on 
serological data, not for obtaining seroprevalence but for estimating positive / negative cut-
offs (Parker RA et aI., 1990). Since then mixture models have commonly been used for 
estimating assay cut-offs (Maple PAC et aI., 2006;Sheppard C et al., 2001). More details 
of this method will be given later in this Chapter. 
Kernel density estimation has also been proposed in the past for estimating assay cut-offs. 
This method involves obtaining a kernel density estimate of the distinction of both 
negative and positive samples, and setting the cut-off to equal one of the local minima. 
However, this does not produce an objective and robust algorithm for determining a cut-off 
(Tong DDM et al., 2007). 
8.3 ROC curve analysis 
Another method commonly used when comparing a new assay to an existing "gold 
standard" assay is the receiver operating characteristic (ROC) curve analysis. The 
sensitivity and specificity of the new assay can be calculated for every possible cut-off 
when compared to the established gold standard assay. Sensitivity results are then plotted 
against I - specificity and the area under the curve (AVC) provides a measurement of 
discrimination between the assays. The point that maximizes the sum of sensitivity and 
specificity may be chosen as a cut-off ( i.e. max (sensitivity + specificity» (Talukder Y et 
al., 2005;Parker RA et al., I 990;Hardelid P, 2(08). 
For the ESEN2 project, ROC curve analysis provides an alternative method for obtaining 
comparable outcomes without using regression equations to standardise serosurvey results. 
ROC curves may be applied to the standardisation panel samples, by calculating sensitivity 
and specificity through the use of the reference centre's qualitative results (defined 
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according to the reference assay's cut-off) for each testing laboratory's quantitative 
measurement. The value that maximises the sum of sensitivity and specificity may be 
chosen as the cut-off, to classify the testing laboratory's serosurvey results into positive 
and negative. 
As an example, a panel of samples tested for VZV was prepared by the Spanish reference 
centre. The panel was subsequently sent to and tested by the Slovakian laboratory. The 145 
samples tested by both laboratories are shown in Figure 8.1, together with the regression 
curve used to standardise the serosurvey results. The reference cut-off at 0.05 IU/ml (or-
1.3 on the 10glO-scale) classified the standardised units into positive and negative. 
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For the ROC curve analysis, the sensitivity and specificity were calculated for cut-offs 
placed between successive Slovakian panel measurements. It is clear from Table 8.1 that 
for -1.16 10glO-transformed units (0.07 IU/ml) the sum of sensitivity and specificity is 
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maximised. Using such a cut-off point for the Slovakian assay the sensitivity is 98% and 
the specificity 97%. 
Table 8.1 Sensitivity and specificity for different cut-off points for Slovakia 
cut-off for Slovakia sensitivity specificity sensitivity + specificity 
-1.46 100.0 63.3 163.3 
-1.40 100.0 71.7 171.7 
-1.34 100.0 73.3 173.3 
-1.28 100.0 81.7 181.7 
-1.22 98.8 93.3 192.2 
-1.16 97.6 96.7 194.3 
-1.09 94.1 98.3 192.5 
-1.03 92.9 98.3 191.3 
-0.97 91.8 100.0 191.8 
• only some of the potential cut-otis are given in this Table 
The validity of the cut-off as estimated using the ROC curve depends on how well the 
positives are separated from the negatives. The separation between negatives and positives 
for the standardisation panel can be assessed by plotting sensitivity against] - specificity 
and calculating the A Uc. Given that A UC takes values between 0.5 and I, an A VC less 
than 0.75 may be interpreted as poor discrimination between the two assays. 
Figure 8.2 shows the sensitivity plotted against I - specificity for the standardisation panel 
shown above_ Here AVe = 0.996 which means that there is very good separation between 
positive and negative results. 
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Figure 8.3 shows a comparison between the estimated seroprevalence for Slovakia (a) 
using the non-standardised serosurvey and the local assay cut-off, (b) the standardised 
serosurvey results and the reference centre's cut-off as used in the ESEN2 project and (c) 
the non-standardised serosurvey results and the estimated cut-off using ROC curve 
analysis. The seroprevalence estimates based on non-standardised results are 
overestimated, especially for ages less than 10 years. The method based on ROC curves 
gave very similar estimates to the standardisation method used for the ESEN2 project. 
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Figure 8.3 Seroprevalence estimates for Slovakia using local assay results, 
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However, it needs to be noted that the AVe is a measurement of discrimination for the 
standardisation panel and not the serosurvey results which is where the estimated cut-off is 
being applied to. In general, for the standardisation panels, there were small number of 
measurements around the area of the negative I positive cut-off which meant there was 
little chance for misclassification and therefore, high AVe estimates. However, there were 
often high numbers of data around the critical area around the cut-off when looking the 
national serosurvey_ 
To demonstrate this point, the Lithuania measles example introduced in Figures 4.9 and 
4. IO is being revisited. Following a ROC analysis, the cut-off was estimated as -0.80 (on 
the 10glO-scale) with very high separation between positives and negatives (AVe = 0.995). 
However, looking at Figure 4.9, it is clear that such a cut-off is overestimated for the 
Lithuanian assay. As shown in Figure 8.4, the ROC method does not adjust well for the 
different assay scale resulting in seroprevalence close to the non-standardised estimates. 
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The main advantage of the ROC analysis described here is that it is a non-parametric 
method and therefore, does not depend on regression assumptions. Another benefit is that 
it provides an easier method to implement, avoiding subjective decisions such as the type 
of equation used. 
The main drawback of the ROC analysis is that it does not make full use of the dataset, 
depending very much on how clear the distinction is between positive and negative results 
around the area of interest. In scenarios where no clear distinction exists between positive 
and negative sample for the national serosurveys as was often the case for the ESEN2 
project, this method is not expected to work. 
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8.4 Are assay cut-offs appropriate for sero-epidemioIogy? 
Serological assays are designed for clinical purposes and therefore, assay cut-offs are 
estimated to suit diagnosis in individuals. In terms of vaccine-preventable infections, the 
aim of the assay manufacturer is usually to ensure that all truly negative samples are 
classified as "negative" by the test. In other words, a cut-off point aims at maximising 
specificity, disregarding the effect this might have on sensitivity. This may lead to some 
protected individuals being classified as "susceptible" (Ades AE, I 990;Vyse AJ et ai., 
2006;Hardelid P, 2008). 
It has been claimed in the past that highly specific tests are important in epidemiology, 
since false-positive results might cause "false" outbreak investigations or unnecessary 
interventions such as antibiotic treatments (Baughman AL et ai., 2006). However, while 
highly specific tests may be desirable in some cases, the requirements for estimating 
seroprevalence in large population studies are different. In this case, the aim should be to 
minimise the bias in seroprevalence. Using a specificity-oriented assay cut-off may result 
in underestimating seroprevalence (Morgan BJT, 2000;Vyse AJ et ai., 2004;Hardelid P, 
2008). 
The Slovakian VZV serosurvey collected in 2002 provides an example of this. The 
Slovakian laboratory used the Euroimmune assay to test their samples with a negative / 
positive cut-off as defined by the assay manufacturer at 0.25 IV/ml or -0.6 on the 10glO-
scale. By observing the distribution of the log-transformed measurements in Figure 8.5, the 
cut-off point seems to lie slightly too high on the left tail of what might be expected to be 
the distribution of positive samples. 
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Figure 8.5 Distribution of non-standardised serological VZV results for Slovakia and 
positive / negative cut-off point as defined by the assay manufacturer 
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Note that a number of amples te ted by the Slovakia laboratory fall outside the detection 
range of the as ay. For some but not all of these samples quantitati ve results were obtained. 
The qualitative result are hown in the graph after the method of simple ubst itution had 
been used (Chapter 5). thu generating the spike in Figure 8.5. 
In the above example, the emphasis has been given to the a say specific ity. However, thi s 
was not the ca e for the Dade Behring assay used by the reference centre to te t Spain 's 
nati ona l erosurvey in 2002. In Figure 8.6, the assay cut-off seems to overlap slightly with 
the distribution of the negative samples (c ul-off = 0.05 IU/ml or - 1.3 on the loglo- cale for 
the Dade Behring as ay), especially in samples ta ken from children. 
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Figure 8.6 Distribution of serological VZV results for Spain and positive / negative 
cut-off point as defined by the assay manufacturer 
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For the purposes of the ESEN2 project it was essenti al that thi s cut-off was well-chosen, 
since the laboratory that implemented the testing (i.e . Spain) was the reference laboratory 
fo r the YZV work package. This meant that this particul ar cut-off wa u ed to re-cla sify 
the tandardi ed re ults from all countries into positive and negati ve. For example, once 
the Slovaki an erosurvey results show n in Figure 8.5 had been standardi ed, the refe rence 
centre 's cut-off was u ed. igure 8.7 shows the standardised Slovakian resul ts togethe r 
with the cut-offs as chosen by the Spanish a say manu facturer. The chosen cut-off seems 
clearly to overlap with the di tribution of the negative re ults. 
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Figure 8.7 Distribution of standardised serological VZV results for Slovakia and 
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Considering the standardi sed re ults the cut-off stands in the ri ght tail of what would be 
expected as the di tribution of the negat ive res ults. Thi contrasts with the non-
standardi ed re ul ts, where the local cut-off was on the left tail of what o ne would expect 
to be the di stribution of posi tive results (Figure 8.5). The re fore, a large number of negati ve 
am pies are expected to be re-c1assified as pos itive after the results have been tandardi sed. 
Gi ven that some of these results may be fa lse ly re-c1 ass ified as pos iti ve. , the 
standardi sation method may not have worked very we ll in this example. 
The estimated seropreva lence by age using both non-standardi sed (cut -off = 0 .25 IU/ml ) 
a nd standard ised measurements (cut-off = 0.05 IU/ml) are g iven in Figure 8.8. 
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Figure 8.8 Standardised vs non-standardised seroprevalence estimates for Slovakia 
serosurvey 
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8.5 Estimating assay cut-offs using mixture models 
An assay cut-off that minimises the misclassification between positive and negative results 
is most suitable for estimating population seroprevalence_ One way to achieve such an 
objective cut-off point is through mixture modelling (Baughman AL et aI., 2006;Talukder 
Y et aI., 2005;Talukder Y et aI., 2007;Dong Z, 1997;Parker RA et aI., 1990)_ 
Assuming a simple mixture model with two underlying populations of positive (past 
infections) and negative samples (uninfected individuals), a two-component mixture model 
can be fitted_ 
Similar to the mixture model shown in Equation 7.3, assuming for simplicity there is no 
age effect, letf andf+ be the density functions of the negative and the positive component, 
respectively_ Then a simple mixture model can be expressed in the following form: 
222 
g(x) = (1-7T:)! (x;(}) + 7if+ (x;8+), 
Equation 8.1 
where ({ and 8+ are the model parameters of the negative and positive components, 
respectively. 
Let F, F+ be the cumulative distribution functions of the density functions! andfh 
respectively. Then for a given cut-off Co, the proportion of incorrectly classified positive 
samples (false negative rate) is F+(Co;8J and the proportion of incorrectly classified 
negatives (false positive rate) is 1- F. (Coll.), where 0. and 0+ are the parameters 
estimated using the mixture model in Equation 8.1 above. 
One approach is to estimate a cut-off Co that minimizes the total misclassification h(Co) 
defined as the sum of the false positive and false negative rates which is equivalent to: 
Equation 8.2 
A drawback of Equation 8.2 is that it does not take into account the proportion of samples 
attributed to each component. The total proportion of misclassified samples depends on the 
estimated seroprevalence Ii derived from Equation 8.1. Thus, to minimize the total number 
of misclassified samples, one can find the cut-off point that minimizes a weighted version 
of Equation 8.2, namely: 
Equation 8.3 
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(Baughman AL et at., 2(06). 
Other cut-off points that present more "conservative" or more "liberal" estimates than the 
cut-off described in Equation 8.3 have been proposed (Tong DDM et al., 2007). 
An alternative option is to seek a cut-off for which the seroprevalence bias is zero, i.e. 
returns equal numbers of false negative and false positive results. This occurs when 
( I - ii) ( I - F. (Co; 8. ) ) = ii F+ (Co; iJ + ) , 
which can be achieved by solving: 
Equation 8.4 
The purpose of re-estimating the negative / positive cut-off of an assay, is to eliminate the 
bias arising from the assay manufacturer's choice of cut-off that is designed for diagnostic 
purposes. In this way, the cut-off proposed in Equation 8.4 is a unique cut-off adjusted for 
the specific purposes of this project. Such unique fixed cut-offs, however they are 
estimated, suffer from a serious limitation: they cannot adjust for the important change in 
seroprevalence that naturally occurs with age (Vyse AJ el ai., 2004;Vyse AJ et ai., 2006). 
Therefore, an alternative method is proposed that results in different cut-off estimates by 
age group. Age-specific cut-offs Co; can be estimated after substituting the parameter 




The weighted cut-off in Equation 8.5 is considered to produce the least biased cut-off for 
the objectives of the project and will mainly be used thereafter. 
In order to find the root of the continuous monotonic functions expressed in Equations 8.4 
and 8.5, the optimize command was used in R (Brent R, 1973). To avoid convergence 
problems the minimization procedure was restricted to a "sensible" area around, e.g. 
between the location parameters of the underlying component distributions. 
Note that the cut-off estimation method shown here was applied to a mixture model with 
two underlying components but can easily be extended to three or more e.g. negative, 
vaccinated and previously infected individuals. For such a scenario, the two (negative I 
vaccinated and vaccinated I past infection) cut-offs can be estimated after adding a third 
component to Equations 8.4 and 8.5 and restricting appropriately the optimisation 
procedure. 
8.6 Estimating an age-specific cut-off for the Spanish VZV serosurvey 
As described above, the assay cut-off used by the VZV reference centre (Spain), seemed to 
overlap with the underlying distribution of the negative results (Figure 8.6). An alternative 
cut-off was estimated using mixture modelling. 
Assuming the existence of two underlying populations - one for previously infected and 
one for negative individuals - a two-component mixture model was constructed. A normal 
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distribution was assumed for individuals with no past infections and a skew normal for 
those previously infected. Note that, the mixture model with skew normal component was 
compared to the model with a normal component, using a likelihood ratio which showed 
that the added skewness parameters significantly improved the model fit (D4 = 99.8; P < 
0.(01). 
Assuming waning immunity for the positive component, a mixture model of the type 
described in Equation 7.16 was used, where i = 1, ... ,4 represents the age groups 1-4,5-9 
10-19 and 20+ years, respectively. The left- and right-censored observations were taken 
into account as shown in Equations 7.5 and 7.6, respectively. 
The resulting estimates were: 
Negative component: il. = -2.21, o. = 0.50. 
Positive component: i\1 = 0.63, 1\2 = 0.52, v , = 0.45 v = 0 38 .; = 0 48 .; = 0 52 +~, '+4.' .. + I . ," +2 . , 
Prevalence estimates: Tr+1 =0.33, Tr+2 = 0.75, Tr+3 = 0.93, Tr+4= 0.94. 
The residual plot in Figure 8.9 revealed a few residuals outside the ±2 range for low 
serological measurements, for age groups 10-19 and more than 20 years. 
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Figure 8.9 Pearson residuals for Spanish VZV serosurvey plotted against IOglO IU/ml 
by age group 
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After applying Equation 8.5, the estimated cut-offs for the age groups were COl = -0.76, or 
0.17 IUlml for ages 1-4, CO2 = -1.03, or 0.09 IVlml for ages 5-9, C03 = -1.13, or 0.07 IUlml 
for ages 10-19 and C04 = -1.20, or 0.06 IUlml for ages 20+ (The estimation program in R is 
given in Appendix I (0». The observed data and the fitted distribution are given in Figure 
8.10 below. The Spanish cut-off, as defined by the assay manufacturer (-1.3 on the 10glO-
scale), and the age-specific cut-offs derived from the mixture models are also shown. The 
age-specific cut-off is much higher than the fixed cut-off for the younger age group (1-4 
years). The age-specific cut-offs are closer to the fixed value for the older age groups. 
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Figure 8.10 Comparison between the fixed cut-off given by the assay manufacturer 
and the age-specific cut-off as estimated using the mixture model estimates 
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Despite the diffe rence in cut-off estimates, seroprevalence estimates are almost ide ntical 
for the two method (Figure 8. 1 I). Thi s is a result of the clear separati on between the 
underly ing distributions, since in this case there are few observations that ca n be 
potentially misclassified. 
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8.7 Application of the estimated cut-offs to other national serosurveys 
As explained above, weighted cut-offs provide a better estimate than non-weighted ones, 
since they take into account the proportion of samples in each component distribution, and 
therefore, minimise misclassification. However, they cannot be applied directly to other 
standardised serosurveys, due to their dependency on the component distribution 
proportions at the reference centre. 
The following method is proposed that makes it possible to apply a mixture model 
estimated cut-off to a serosurvey, without actually fitting a mixture model to these data 
(given that the data have initially been standardised): 
1. A mixture model is fitted to the reference centre's data as shown in the example in the 
previous Section. 
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2. Rough estimates of the proportion of the testing laboratory serosurvey samples for each 
component are obtained using the assay cut-off or the reference centre's cut-off (since the 
data have been standardised). 
3. The mixture model parameters from Step I are used in combination with the 
seroprevalence estimates obtained from Step 2 to estimate a cut-off for the national assay 
using Equation 8.5. 
4. The cut-off is used to re-c1assify samples and obtain new seroprevalence estimates. 
5. The mixture model parameters from Step I are used again in combination with the 
seroprevalence estimates obtained from Step 4 to obtain a new estimated cut-off. 
Steps 4 and 5 may be repeated in an iterative process until converged to a final cut-off 
estimate. 
The process for estimating a cut-off for both reference and national serosurveys is shown 
in Figure 8.12 below. 
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Figure 8.12 Flow-chart showing the process of estimating a cut-off point 
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There is a key assumption which must be satisfied if the iterative method is to succeed, 
namely that the component distributions should be the same at the reference centre and the 
testing laboratory serosurveys. 
The Slovakian standardised serosurvey results presented previously will serve as an 
example of cut-off estimation. Using the Spanish reference centre's assay cut-off (0.05 
IU/ml), seroprevalence estimates were obtained for Slovakia by age group (7r) = 0.33 for 
ages 1-4, 7r2 = 0.70 for 5-9, 7rJ = 0.93 for 10-19 and 7r4 = 0.98 for 20+). These 
seroprevalence estimates, in combination with the mixture model parameter estimates 
obtained previously (negative component: ft. = -2.21, 8. = 0.50; positive component: 
i = -2.81 2 1 = -2.19, 2+~ = -1.69, 2+4 = -1.62), allowed for age-specific cut-offs to be 
+1 ' +- -
obtained (Equation 8.5) by the iterative process described above. 
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Table 8.2 presents a compari on of the different methods for estimating assay cut-offs for 
the Slovaki an (s tandardi sed) assay. 
Table 8.2 Comparison between the cut-offs as estimated by the different methods 
age groups 
Methods 1-4 yrs 5-9 yrs 10-19 yrs 20+ yrs 
Slovakian assay cut-off 
(applicable to non-standardised results) 0.25 (-0.60) 0.25 (-0.60) 0.25 (-0.60) 0.25 (-0.60) 
Spanish ref assay cut·off 
(used in ESEN2 project) 0.05 (-1.30) 0.05 (-1.30) 0.05 (-1.30) 0.05 (-1.30) 
mixture modet cut-off (i terative method) 
(Equation 8.5) 0.19 (-0.72) 0.1 0 (-1.00) 0.08 (-1.12) 0.05 (-1.29) 
* cut-orrs in IU/m l. The loglu transformation is given in bracket . 
The standardised re ults in Figure 8. 13 show that the reference centre cut-off is placed at a 
very low point, well within the tail of the underlying di stribution of non-infected 
indi viduals. The ite rat ive method gave higher estimates for age less than 20 years. 
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8.8 Impact of cut-off estimates on population seroprevalence 
In Section 8.7, different methods for obtaining assay cut-offs were compared. In this 
Section, the impact of the different cut-offs on population seroprevalence will be assessed. 
These will be compared to estimates obtained by applying mixture modelling directly on 
the Slovakian results as shown in Chapter 7. 
A mixture model was fitted on the Slovakian standardised units (alternatively it may be 
applied to non-standardised units), assuming a normal underlying component for the non-
infected individuals and a skew normal for past infection. The likelihood ratio test showed 
significant evidence that the added skewness parameter provided a better model fit 
(D4 = 83.9; p < 0.00 I). The estimated model is shown in Figure 8.14 (negative component: 
i = 1.64. i 0= 0.89, i ~ = 0.87, i+4 = 0.76, i.r = -11.06, 1+2 = -2.47, 1 ~ = -2.24, +1 +- +. +. 
2+4 = -1.50; prevalence estimates: ii+ , = 0.28, ii+2 = 0.68, ii+3 = 0.93, ii+4= 0.98). The 
underlying component that describes the positive results (past infections) is clearly skewed 
to the left for all age groups. 
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Figure 8.14 Observed data and fitted mixture model for Slovakia standardised 
se rosurvey results 
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The residua ls are shown below in Figure 8. 15. There were some res iduals outside the ±2 
range for age group 1-4, which sugge ts that there were orne diffe re nces between the 
ob erved data and the fitted di stributions for the negati ve underlying compone nt 
(measurement less than -2 on the loglO- cale). 
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Figure 8.1S Pearson residuals for Slovakian VZV serosurvey plotted against loglO 
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A comparison between population seroprevalence estimates produced by different methods 
is shown in Table 8.3_ 
In these comparisons the results using the mixture model are regarded as the gold standard. 
Relative to these, the method using the Slovakian assay cut-off underestimate 
seroprevalences, whereas the method using the Spanish assay cut-off (used in ESEN2) 
overestimates the seroprevalences_ The iterative method gave seroprevalence estimates 
closer to the "gold standard" mixture model method except for the youngest age group 
where the Spanish assay cut-off gave a slightly less biased estimate. 
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Table 8.3 Comparison of seroprevalence estimates between the different methods 
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8.9 Method comparison using simulations 
age groups 
5-9 yrs 10-19 yrs 20+ yrs 
(n = 538) (n = 1055) (n = 1551) 
68.2% 92.9% 97.9% 
(64.0%,72.1%) (91.1%,94.4%) (97.0%,98.6%) 
64.9% 87.4% 93.1% 
(60.7%,68.9%)" (85.2%, 89.3%)" (91.7%, 94.3%)" 
69.9% 93.2% 97.9% 
(65.8%,73.7%)" (91.5%, 94.6%)" (97.1%,98.6%)" 
67.3% 92.0% 97.9% 
(63.1%,71.2%)" (90.2%, 93.6%)" (97.1%,98.6%)" 
A number of simulations were undertaken aiming to compare seroprevalence estimates 
after applying (a) the reference centre's cut-off (as used in the ESEN2 project) and (b) the 
iterative process described in Section 8.7. 
The simulation process was as follows: 
I. The reference centre's serosurvey was assumed to follow a mixture distribution, with 
two underlying components representing the susceptibles (negative group) and the 
protected individuals (positive group). Location, dispersion and seroprevalence parameters 
were selected to define this model. The reference centre's cut-offs were estimated using 
Equation 8.5. 
2. A second mixture model of the same type but with different parameter values was 
selected for the testing laboratory (true model), and the true model cut-offs were estimated 
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using Equation 8.5. One thousand sample datasets were generated from this mixture 
model. 
3. For each simulated dataset, seroprevalences were estimated (a) by using the reference 
centre's cut-offs estimated in Step I and (b) by estimating the cut-offs by the iterative 
method based on the location and dispersion parameters derived from the reference 
centre's model defined in Step I. 
Normal underlying distributions were assumed for the mixture models used in the 
simulations examples. These were of the general form shown in Equation 7.15. 
Simulations - Part I 
The models initially defined for the reference centre and the testing laboratory were 
assumed to have the same underlying distributions, but different seroprevalences for each 
age group. These are given in Table 8.4 below. 
Table 8.4 Definition of mixture models for testing laboratory (true model) and 
reference centre (Simulations - Part I) 





1-4 yrs 5-9 yrs 10-19 yrs 20+ yrs 
p., tIot f.1 t~ lI+:!. p., (/t.' P.4 tI04 
0.60 0.48 0.50 0.50 0.45 0.49 0.38 0.47 
prevalence estimates 
11", 
0.20 0.50 0.80 0.88 
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1-4 yrs 5-9 yrs 10-19 yrs 20+ yrs 
p . , II" p. , (]t "!. Il l.' at J p .. 1I.4 
0_60 0.48 0_50 0.50 0.45 0.49 0.38 0.47 
prevalence estimates 
"., 
0.60 0.80 0.92 0.98 
The mi xture mode ls and the cut-offs are shown in Figure 8_ 16, toge ther with the mi xture 
model s (described in Table 8.4) and the results of one s imulation for illu stration purposes_ 
Beca use the testin g laborato ry had higher sero prevalence than the refere nce laboratory for 
all age grou ps, the c ut-off estimated us ing the ite rative method, which take into account 
the differences in seropreva lence, was lower than the reference centre cut-off. 
Figure 8.16 Comparison between cut-off e timates using the mixture models defined 
in Table 8.4 
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The age-specific cut-offs were estimated by the different methods following 1,000 
simulations. The average cut-off and the seroprevalence estimates obtained by simulation 
using the different methods are shown in Table 8.5. The cut-offs obtained by the iterative 
method closely match the cut-offs for the model. There was very little difference between 
seroprevalence estimates since the underlying distributions were clearly defined and only a 
small number of samples were around the area where the components meet. 
Table 8.5 Comparison between cut-ofT and seroprevalence estimates methods using 
the mixture models defined in Table 8.4 (95% percentile intervals in brackets) 
age groups 
models 1·5 yrs 6-9 yrs 10-19 yrs 20+ yrs 
prevalence (%) 
true model 0.60 0.80 0.92 0.98 
applying true model'S cut-oil 0.61 (0.56, 0.64) 0.80 (0.78, 0.83) 0.92 (0.90, 0.94) 0.98 (0.97, 0.99) 
applying directly rei centre's cut-oil 0.59 (0.55, 0.63) 0.79 (0.77, 0.82) 0.91 (0.90, 0.93) 0.97 (0.97. 0.98) 
iterative method 0.61 (0.56, 0.65) 0.80 (0.78, 0.84) 0.92 (0.90, 0.94) 0.98 (0.97, 0.99) 
cut-off 
true model -0.52 -0.69 -0.81 -0.97 
ref centre's cut-oil -0.35 -0.55 -0.71 -0.78 
iterative method -0.52 (-0.53, -0.50) -0.69 (-0.71, -0.68) -0.81 (-0.84, -0.79) -0.97 (-1.02. -0.93) 
Simulations - Part 2 
The simulations were repeated for a scenario with a less clear separation between the 
underlying distributions. The models defined for the reference centre and the testing 
laboratory are given in Table 8.6 below. 
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Table 8.6 Definition of mixture models for testing laboratory (true model) and 
reference centre - overlapping underlying distributions 





1-4 yrs 5·9 yrs 10-19 yrs 20+ yrs 
"., "., 
0.60 0.48 0.50 0.50 0.45 0.49 0.38 0.47 
prevalence estimates 
Ir, Ir, 
0.20 0.50 0.80 0.88 
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0.60 0.80 0.92 0.98 
The mixture models and the estimated cut-offs obtained through the different methods are 
shown in Figure 8.17. The underlying components are close together, however, there are 
clear peaks that are especially visible for the younger age groups which include higher 
numbers of negative samples. 
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Figure 8.17 Comparison between cut-off estimates using the mixture models defined 
in Table 8.6 
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The imulated cut-off from 1,000 run and the seroprevalence es timate obtained with the 
different methods are given in Table 8.7. Again the iterative method gave cut-off est imates 
close to the truth , wherea the reference centre ' s cut-offs were underestimates. The 
seropreva lences obtai ned using the iterative method are c lose to those of the true mo le I, as 
in the previous example. In contrast, direct application of the es timated reference ag -
specific cut-offs undere timates the true eropreva lence. The reason fo r lhis is th at there is 
hi gher number of ob ervalions around the area where the underlying component 
di st ribution inter ecl which affects the sample c lass ificat ion. 
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Table 8.7 Comparison between cut-off and seroprevalence estimates methods using 
the mixture models defined in Table 8.6 (95% percentile intervals in brackets) 
age groups 
models 1-5 yrs 6-9 yrs 10-19 yrs 20+ yrs 
prevalence (%) 
true model 0.60 0.80 0.92 0.98 
applying true model's cut-oil 0.61 (0.57, 0.65) 0.80 (0.78,0.83) 0.92 (0.90,0.94) 0.98 (0.97, 0.99) 
applying directly ref centre's cut-oil 0.56 (0.52, 0.60) 0.76 (0.73, 0.80) 0.90 (0.88, 0.92) 0.96 (0.95, 0.97) 




-0.43 -0.58 -0.78 
ref centre's cut-oil 
-0.02 -0.25 -0.45 -0.54 
iterative method 
-0.24 (·0.26, -0.21) 
-0.43 (-0.46, -0.41) -0.58 (-0.62, ·0.55) -0.78 (-0.87, -0.72) 
Simulations - Part 3 
The simulations were repeated once more, after violating the iterative method assumption 
i.e. that the underlying component distributions are the same, and hence have the same 
location and dispersion parameters_ The mixture models defined for the reference centre 
and the testing laboratory are given in Table 8.8 below. 
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Table 8.8 Definition of mixture models for testing laboratory (true model) and 
reference centre - varying location and dispersion parameters between testing and 
reference laboratories 





1-4 yrs 5-9 yrs 10-19 yrs 20+ yrs 
fl·' iT., fl., (J.'2 11+:. O+J 11., iT.., 
0.60 0.48 0.50 0.50 0.45 0.49 0.38 0.47 
prevalence estimates 
If, 
0.20 0.50 0.80 0.88 





1-4 yrs 5-9 yrs 10-19 yrs 20+ yrs 
iT., 11·, 
0.70 0.68 0.60 0.70 0.55 0.69 0.69 
prevalence estimates 
If, 
0.60 0.80 0.92 0.98 
The mixture models and estimated cut-offs are given in Figure 8.] 8. There is a clear 
difference between the reference centre and the testing laboratory's models for both 
underlying components. 
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Figure 8.18 Comparison between cut-off estimates using the mixture models defined 
in Table 8.14 
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Simulalions - Part 3 
Note: for graphi cal purposcs one set of simulated re ult. was plotted 
The simulated cut -offs (from 1000 runs) and seroprevalence estimates obtained by 
different methods are give n in Table 8.9. Examining the iterative method cut-off estimates, 
it is clear that the e are not as close to the true model' s cut-off as for the simulation 
examples . hown before , Still , however, they are better than the cut-offs estimated us ing the 
reference centre's model. The differences in seroprevalence between the two methods were 
sma ll , due to the fact that there were not many samples around the area where the 
underlying component distribution meet. 
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Table 8.9 Comparison between cut-off and seroprevalence estimates methods using 
the mixture models defined in Table 8.8 (95% percentile intervals in brackets) 
age groups 
models 1-5 yrs 6-9 yrs 10-19 yrs 20+ yrs 
prevalence (%) 
true model 0.60 0.80 0.92 0.98 
applying true model's cut-off 0.61 (0.57, 0.65) 0.80 (0.78, 0.83) 0.92 (0.90, 0.94) 0.98 (0.97, 0.99) 
applying directly ref centre's cut-off 0.58 (0.54, 0.62) 0.78 (0.75, 0.81) 0.90 (0.88, 0.92) 0.96 (0.95, 0.97) 
iterative method 0.59 (0.55, 0.63) 0.79 (0.76, 0.82) 0.90 (0.89, 0.92) 0.97 (0.95, 0.98) 
cut-off 
true model -0.93 -1.06 -1.17 -1.35 
ref centre's cut-off -0.51 -0.70 -0.84 -0.90 
iterative method -0.66 (-0.67, -0.64) -0.82 (-0.84, -0.81) -0.92 (-0.94, -0.90) -1.03 (-1.07, -1.00) 
8.10 Advantages and disadvantages of each method 
The method used for the ESEN2 project has the advantage of transforming serological 
results from different sources into comparable units, making it possible to carry out 
different types of analysis_ One disadvantage is its great dependency on the (reference 
centre) assay manufacturer's cut-off point, which was constructed solely for diagnostic 
purposes. 
ROC analysis can be used to obtain cut-offs for national serosurveys by comparing each 
country's results to the reference serosurvey. The advantage of this method is that it is easy 
to apply and avoids fitting regression equations. However, it is only expected to work for 
assays with a clear distinction between positive and negative results. 
Reliable seroprevalence estimates can be achieved by the use of mixture modelling on each 
laboratory's results. However, abandoning standardisation in favour of such an approach 
would mean that no direct comparisons would be possible between quantitative serological 
results. Moreover, in order to obtain unbiased seroprevalence estimates using mixture 
modelling, an appropriate mixture model must be selected. This is not always easy or even 
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possible, especially when underlying distributions are not well separated (see previous 
Chapter). 
In this Chapter, a combination of standardisation and mixture model methods has been 
proposed for estimating seroprevalence. Specifically, mixture modelling may be used to re-
estimate a cut-off for the reference centre, and subsequently, this may apply to the other 
standardised serosurveys in an iterative process. The idea was to compare the two methods, 
and in particular the method based on standardised results, with that based on cut-offs that 
are more appropriate for seroprevalence studies. The disadvantage of the iterative method 
is its dependence on the assumption that the components should be identical between 
serosurveys. While this should be addressed to some extent by standardisation, some 
variation may be expected owing to differences between the populations due to other 
factors. 
8.11 Conclusions 
The seroprevalence estimation method used during ESEN2 was based on assay cut-offs. 
The aim of this Chapter was to propose techniques for re-estimating assay cut-off for sero-
epidemiology. The iterative method described above qualifies as an alternative to the assay 
cut-off method, especially when (a) there is no widely accepted cut-off or the reference 
centre's cut-off is clearly not appropriate, and (b) it is not possible to use mixture models 
as an alternative due to non-separable underlying distributions. For the VZV example used, 
an established cut-off existed for the Spanish serosurvey, but mixture models could also be 
fitted given the well-separated distributions between past infections and uninfected 
individuals. This particular example was selected to present the different methods and 
compare the estimated seroprevalences. 
246 
In the example shown in this Chapter, the method used for the ESEN2 project provided 
robust for all ages apart for the youngest age group, and the resulting estimates were 
comparable to those obtained with the iterative method. This provides re-assurance with 
regards to the suitability of the manufacturer's cut-off, in spite of its lack of motivation for 
the purpose of estimating seroprevalence. The iterative method proposed may be used as a 
suitable alternative in a future ESEN project. 
The key assumption for the iterative method to be successful is that the underlying 
components between the reference centre and the testing laboratory are the same (and 
hence, have similar location and dispersion parameters), given the serological data have 
been standardised. As was shown in the last simulation example, varying the parameter 
estimates affects the estimated cut-offs, although in that particular scenario it did not much 
alter the seroprevalence estimates. 
Finally, despite the fact that mixture models often provide better seroprevalence estimates 
than the fixed cut-offs methods, there are circumstances where such cut-offs may be 
useful. For example, once fixed cut-offs have been specified, they can be easily applied to 
other serosurvey studies, assuming there is no change in the serological methods. This 
means that more reliable seroprevalence estimates can be obtained from smaller studies 
than those that would need to apply mixture modelling techniques. 
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Chapter 9: Seroprevalence estimation taking into 
account plate-to-plate variability 
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9.1 Introduction 
In the previous Chapters various methods for obtaining comparable population 
seroprevalence estimates have been presented. Using these methods it is possible to adjust 
for sources of variability such as those between different laboratories or assays. However, 
a certain amount of variability would still be present even if samples were tested using a 
unique assay within the same laboratory. 
Some of the unexplained variability may be attributed to the fact that not all samples are 
tested simultaneously. Instead batches are placed and tested on different assay plates. For 
many of these assays, the manufacturers adjust for such variability by transforming the 
optical density (00) results from each plate into International Units (lU/ml) (Chapter 2). 
The aim of this Chapter is to investigate the impact of variability due to plate differences 
on the seroprevalence estimate comparisons, and to propose a method to adjust for this. 
9.2 Rubella sero-survey 
The UK rubella sero-survey example, which will be used throughout this Chapter, was 
tested in 2000 and comprised 3,460 samples. A Mercia Rubella-G test was employed 
(Microgen Bioproducts Ltd, Camberley, UK) to classify individual samples into positive 
and negative using a cut-off at 8 IU/m!. Sera from individuals aged from I to 69 years of 
age were included (Vyse AJ et al., 2006). For the purposes of the analysis the data were 
divided into 4 different age groups: 1-9,10-17, 18-43 and 44+. To understand the reasons 
for selecting these particular age groups it is essential to briefly describe the history of 
rubella vaccination in the UK. 
The single rubella vaccine was introduced in the UK in 1970, targeting schoolgirls aged 
11-13 years-old, susceptible women (mainly identified through antenatal testing) and 
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healthcare workers. The combined vaccine against measles, mumps and rubella (MMR) 
was introduced during 1988 for all children aged 12-15 months. It was also offered to 
children aged between 4 and 5 for 3 years until 1991, administered at the same time as the 
pre-school doses of the diphtheria I tetanus vaccine. The idea was for children of these ages 
to be protected until the first cohort that received the first dose at 12-15 months reached the 
age of 4 years (Miller E, 1991). Due to a rubella outbreak in 1993, a "catch-up" campaign 
was introduced in November 1994. The combined measles and rubella vaccine was then 
offered to all children between 5 and 16 years-old. Since 1996 the MMR vaccine is given 
in 2 doses, the second administered to 3-5 years-olds (Vyse AJ et aI., 2002;Nardone A et 
al., 2008;Tookey P, 2004;Hardelid P, 2008). Figure 9.1 shows the history of the rubella 
vaccination strategy in the UK. 
Figure 9.1 Rubella vaccination programme for the UK 
Vaccine: single Rubella 
Target: 11-13 years-old girls 
Adu~women foundto be susceptble 
Health workers 




Target: All children aged 12-15monlhs 
Children between 4-5 years-old 
TImepenod: 19BB-now(lor 12-15monlhs) 
1988-1991 (lor 4-5 years-olds) 
iii 
198B 
Vaccine: MMR - 2"" dose inboduced 
Target: All ch~dren aged4 years-old 
TImepenod: 1996-now 
Vacclne:MR 
Target: All ch~dren aged 5-16 years-old 




Using this information, the rationale for grouping the data from the ESEN2 serosurveys 
into 4 broad age groups was the following: 
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(a) Individuals who were older than 13 years in 1970 did not receive any vaccine (i.e. at 
least 44 years old in 2000 when the sero-survey took place). 
(b) Those older than 5 years in 1988 (and younger than 13 years in 1970) were targeted in 
the single rubella campaign (these would have been 18-43 in 2000). 
(c) Those older than 4 years in 1996 (and 5 years or younger in 1988) were part of the 
single MMR or part of the MR catch-up campaign (these would have been 10-17 in 2000). 
(d) Those younger than 9 years old were all part of the 2 dose MMR programme, although 
those less than 3 had not received the second dose at the time the sero-survey was carried 
out (these would have been 1-9 years-old in 2000) (Table 9.1). 
Table 9.1 Age group classifications according to vaccination status 
age groups birth cohort Vaccination status 
1-9 > 1991 two MMR doses' 
10-17 1983-1990 single MMR or MR dose 
18-43 1957-1982 single rubella vaccine 
44+ < 1956 no vaccination 
* except for those who were too young to have received the 2nd dose (2nd dose given between 3-5 years) 
Although gender differences are important, since the single rubella programme was 
initially aimed mainly at women, unfortunately, gender information was not available and 
therefore. could not be taken into account in the analysis. 
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9.3 Optical Density (00) measurements 
As was explained in Chapter 2, the samples from each population serosurvey are placed on 
different plates. In this research each plate had 12 columns and 8 rows of wells, and 
therefore, a maximum of 96 samples could be tested (Figure 2.4 and Figure 9.2). 
Figure 9.2 The design of the serological plates used for the rubella tests by the UK 
laboratory 








After each plate was tested, the outcomes were reported quantitatively as ODs (Chapter 2). 
For the UK rubella serosurvey, the frequency distribution of the log-transformed OD 
measurements by each age group is shown in Figure 9.3. The distribution consists of two 
peaks that denote the underlying groups of negative and positive results. 
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Figure 9.3 Frequency distribution of loglo OD measurements for UK rubella 
serosurvey 
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UK rubella serosurvey - 00 resul1s 
The unde rl ying distribution of the po itive results would be expected to include both past 
infections and vaccinated individuals, a lthough the antibody response resulting from 
vaccination may be lower than that ari ing from infection by the wild virus. Assuming a 
norm al di ·tribution for the negative results and a skew normal for the positive a mixture 
mode l of the typ ex pres ed in Equation 7.16 was fitted with age groups 1-9, 10- 17, 18-43 
a nd more [han 43 year . 
The resulting estimate were: 
Negative component: fL-= - I A8, B_ = 0.23. 
Positive component: V+I = 0.07, \1+2 =0.06, \1+3 =0.15, \1-+4 =0.18, [ +I=OAI, [ +2 =OAO, 
.r = 0 32 [ = 0.36, 1., = -2.57, }., = -2.32, }'1 = -2_69, 24 = -4.17. 
L +3 . , +-I _.
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Preva le nce estimates : iii = 0. 84, ii2 = 0.91 , ii, = 0.92, ii4 = 0.96. 
The fitted model is plotted in Figure 9.4 be low. The underlying component of the positi ve 
re ults is skewed to the left which is indicative of waning immunity. 
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The Pearson re idual plot i g iven in Figure 9.5. The re idua l a re generally within the ±2 
limits for a ll age groups apart fro m age 18 to 43 years where the re were diffe rences 
be twee n the o b e rved data and the fitted di tribution between the range of -0 .9 and 0 . 1 on 
the 10gIO OD sca le. 
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Figure 9.5 Pearson residuals by age group for log1o OD measurements 
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The drawback of 00 measurements is that they are not comparable between plates. Any 
slight change in the conditions in which a plate is tested or in the individual carrying out 
the test might affect the outcomes. The variation in 00 measurements between the plates 
will be referred to as plate-ta-plate variability. 
9.4 Control samples 
Assay manufacturers are aware that 00 is not a reliable measurement owing to plate-to-
plate variability. A simple way to adjust for this is to include a small quantity of a unique 
negative sample in each plate to be tested to act as a control sample (Vyse AJ et al., 2(06). 
Adjusted OD measurements ODA, may then be calculated by using the following equation: 
Equation 9.1 
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where ODij refers to the OD result from the ilh sample on the jIll plate and o[)c, is the 00 
measurement of the control sample on the /' plate. The adjusted on is often known as 
"test to negative control ratio" (TIN) (Vyse AJ e/ ul., 20(6). 
Assuming, as before, a normal distribution for the negative underlying component and a 
skew normal for the positive, a mixture model of the type shown in Equation 7.16 was 
fitted for the adjusted OD measurements. The resulting estimates were: 
Negative component: 1'_ = 0.28, 0- = 0.24. 
Positive component: V+I = 1.56, l\~ = 1.84, v+J = 1.66, V +4 = 2.05, i + I = 0.31, i +~ = 0.45. 
i+J =0.26, i+4=0.42, ,t=O.OI, 2+~=-2.41, 2+1=0.00, 2+4 =-3.39. 
The frequency distribution and the resulting fitted model are shown in Figure 9.6. 
Although the scale measurements are naturally different in comparison to the crude ODs, 
the shape of the distributions is similar. 
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The residual plots are given in Figure 9.7 below. There are differences between the 
observed data and the fitted di stribution for the positive underlying component for ages 
between 18 and 43 years. 
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9.5 Calibration curves 
A major drawback of the adjusted OD measurements is their heavy dependence on the 
value of a unique control sample. An alternative method often used is to adjust for plate-to-
plate variability by converting ODs into IUlml through a numher of l'ontrols instead of a 
unique sample. This method, implemented in the ESEN2 project. was as follows: 
I. Together with the samples tested on each assay plate like the one shown in Figure 9.2. a 
number of control samples of known IUlml values, say IV /iI, where i is the ilh sample 
positioned in the j'h plate, were also included. 
2. Following the sample test, OD measurements were also ohtained for these known 
control samples. say ODLij. 
3. After regressing IV Iii} against OD/jj , plate-specific calibration curves were estimated. 
4. The calibration curves from (3) were used to transform the samples' OD results in each 
plate (ODi) into IUlml (/Vij). 
The UK rubella serosurvey included 3,460 samples tested on 45 serological plates. On 
each plate, together with the test samples, 8 control samples were included. These samples 
were of known unitage at I. 2,5, 10, 15,20,40 and 80 IUlml. 
The calibration step is performed automatically by the assay reader. Unfortunately. the 
exact equations of the calibration curves originally used to transform the UK rubella 
serosurvey OD results to IUlml measurements were not available for this project 
Therefore, as an example, an attempt to reconstruct the process of generating IUlml from 
OD measurements was carried out using a calibration curve of the following type: 
ex. - i5 
, I} 
ODt1j = ()j + ( )/1 +£:ij' JU K ·· 1+ --" 
)'j 
Equation 9.2 
where i refers to the i1h sample placed on the fh plate (j = I, ... , 45) and aj, Pj, Yj and (5j are 
plate-specific equation parameters, and cij - N (0,lT2). Note that for the function 
. a-i5 y(x) = () + /1 with x::::: 0, the lower horizontal asymptote is y(O) = a, the upper 
I+(~) 
lim (y(x)) = (5, whereas the parameters P and Y correspond to the slope and location, 
t-)+OO 
respectively. The calibration curve shown has been used to transform OD results into 
IUlml for another assay than the one shown in this example. Although different curves are 
used by different assays these are often of similar types so it was hoped that the impact on 
the outcome would be limited. 
Using maximum likelihood for Equation 9.2, the following parameters were estimated: aj, 
Pj, Yj, (5j and lTj. The variability between calibration equation estimates may be viewed by 
plotting the 45 estimated calibration equations (Figure 9.8). 
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Since the calibration equations were estimated using control samples with known unitage, 
it was possible to obtain IVlml measurements for the rest of the samples on the plates by 
inverting Equation 9.2 as shown below: 
I 
( 
A ~ )" IU.=y (1.j-i\_1 
Ij I OD _. 
ij () j 
Equation 9.3 
A comparison between the IVlml generated automatically by the assay reader (x-axis) and 
those estimated by the Equations 9.2 and 9.3 (y-axis) is given in Figure l).l) after these were 
loglO-transformed. The samples measured outside the range 0.01 to HO IVlml were treated 
as censored and were replaced with "0.01 IV/ml" or "80 IVlml" if they were below or 
above the range, respectively. The assay cut-off, given as 4 IVlml (or 0.6 on the 10glO-
scale), is also shown in Figure 9.9. A quadratic equation was filled to the quantitative 
results, aiming to describe the relationship between the two sets of results (the quadratic 
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term was tested significant p < 0.00 I). In general, the fitted lines explain well the data 
(coefficient of determination R2 = 0.97), however, there is clearly larger variability for 
lower readings. 
Figure 9.9 Comparison between IU/ml given by the assay reader (IogHl IU/ml) and as 
estimated using the generated calibration curves (I0glO new IU/ml) 
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The conversion of OD measurements into IVlml shown in this Section can only serve as an 
example as to how the transformation had been implemented, given that the actual 
calibration equation used was unknown. From this point onward, the IVlml measurements 
provided by the UK laboratory will be used for the analysis. 
9.6 Estimating plate· to· plate variability using the control samples 
As mentioned above, each plate had a number of control samples of known IU/ml value, 
say IV Kij, from which an OD measurement was obtained following the test (say ODLij). 
Following the estimation of the calibration equations, the ODLij measurements were 
transformed to IUlml, say IV Lij for the i'h control sample placed in the j'h plate. 
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The variability between plates was investigated using the control salllple,. A one-way 
analysis of variance (ANOY A) was performed using the model helow. 
Equation 9.4 
where p stands for the total mean, 0, is the deviation from the total mean for the j'h plate (j 
= I •...• 1jI) and [;ij the error term assumed to he identically and independently normally 
distributed with zero mean and constant variance (1~ i.e. 1:
'1 - MO, (12) (Zar JII, 1(99). 
For the 357 control samples placed on 45 plates (three controls were missing from one 
plate), the one-way ANOY A using loglO fU1. 11 measurements as a response variable, 
showed no significant evidence that the samples were drawn from different populations (p 
= 1.00). The between-plate variability was quantified using the fIIl'IUl ,H/lwrc amr (MSE) 
which was estimated as 0.02. This was much lower comparl'd to the l",timate obtained after 
using the logro ODu} measurements as a response variable (M,~'/:' = 0.15), which indicates 
that the transformation of 00 results to Ill/1ll1 corrected for plate-to-plate variahility. 
9.7 International Units (IU/ml) 
A comparison between 00 and IU/ml measurements by age group is given in Figure 9.10. 
A quadratic equation was selected to describe the relationship betwcl'n the two sets of 
results given that the quadratic term significantly improved the model fit (p < o.on I). 
, 
Although the proportion of the variance explained by thc regression is high (overall f{ = 
0.85), there are a number of discrepant observations that have high on but low IV/ml 
results (age groups 10-17 and 18-43) or low 00 and high Ill/1ll1 (age group IK-43). 
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Looking at the extreme observations, it turns out that they all belong to one plate (plate 
number 38)_ Table 9.2 shows the true IU/ml of the control samples and the values 
generated from the machine reading for plate 38. Given that the machine-generated IU/ml 
measurements (lVU .IR ) are close to the true IVlml (IV Ki38), this suggests that the calibration 
equation has been successfully estimated but not correctly applied to the rest of the 
samples on the plate. 
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Table 9.2 Comparison between the true Ill/ml, the on urul thl' 1II1U"him'-J:l'nerated 
IU/ml for the control samples of plate ]8 
IUKfJ8 (IU/ml) ODUJ8 IUUJ8 (IU/ml) 
- - ------
0.043 1.242 
2 0.055 1.855 
5 0.117 636 
10 0.128 8.64 
15 0.354 9.913 
20 0.406 27.415 
40 0.727 38.823 
80 1.101 81.237 
Since the generated IU/ml re ... ult ... for plate 3X were l"oll ... itil-rnl to lx' hi""l'd, thl'Y were 
dropped from any further analysis. Figure 9.1 I shows the rclatiomhip IlI."tWl'l"1l 01> and 
IU/ml after plate JX was excluded from the analysis. 
Figure 9.11 Comparison between login Of) and lo~1O Ill/ml by age J:roup 'after 
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9.8 M ixtu re modelling using IU/ml 
A mi xtu re mode l was fitted to the machine-generated 10glO-transformed lU/ml using 
Eq uati on 7. 16, afte r adjusting to take into account the censored observations as shown in 
Equation 7.6. TIle re ulting es timates were : 
egati ve component : ft. = O. I I , 8. = 0.23. 
~ ~ ~ 
T+3 = 0.43, f +-I = 0.4 1, )'+1 = -0 .76, }'+2 = -0.73 , }'+3 = -0.84, }'+4 = -0.88. 
Pre alence e timate Tr, = 0.86, Tr2 = 0.9 1, Tr, = 0 .93, Tr4 = 0.96. 
The fitted and ob erved di stributions are shown in F igure 9. 12. The figure shows that 
approx imately, a third of the samples were measured as "> 80 IV lml" (right-censored). 
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The residuals plot are gl en In igur 9. 13. or a c 'roup 1-( year!\ til r ar ~ a r \ 
measurement at higher IU value that have res iduals outsiue til ' _~ limit )., hi ' h SUgg t ' 
orne lack of fit on the po itive underl ying mp n nt of the IlI )U I. r)r a , ~ roups I -4 
and more than 44 years, there are a couple f lower m asur ment s with c tr me re: idual 
that sugge t orne lack of fit on the negativ c mp nent. 
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9.9 Comparison between exi ting method 
The mixture mode l seropreva lence estimate btain d from , ad j u ~ t 'u and I Iml 
measurement were all compared t tho btain dafter applyin th assa l11anufa ' wr r' , 
cut-off (Table 9.3). A menti ned ab ve, a mixture m d I f th f( rill d s -rib'u in 
Equation 7.16 was u ed for the diff rent fitt d m d Is. 
Using the cut-off pec ified by the as ay manufa tur r produ 'd s 'ropr al ~ tilll a t 
that were much lower than tho e of the mi xtur m dIs, sp r ag <; . 
These differences may be due t the ch i of ut-off (as di s 'uss d ill hapt 'r 8 . 
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There were no large differences between seroprevalence estimates resulting from the 
mixture models. However, the seroprevalence estimates generated from IU/ml were 
slightly higher than those derived from OD or adjusted 00 (especially for the younger age 
groups), which may suggest that this method corrects for slight bias resulting from plate-
to-plate variability. 
Table 9.3 UK population seroprevalence estimates for rubella given by age groups 
(95 % CI in brackets) 
age groups 
methods 1-9 yrs 10-17 yrs 18-43 yrs 44+ yrs 
assay classification (IU/ml) 78.9% 86.1% 91.6% 93.6% 
(75.6%, 81.8%)" (83.5%,88.5%)" (90.1%, 93.0%)" (91.0%,95.6%)" 
mixture model - 00 84.1% 90.8% 92.4% 95.5% 
(81.0%,86.7%) (88.3%,92.7%) (90.9%,93.7%) (93.2%,97.1%) 
mixture model· adjusted 00 83.2% 90.8% 92.5% 95.7% 
(80.1%,85.9%) (88.2%,92.8%) (91.0, 93.8%) (93.3%,97.3%) 
mixture model - IU/ml 85.9% 91.0% 93.3% 95.6% 
(82.8%, 88.5%) (88.6%, 93.0%) (91.8%, 94.5%) (93.3%, 97.2%) 
• 95% Binomial exact CI 
9.10 Mixture model on OD measurements adjusting for plate-to-plate variability 
An alternative method to adjust for plate-to-plate variability is to fit a mixture model 
whose parameters vary by plate. Extending Equation 7.16 to account for plate-to-plate 
variation - assuming random allocation of samples to each plate - the mixture model 
becomes of the form 
Equation 9.5 
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where i = I, ... , (are the age groups and t = I. ... , V' are the plates. Therdorc, in addition to 
varying the parameters of the positive component hy age group, the location parameters of 
both components vary by plate. 
The problem with this method is that it requires large numhers of parameters. For the UK 
rubella serosurvey example, there are 4 age groups and 44 plates (after the exclusion of 
plate 38). This translates to 5 additional parameters for each plate i.c. 233 parameters 
would be needed (44 parameters for J1" I for fT, 44 x 4 = 176 for I'", 4 for r
" 
4 for ;" and 4 
parameters for 7ri). 
A solution to this problem is to restrict the parameters, by grouping the platcs using the OD 
measurement of the control samples on each plate. For the UK ruhella example the 44 
plates were divided into 6 groups as shown in Table 9.4. 
Table 9.4 Plate groups with respect to negative controls 
00 of (negative) 
control sample 
0.009 - 0.011 
0.012 - 0.014 
0.015 - 0.017 
0.018 - 0.023 
0.027 - 0.036 







6, 11 6 
Using the mixture model expressed in Equation 9.5 for <: = 4 and V' = 6. the resulting 
estimates were PI= -1.55, P2= -1.54, ilJ= -1.56, P4= -1.40. il,= -1.37. iit.= -1.32, 
8 = 0.21 forthe negative component, and VII = 0.23, V21 = -0.10. '\ = 0.21. '\1 = 0.21. 
vI2 =0.02. "22 =0.08, vJ2 =O.09. V42 =0.17. vIJ =0.05. vn =(>'()6. '';11=0.16. "41=0.19. 
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J, = -2.43, }"2 = -3.28, },:) = -4.17, 24 = -4.43 for the positive component. Note that there 
were not enough samples for ages greater than 44 years in plate groups 5 and 6, and 
similarly, for age group 1-9 in plate group 6. In these cases fixed parameters were used 
based on the simpler model (Equation 7.16). 
Figure 9.14 shows the observed frequencies and fitted distribution by age and plate groups. 
The low number of observations, which influence the model fit is depicted clearly for plate 
groups 5 and 6. 
Figure 9.14 Observed frequencies and fitted mixture model by age and plate groups 
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il' "1 Plate group 1: 44+ years 
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Figure 9.15 shows the Pearson residuals plotted against the 10gIO OD measurements by age 
and plate groups. The residual plots indicate a lack of fit in the area -I to -o.x (on the 10gIO 
OD scale), where the underlying distribution components meet for ages I X to 43 years, 
especially for plate groups 3. 4. 5 and 6. Residuals far outside the ±2 limits were also 
apparent for the negative underlying components for plate 3 and those older than 44 years 
of age and also for plate 5 and ages between I and <) years. In these cases fixed parameters 
were used. 
Figure 9.15 Pearson residuals by age group and plate groups for logJO 00 
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The seroprevalence estimated from Equation 9.5 was 84.2%, 90.9%, 93.3% and 95.7% for 
age groups 1-9, 10-17, 18-43 and 44+, respectively. These estimates are closer to the 
seroprevalences estimated using the IVlml, which suggests that this may be a better 
method to adjust for plate-to-plate variability than the adjusted 00. 
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9.11 Conclusions 
The aim of this Chapter was to investigate the effect that plate-to-plate variability has on 
seroprevalence estimates. A mixture model fitted on the crude OD measurements (not 
adjusted for plate-to-plate variability) gave slightly different seroprevalence estimates than 
the IV/ml where any bias had been corrected by calibration curves. The adjusted OD 
measurements (OD measurements divided by a control sample in each plate) gave similar 
estimates to the crude OD, which suggests that this method might not be sufficient to 
correct for plate-to-plate variability. 
A new method was also proposed which involves adjusting for plate-to-plate variability by 
fitting separate mixture models to the crude OD measurements on each plate. The main 
disadvantage of this method is that it requires more complex models which may lead to a 
high number of parameters, depending on how many samples are tested on each plate (this 
problem may be overcome by grouping the plates as shown in Section 9.10). 
Another method which was not examined would be to treat the plates as random effects 
assuming two sources of variability, i.e. between-measurements and between-plates. Then 
seropreva1ence can be estimated by adjusting plate-to-plate variability using a random-
effect mixture model. 
Adjusting for plate-to-plate variability during mixture modelling could be a useful method 
for estimating seroprevalence. By avoiding testing for control samples one could reduce 
the cost of a serosurvey. For example, for the UK serosurvey tested against rubella, a 
serological plate contained 96 wells, 8 of which were filled by control samples for 
calculating the calibration equations. By not testing these samples and using the crude OD 
results, it would require testing 8.3% fewer samples which is an important saving for 
serosurveys containing a large numbers of samples. However, the idea behind this method 
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that is based on mixture models is to be used as a complcmentary mcthod to the existing 
method using calibration curves. As mentioned in Chapter 5. mixture modelling is based 
on certain assumptions that, when violated, may result in biased estimates. 
In the UK example presented, small differences (less than 2%) in seroprevalcnce estimates 
were found using different mixture modelling methods. These may not be of major concern 
from a public health point of view and suggest that there is little effect of plate-to-plate 
variability on seroprevalence estimation. However, it is important to stress that these 
conclusions are based on one serosurvey where a specific rubella assay was used. It is 
likely that the impact of plate-to-plate variability on seroprevalence estimates will be 
higher for other assays or antigens. Therefore, further research on the issue is necessary 
before more definite conclusions can be drawn. 
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Chapter 10: Discussion 
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10.1 Introduction 
Infectious diseases account for 23.4% of the global deaths. and this proportion is 
continuously decreasing (using 2004 mortality estimates as baseline) (World Health 
Organization, 2008d). Much of the mortality reduction can be attributed to the success of 
vaccines, which could have been much greater if more efficient vaccination programmes 
had been applied (World Health Organization. 2008d;Worid Health Organization. 2009). 
Even developed countries with long-established vaccination campaigns have morbidity and 
mortality resulting from vaccine-preventable diseases. WHO estimates that. in Europe. 
approximately 32,000 deaths could have been prevented by more efTective use of existing 
vaccines (World Health Organization, 2009). 
The ESEN2 project was a European study funded by the European Commission in 2001. 
The project aimed to identify susceptible cohorts for a number of vaccine-preventable 
infections across Europe by harmonizing serological markers. The main benctit of such 
harmonisation for each participant country is that this information may he used to target 
and subsequently amend any weaknesses in vaccination campaigns. In addition. the 
comparison of the various vaccination programmes between different countries may lead 
to optimisation of vaccination strategies at an international level. 
In this thesis, the information collected as part of the ESEN2 study was used to establish a 
statistical-based algorithm for standardising serological outcomes tested in different 
laboratories into comparable units. This algorithm - based on methods used in the past -
was employed during the ESEN2 project. Initially the impact of data outside the assay 
detection limits was examined and, after comparing different statistical techniques. 
censored regression was proposed for improving standardisation equations. The impact of 
the standardisation algorithm on seroprevalence estimation was examined. Differences 
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between standardised and non-standardised seroprevalence were mainly attributed to 
differences between antigens and laboratory procedures. 
Mixture modelling was proposed as an alternative method to standardisation for estimating 
population seroprevalence. Although mixture modelling may provide better seroprevalence 
estimates in certain situations, it is heavily dependent on specific assumptions, mainly of 
well-separated underlying component distributions. In terms of seroprevalence estimation 
using standardisation, the validity of the assay cut-off point was examined. A method for 
estimating cut-offs was proposed based on mixture modelling. This method might improve 
seroprevalence assuming the distributional assumptions hold. 
The impact of plate-to-plate variability, occurring due to samples tested in batches, on 
seroprevalence estimates was also examined. A comparison of seroprevalence estimates 
based on the raw 00 results and the plate-adjusted IV measurements showed very small 
seroprevalence differences. An alternative method to adjust for plate-to-plate variability 
without transforming 00 results into IV was proposed, again through the use of mixture 
modelling. 
10.2 Standardisation methodology 
The main aim of the first part of the thesis was to establish a statistical algorithm for 
obtaining regression equations. In the ESEN2 project these would be used for 
standardising serological results into common units based on the statistical methods 
employed in a previous European study (ESEN). Other objectives were to validate and 
further develop the algorithm and evaluate the impact of standardised units on 
seroprevalence estimation. 
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Twenty two countries participated in the ESEN2 project by collecting and testing national 
serosurveys of between 1,000 and 3,500 blood samples for all or some of the eight 
infections included in the project. In order to standardise the serological output, 
standardisation panels of approximately 150 samples - ranging from negative and 
equivocal (or low positive) to positive samples - were tested by a reference laboratory for 
each antigen. These panels were subsequently sent and tested by each participant 
laboratory using the assay method of their choice (Andrews N ('Ial., 200m. By regressing 
national panel test results against those of the reference centre, equations were generated 
which were used for standardising the main serosurvey results. 
There were three statistical issues affecting standardisation equation estimates, namely (a) 
extreme measurements (outliers), (b) type of the regression model and (c) effect of 
measurements outside the quantitative assay limits (censored observations). 
A statistical algorithm was developed to deal with these issues in three steps: (a) a 
quadratic regression equation was initially fitted and any observations with intlated 
standardised residuals were flagged as outliers. Following an investigation to ensure that 
no error existed during testing or data entry, these measurements were omitted from the 
analysis in a two-step process. (b) Linear and quadratic equations were considered. The 
simple linear regression model was generally used unless there was significant evidence 
that the quadratic term provided a better tit. In the few cases, where a clear lack of fit by 
both models was observed, a sigmoid-type model was used. (c) Two methods were 
considered for taking into account measurements outside the assay detection limits: The 
selected regression model was fitted once after omitting censored observations and again 
after substituting these with a constant (D,. / 2 and 2Du for left- and right-censored data. 
respectively). In most cases the simple substitution method was used. However. in 
situations where substituted measurements greatly influenced the model in the area of 
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interest where misclassification was likely to occur (positive / negative cut-off for the 
reference assay), censored observations were omitted from the regression model. 
The statistical algorithm described above was developed as part of this thesis and was used 
to standardise serological outcomes for the ESEN2 project. The validity of this algorithm, 
in terms of censored outcomes, was examined in detail and alternative methods were 
proposed. Apart from the methods of deletion and simple substitution employed for the 
ESEN2 project, censored regression, multiple imputation and other simple substitution 
methods were considered. Simulation results showed that although all methods used in the 
ESEN2 project gave estimates close to truth, and therefore may be considered valid, 
censored regression and multiple imputation methods provided still more robust estimates, 
especially for higher amounts of censored data. Moreover, interval censored regression 
was suggested for serological measurements in the form of dilution series. Finally, a non-
parametric test was proposed for confirming the validity of a regression equation for x-
censored data. 
Seroprevalence estimates were obtained by classifying serological results as positive or 
negative according to a cut-off point. The impact of using standardised units on 
seroprevalence estimates was evaluated by comparing the estimates before and after 
standardisation was implemented. The median seroprevalence change following 
standardisation was 1.6 (lQR: [0.4, 5.1]) and the geometric mean 3.5 (95% CI: [2.5,4.5]). 
The results showed differences in seroprevalence estimates, especially between antigens, 
with mumps and HA V having the highest numbers of samples re-c1assified following 
standardisation. There were important changes between seroprevalence estimates 
following standardisation between laboratories. 
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10.3 Seroprevalence estimation 
The second part of the thesis aimed at validating the techniques used during the ESEN2 
project for obtaining seroprevalence estimates and to propose alternative methods. A 
further objective was to investigate the impact of plate-to-plate variahility on 
seroprevalence estimation. 
Seroprevalence estimation as used in the ESEN2 project depended on two assumptions: (a) 
as discussed in Section 10.2, successful standardisation of the serological data and (b) a 
suitable choice of the assay cut-off. Both these assumptions may he hypassed when using 
an alternative method for seroprevalence estimation i.e. mixture modelling. 
Using mixture modelling directly on non-standardised serological data makes it possible to 
obtain seroprevalence estimates without applying assay cut-offs, and therefore. avoiding 
the time-consuming and costly process of standardisation. However, there are two major 
disadvantages associated with this method: (a) there is a certain clement of suhjectivity 
associated with choosing the shape (and the number) of the underlying components of 
mixture models and (b) the distributions of the underlying components need to he well-
separated which was not always the case for the serosurveys examined in the project. 
For the ESEN2 project, the reference centre' s assay cut-off was used to classify the 
standardised units into positive and negative. The suitahility of the assay manufacturer's 
cut-offs for seroepidemiology purposes have been questioned in the past (Vyse AJ et lll .• 
2004). Therefore, an iterative method for estimating age-specific assay cut-offs for 
seroprevalence estimation was proposed. The cut-off was defined as the point that 
generated equal numbers of false positive and false negative samples. based on the 
underlying components of a mixture model. 
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Plate-to-plate variability was taken into account during the ESEN2 serosurvey tests by 
including control samples of known IU measurements on each plate. Calibration curves 
were generated from these control samples after regressing the known IU measurements 
against the ODs. The calibration curves were subsequently used to transform the 00 
measurements in each plate into IU/mi. There was little impact of this variability 
adjustment on seroprevalence estimation on the example examined. A novel method was 
proposed to adjust for plate-to-plate variability using mixture modelling without having to 
generate calibration curves. 
10.4 Limitations of the standardisation methodology 
This thesis has thoroughly examined the standardisation methodology used in the ESEN2 
project for estimating population seroprevalence. Different aspects of the process of 
standardising serological results were investigated and validated. Obtaining seroprevalence 
estimates through the application of the assay manufacturer's cut-off point was assessed. 
Examples of distributions with well-separated underlying components presented in this 
thesis show that a manufacturer's cut-off is usually suitable for seroprevalence estimation, 
and is often close to the optimal cut-off. If the cut-off is slightly biased, the effect on 
seroprevalence estimates may be limited, if there is small number of samples around the 
area where the underlying components meet. 
However, in situations where the underlying distributions are not well separated - such as 
the mumps serosurveys - the appropriateness of the assay cut-off for seroepidemiology is 
not so obvious. In the example introduced in Section 7.15, showing the distribution of the 
UK serosurvey samples tested for mumps, the underlying components were not well 
separated. The titre distribution together with the assay cut-off point is given in Figure 
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10. 1. Given the large number of sample around the cri ti ca l area wh re the cut-off lie , it i 
clear that a bia in the cut-off will greatly affect the seropreva len e estimates. 
Figure 10.1 Distribution of the mumps serosurvey re ults for UK and assay cut-off 
o 2 3 4 5 
10910 standardised units 
_ leh'censored dala «8.3 unils) - - - assay cul·off 
UK mumps serosurvey 
10.5 Extending mixture modelling methodology: current work 
The reason why the re is no c lear separation between the negati ve and p si tive und d yi ng 
components could be due to the presence of vaccinated individua ls. In theory, th . e could 
be repre ented by a third , " inte rmediate", component, and separa te es timates for Ih 
proportion of indi vidua ls vacc inated, pas t in fected and non-infec ted Inn-va c ina l d may 
be obtained by mixture mode lling. However, this is not a practi ca l ption ror the UK 
resu lt, ince there is no separation between the distributions f th und r1 yin 
components. 
Vacc inated groups are present in a ll nat iona l serosurveys included in S N2, apa rt fr m 
Romania, where there was no routine va c ination against mump wh n th ser ur y wa 
collec ted (2002). Therefore, the di tribution of R mani an r suIts may s rve to d fin th 
underlying distribution of the UK e rosurvey, by h Iping t id ntify an add iti na l 
2 0 
component for the vacci nated group. Figure 10.2 shows the distribution of the standardi sed 
Roman ian and UK mumps results. The samples from the UK serosurvey measuring 
between 1.8 and 2.7 on the 10glO-scale may correspond to weaker (compared to natural 
infection) immunological responses induced by vaccination. 
Figure 10.2 Distribution of the mumps serosurvey results for UK and Romania and 
reference centre's assay cut-off 
o 2 3 4 5 
log10 standardised units 
UK serosurvey -- Romania serosurvey - - - reference assay cut·off 
This suggests an ex tension of the mixture modelling presented in this thes is, using data 
from countries with contrasting vaccination schedul es to identi fy the components of 
mixture models. 
Figure 10.3 shows the results from an initial analysis of the UK mumps seroprevalence 
data along these lines using mixture modelling. Seroprevalence by age is presented in 
combination with vaccine coverage of the first and second MMR dose. This suggests that 
high vaccine coverage corresponds to lower proportions of natural infec tions (high positive 
and higher proportions of positives) . For ages older than 15 years , high titre measurements 
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may be attributed to natural in fection , given that no vacci nation programme had been 
introduced at the time. 
Figure 10.3 Estimates of negative, vaccinated and past infected groups as well as 
















low positive _ high positive -&- MMR dose t 
Note: coverage data were coll ected a part of the ESEN2 project 
Further work based on these ideas is ongoing. 
10.6 Future applications 
This research demonstrate the va lidity of the methods used for the ~ N2 proj l and 
propo e some improvement , as we ll as new methods for standardi sin s ro lo i al 
outcomes and estimating population ·eropreva lence. An obvious appli alion f Ih 
techniques evaluated and developed during thi s thes is w uld b a future scr pid miol gy 
project. Initial di scu ions include prop sa ls ~ r a new projecI rlwl could in lude a number 
of additional infections. Example of infecli ns c uld b Hcpaliti · Virus (H V), Human 
Papillomavirus (HPV) or Haemophilu · InOuenzae type B (HI S). 
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Apart from a future European study similar to the ESEN and ESEN2 projects, the methods 
developed during this thesis could be used in a variety of seroepidemiological applications, 
mainly with regards to assay comparison and seroprevalence estimation. 
10.7 General conclusions 
Seroepidemiological studies play an important role in identifying susceptible population 
cohorts through seroprevalence estimation, and in improving vaccination campaigns by 
targeting these susceptible groups. International seroepidemiological studies comparing 
different immunisation strategies may provide valuable information for assessing factors 
such as vaccine types, number of doses or age at vaccination. Quantification of the impact 
of these factors in terms of popUlation seroprevalence can aid the development of more 
effective vaccination strategies. 
Providing unbiased seroprevalence estimates is very important for assessing the progress 
towards WHO targets for vaccine-preventable diseases in Europe. Part of this thesis was to 
develop an algorithm for the standardisation method. Standardisation was used for 
obtaining seroprevalence estimates as part of the ESEN2 project and was validated by the 
work presented here. Moreover, different aspects of this method were examined and 
advanced in order to be used in future studies. A future addition to the standardisation 
algorithm might include the use of censored regression models. The impact of the 
algorithm on seroprevalence estimation was highlighted by estimating seroprevalence prior 
to and following standardisation. 
Other methods for obtaining seroprevalence estimates such as mixture modelling were also 
considered. In many cases, mixture modelling may provide better estimates compared to 
the standardisation method that is based on fixed assay cut-offs. However, in order to 
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obtain robust estimates using mixture modelling, clear distinction between the underlying 
distributions is needed. Unfortunately this is not the case when sampling from a vaccinated 
population, where vaccine-induced antibody response is weaker than natural infection and 
wanes in time. In general, although the fixed cut-offs used during the ESEN2 project can 
be considered valid, a method was introduced for estimating age-specific cut-offs in an 
iterative way based on the reference centre's serosurvey distribution. However, this 
method is heavily dependent on the assumption of similar location and dispersion 
parameters for the underlying distributions between the reference and the participant 
laboratories. 
Finally, the impact of the variability occurring by testing the serological samples in batches 
(plate-to-plate variability) on seroprevalence was assessed. Using a VZV assay example, 
there was maximum 2% difference in seroprevalence after using the variability-adjusted 
IUlml measurements. A new method was proposed to account for plate-to-plate variability 
in seroprevalence estimation without having to estimate calibration curves. 
In conclusion, the standardisation method as used in the ESEN2 project is a simple and 
robust method for obtaining seroprevalence when combining samples tested in different 
laboratories by various assays. Therefore, following some method improvements suggested 
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Appendix I Programmes 
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Maximum likelihood in Stata 
The maximum likelihood programmes (.ado files in Stata) were run using the Stata 
maximum likelihood estimation program ml. 
(A) Programmes for censored data 
The programmes shown below can be combined to provide more flexibility than the Stata 
built-in commands cnreg and intreg. For example, sigmoid censored regression models can 
be fitted for interval censored data. 
The loglO-transformed serological for the testing laboratory and the reference centre are 
included in variables y and x, respectively. Variable cens indicates whereas data are 
continuous (cens = 0), left-censored (cens = -1) or right-censored (cens = I). 
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Maximum likelihood for a censored regression model (equivalent to cnreg command) 
program cenlin 
args Inf alpha beta sigma 
/* program cenlin.ado produces parameter 
estimates for constant (alpha), slope 
(beta) and standard deviation (sigma) for 
a simple linear censored regression 
model *j 
/* defining model parameters *j 
qui replace 'Int' = In( normalden(y, 'alpha' + 'beta' * x, 'sigma') ) if cens == 0 
j* non-censored data * j 
qui replace 'Int' = In( normal( (y - ('alpha' + 'beta' • x) ) j 'sigma') ) if cens == -1 
/* left-censored data *j 
qui replace 'Inf' = In( 1 - normal( (y - ('alpha' + 'beta' * x) ) / 'sigma' ) ) if cens == 1 
/* right -censored data' / 
end 
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Maximum likelihood for a sigmoid censored regression model 
program censigmoid 
args Inf alpha beta gamma delta sigma 
/* program censigmoid.ado produces 
parameter estimates alpha, beta, gamma, 
delta and standard deviation (sigma) for 
a censored regression model of sigmoid 
type *1 
/* defining model parameters *1 
qui replace 'Inf' = In( normalden(y, 'alpha' + ('beta' I (1 + exp( - ('gamma' + 'delta' * x)) )), III 
'sigma') ) if cen == 0 /* non-censored data *1 
qui replace 'Int' = In( normal( (y -('alpha' + ('beta' 1(1 + exp( - ('gamma' + 'delta' * x) ) ) ) ) ) III 
f'sigma') ) if cens == -1 /* left-censored data *1 
qui replace 'Int' =In( 1- normal(y - ( ('alpha' + ('beta' 1(1 + exp( - ('gamma' + 'delta' * x) ) )) ) III 
f'sigma') )) if cens == 1 /* right-censored data *1 
end 
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Maximum likelihood for interval censored regression model (equivalent to intreg 
command) 
program intlin 
args Inf alpha beta sigma 
1* program intlin.ado produces parameter 
estimates for constant (alpha), slope 
(beta) and standard deviation (sigma) for 
a simple linear interval censored 
regression model *1 
1* defining model parameters *1 
qui replace 'Inf' = In( normal( (high - ('alpha' + 'beta' * x) ) I 'sigma') III 
- normal( (low - {'alpha' + 'beta' * x) ) I 'sigma') ) if cen == 0 
/* interval censored data *1 
qui replace 'Inf' = In( normal( (inty - {'alpha' + 'beta' * x) ) I 'sigma') ) if cen == -1 
/* left-censored data *1 
qui replace 'Int' = In(1 - normal( (inty - ('alpha' + 'beta' • x) ) I 'sigma') ) if cen == 1 
/* right-censored data *1 
end 
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(B) Programme for multiple imputations 
The following code shows an example of how censored data can be imputed in Stata. 
The loglO-transformed serological for the testing laboratory and the reference centre are 
included in variables y and x, respectively in the file "panel dataset.dta". Variable cen 
indicates whether data are continuous (cens = 0), left-censored (cens = -1) or right-
censored (cens = I). 
* fitting a simple censored regression model like the one shown in Appendix I(A) 
matrix initial=[-0.3\ 1.1 \0.25) 
ml model If cenlin /alpha /beta /sigma 






/* initial values given for the maximum 
likelihood command (assuming a straight 
line */ 
/* calling the maximum likelihood 
programme cenlin */ 
/* maximisation of the model */ 
/* saving model estimates in a 1 x 3 matrix 
named cens where cens[1 ,1) is the 
constant, cens[1 ,2) is the slope and 
cens[1 ,3) the standard deviation */ 
/* defining the number of imputations * / 
/* creating a zero m x 3 matrix mi for 
saving the results of the 3 estimates and 
m imputations * / 
g fit=cens[1, 1]+cens[1 ,2]*x 
local i=1 
while 'i'<='m' { 
set seed 'i' 
qui g simres'i'=(invnorm(uniform()))*cens[1 ,3] 
qui g simy'i'=fit+simres'i' 
qui drop simres'i' 
qui replace simy'i'=y if cen==O 




/* generating variable that includes the 
fitted values based on the censored 
regression estimates *f 
/* beginning of m imputations· f 
/* generating results from a normal 
distribution with mean = 0 and standard 
deviation = cens[1 ,3] which as estimated 
from the censored regression model 
above *f 
/* generating the simulated data *f 
/* for non-censored data replace the 
original data i.e, keep the imputed data 
only for censored observations * f 
/* fit a linear regression on the imputed 
dataset *f 
/* save the model output in a 1 x 2 matrix 
named a, where a[1,2] is the constant and 
a[1,1] is the slope *f 
/* saving the variance as a local variable 
named b *f 
o saving the estimates of each imputation in matrix mi 
mat miri',1]=a[1,2] 
mat miri',2]=a[1,1] 




o calculation of the overall MI estimates 
qui summ mi1 
loc qmean1 =r(mean) 
qui summ mi2 
loc qmean2=r(mean) 
/* end of m imputations OJ 
/* inserting the imputation estimates 
saved in the matrix mi into a dataset of 
m rows and 3 columns (mi1 for constant, 
mi2 for slope and mi3 for standard 
deviation) OJ 
/* saving constant estimate as the local 
variable qmean1 OJ 
/* saving slope estimate as the local 
variable qmean2 * j 
o calculation of the overall standard error (within-imputation) 
qui summ mi3 
loc umean=r(mean) 
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/* saving standard error estimate as the 
local variable umean *j 
* calculation of the between-imputation variance 
qui g bml=(mil-'qmeanl')112 
qui summ bm1 
lac bmean1=r(sum)/Cm'-1) 
qui g bm2=(mi2-'qmean2')1\2 
qui summ bm2 
lac bmean2=r(sum)/Cm'-1) 
* calculating the total variances 
lac sd1 =sqrtCumean'+(l +(1/'m'))*'bmean1') 
IDe sd2=sqrtCumean'+(1 +(1/'m'))*'bmean2') 
/* saving variance estimate for the 
constant as the local variable 
bmean1 */ 
/* saving variance estimate for the 
slope as the local variable 
bmean2 */ 
/* saving the total variance estimate for 
the constant as the local variable sd1 */ 
/* saving the total variance estimate for 
the slope as the local variable sd2 *1 
* calculating and displaying the MI estimate together with the 95% CI for the constant 
lac df1 =Cm'-l )*((1 +(Cm'*'umean')/(Cm'+ 1 )*'bmean1')))1\2) 
di "alpha= .. 'qmean1' 
di "95% CI= " 'qmean1'-((invttaiICdfl',O.025))*'sd1') ", " 'qmean1'+((invttail('df1 ',O.025Jr'sd1 ') 
* calculating and displaying the MI estimate together with the 95% CI for the slope 
loc df2=Cm'-1 )'((1 +(('m'*'umean')/(Cm'+ 1 )*'bmean2')))"2) 
di "alpha= "'qmean2' 
di "95% CI=" 'qmean2'-((invttailCdf2',O.025))*'sd2') ", "'qmean1'+((invttaiICdf2',O.025))*'sd2') 
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(C) Programme for mixture models 
The programme norm2age4 is an example of how the mixture model described in Equation 
7.3 can be implemented in Stata. 
The 10glO-transformed results of the serosurvey are included under variable y, whereas 
variable cens indicates whereas data are continuous (cens = 0), left-censored (cens = -1) or 
right-censored (cens = 1). Variable agegrp2 indicates which age group the individual 
sample belongs to. 
program norm2age4 
args Inf m1 s1 m2 s2 p1 p2 p3 p4 
loc i = 1 
while 'i' <= 4 { 
/* file norm2age4.ado */ 
/* model parameters - Inf stands for log 
likelihood, m1 s2 is the mean and 
standard deviation of the negative 
component, respectively, and similarly 
m2, s2 the mean and standard deviation 
of the positive component. p1 - p4 are the 
proportion positives for 4 age groups */ 
/* maximising over 4 age groups */ 
qui replace 'Inf' = In { (1 - 'p'j") * normalden (y, 'm1', 's1') + 'p'j" * normalden (y, 'm2', '52'») /11 
if cens == 0 & agegrp2 == 'i' /* non-censored data *1 
* left-censored data 
qui replace 'Inf' = In { (1 - 'p'j") * normal ({y - 'm1') I '51') + 'p'j" * normal ({y - 'm2') I '52')) III 
if cens == -1 & agegrp2 == 'i' /* left-censored data *1 
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* right-censored data 
qui replace 'Inf' = In ( (1 - 'p'i") * (1 - normal ( (y - 'm1') I 'sl'}} + III 
loc i = 'j' + 1 
end 
'p'j" * (1 - normal ((y - 'm2') I 's2'}}} if cens==l & agegrp2=='i' 
/* right-censored data *1 
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(D) Programme for cut-off estimation using R (Equation 8.5) 
The following code is an implementation in R of Equation 8.5 for estimating assay cut-off 
using the mixture model described in Section 8.5. 
# The skew normal distribution library sn was used 
library (sn) 
# parameter estimates as given by the mixture model in Section 8.5 
ma = -2.214302 
sa = 0.5014619 
mb1 = 0.6253432 
mb2 = 0.5231688 
mb3 = 0.4518782 
mb4 = 0.3778452 
sd1 = 0.47796613 
sd2 = 0.52420586 
sd3 = 0.48913248 
sd4 = 0.49233756 
11 = -2.807696 
12 = -2.186895 
13 = -1 .686308 
14 = -1 .616152 
p1 = 0.32560735 
p2 = 0.75491795 
p3 = 0.92710461 
p4 = 0.94356571 
3]6 
# matrix for saving results 
results <- matrix(O, nrow = 1, ncol = 10) 
# age group 1 
# 
hc = function (x) { 
fneg = pnorm ( (x - ma) / sa) 
# defining function hc that needs to be 
# solved (Equation 8.4) for age group 1 
# normal density for negative component 
fpos = psn (x, location = mb1, scale = sd1, shape = 11) 
y = abs ( (p1 • fpos) - ( (1 - p1) • (1 - fneg) ) ) 
return (y) 
co = optimize(hc, lower = -2, upper = 0) 
co 1 = co$minimum 
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# skew normal density for positive 
# component 
# Equation 8.4 
# function optimize finds the local 
# minimum or maximum within the area 
# specified (in this case (-2, 0) 
# local minimum of age group 1 stored in 
# co1 
# age group 2 
# 
hc = function(x) { 
fneg = pnorm ( (x - ma) / sa) 
# defining function hc that needs to be 
# solved (Equation 8.4) for age group 2 
fpos = psn (x, location = mb2, scale = sd2, shape = 12) 
y =- abs( (p2 * fpos) - ( (1 - p2) * (1 - fneg) ) ) 
return (y) 
co =- optimize(hc, lower = -2, upper = 0) 
co2 = co$minimum 
# age group 3 
# 
hc = function (x) { 
fneg = pnorm ( (x - ma) / sa) 
# local minimum of age group 2 stored in 
# co2 
# defining function hc that needs to be 
# solved (Equation 8.4) for age group 3 
fpos = psn (x, location = mb3, scale = sd3, shape = 13) 
Y = abs( (p3 * fpos) - ( (1 - p3) * (1 - fneg) ) ) 
return (y) 
co = optimize(hc, lower = -2, upper = 0) 
c03 = co$minimum 
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# local minimum of age group 3 stored in 
#c03 
# age group 4 
# 
hc = function (x) { 
fneg = pnorm ( (x - ma) / sa) 
# defining function hc that needs to be 
# solved (Equation 8.4) for age group 4 
fpos = psn (x, location = mb4, scale = sd4, shape = 14) 
Y = abs( (p4 * fpos) - ( (1 - p4) * (1 - fneg) ) ) 
return (y) 
co = optimize(hc, lower = -2, upper = 0) 
c04 = co$minimum 






# local minimum of age group 4 stored in 
# co4 
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